Surgical strategy and clinical outcome in patients with aortic root disease by Arabkhani, B. (Bardya)
UITNODIGING
voor het bijwonen van de openbare 
verdediging van het proefschrift
SURGICAL STRATEGY
AND CLINICAL OUTCOME
in patients with Aortic Root Disease
door
Bardya Arabkhani
op woensdag 28 juni 2017 
om 15:30 uur
in de Medische Bibliotheek
Andries Queridozaal
Erasmus Medisch Centrum
Dr. Molewaterplein 50
Rotterdam
Na afloop van de promotie bent u
van harte uitgenodigd
voor de receptie ter plaatse
Bardya Arabkhani
Louisapolder 13
2992 ZX Barendrecht
B.Arabkhani@lumc.nl
Paranimfen
Arya Arabkhani 
Bob van Kempen
SURGICAL STRATEGY
AND CLINICAL OUTCOME
in patients with Aortic Root Disease
S
U
R
G
IC
AL
 S
T
R
AT
E
G
Y AN
D
 C
L
IN
IC
AL
 O
U
T
C
O
M
E
 IN
 P
AT
IE
N
T
S
 W
IT
H
 AO
R
T
IC
 R
O
O
T
 D
IS
E
AS
E
 
B
AR
D
YA AR
AB
K
H
AN
I B A R D Y A  A R A B K H A N I
14570-arabkhani-cover.indd   1 09/05/2017   16:46
voor het bijwonen van de openbare 
verdediging van het proefschrift
S I A  S A Y
A  I I A  
in patients with Aortic Root Disease
door
Bardya Arabkhani
op woensdag 28 juni 2017 
o  15:30 uur
in de Medische Bibliotheek
Andries Queridozaal
Eras us Medisch Centru
Dr. Molewaterplein 50
Rot erda
Na afloop van de pro otie bent u
van harte uitgenodigd
voor de receptie ter plaatse
Bardya Arabkhani
Louisapolder 13
2992 ZX Barendrecht
B.Arabkhani@lu c.nl
Parani fen
Arya Arabkhani 
Bob van Ke pen
i  tie t  it  ortic oot i e e
S
U
R
G
IC
AL
 S
T
R
AT
E
G
Y AN
D
 C
L
IN
IC
AL
 O
U
T
C
O
M
E
 IN
 P
AT
IE
N
T
S
 W
IT
H
 AO
R
T
IC
 R
O
O
T
 D
IS
E
AS
E
 
B
AR
D
YA AR
AB
K
H
AN
I A Y A  A A A I
14570-arabkhani-cover.ind    1 09/05/2017   16:46
SURGICAL STRATEGY AND CLINICAL 
OUTCOME 
IN PATIENTS WITH AORTIC ROOT DISEASE
Bardya Arabkhani
SURGICAL STRATEGY
AND CLINIC L OUTCOME
in patients with Aortic Root Disease
B A R D Y A  A R A B K H A N I
14570-arabkhani-layout.indd   1 10/05/2017   10:39
COLOFON
Cover & layout design: Design Your Thesis, www.designyourthesis.com
Printing:   Ridderprint, www.ridderprint.nl
ISBN:   978-94-6299-617-5
Copyright © Bardya Arabkhani, 2017
ALL RIGHTS RESERVED. Any unauthorized reprint or use of this material is prohibited. No 
part of this thesis may be reproduced, stored or transmitted in any form or by any means, 
without written permission of the author or, when appropriate, of the publishers of the 
publications.
14570-arabkhani-layout.indd   2 10/05/2017   10:39
SURGICAL STRATEGY AND CLINICAL OUTCOME
IN PATIENTS WITH AORTIC ROOT DISEASE
CHIRURGISCHE STRATEGIE EN KLINISCHE UITKOMST
IN PATIËNTEN MET AORTAWORTEL PATHOLOGIE
P R O E F S C H R I F T
ter verkrijging van de graad van doctor aan de  
Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus 
Prof.dr. H.A.P. Pols 
en volgens besluit van het college voor Promoties 
De openbare verdediging zal plaatsvinden op 
28 juni 2017 om 15:30 
 
 
door
Bardya Arabkhani
Geboren te Teheran, Iran
 
 
14570-arabkhani-layout.indd   3 10/05/2017   10:39
DOCTORAL COMMITTEE 
Promotors:  Prof.dr. A.J.J.C. Bogers 
   Prof.dr. J.J.M. Takkenberg
 
Other members: Prof.dr. R.J.M. Klautz 
   Prof.dr. J.W. Roos-Hesselink 
    Prof.dr. E.W. Steyerberg
Financial support by the Dutch Heart Foundation and H.Huysmans Foundation for the 
publication of this thesis is gratefully acknowledged.
14570-arabkhani-layout.indd   4 10/05/2017   10:39
Voor mijn ouders
Yek chand be koodaki be ostaad shodim
Yek chand be ostadi khod shaad shodim
Payan sokhan sheno ke ma ra che rasid
Az khaak bar-amadim o bar baad shodim
 
With them the Seed of Wisdom did I sow,
And with my own hand labour’d it to grow:
And this was all the Harvest that I reap’d —
From the Water I came, and like Wind I go
Omar Khayyam
14570-arabkhani-layout.indd   5 10/05/2017   10:39
14570-arabkhani-layout.indd   6 10/05/2017   10:39
TABLE OF CONTENTS 
1. General Introduction 11
2. The Long Term Results Of Aortic Valve Repair And Replacement: Chapter 10 
from the book “Aortic Regurgitation”
B. Arabkhani and J.J.M. Takkenberg
Vojáček J., Žáček P. and Dominik J., October 2016, Aortic Regurgitation, Skladem, Czech Republic, 
GRADA (ISBN: 978-80-247-5685-1)
23
3. Bentall Procedure: A Systematic Review And Meta-Analysis
Aart Mookhoek, Nelleke M Korteland, Bardia Arabkhani, Isabelle Di Centa,
Emmanuel Lansac, Jos A Bekkers, Ad JJC Bogers, Johanna JM Takkenberg
Ann Thorac Surg. 2016 May;101(5):1684-9 
45
4. Mechanical Aortic Valve Replacement In Non-Elderly Adults: Meta-Analysis And 
Microsimulation
Nelleke M. Korteland, Jonathan R.G. Etnel, Bardia Arabkhani, M. Mostafa Mokhles, 
Arezo Mohamad, Jolien W. Roos-Hesselink, Ad J.J.C. Bogers, Johanna J.M. Takkenberg
European Heart Journal, article in Press
67
5. Reported Outcome After Valve-Sparing Aortic Root Replacement For Aortic 
Root Aneurysm: A Systematic Review And Meta-Analysis
Arabkhani B, Mookhoek A, Di Centa I, Lansac E, Bekkers JA, De Lind Van Wijngaarden R, 
Bogers AJ, Takkenberg JJ
Ann Thorac Surg. 2015 Sep;100(3):1126-31
87
6. Bioprosthetic Aortic Root Replacement: A Meta-Analysis And Microsimulation 
Model
Bardia Arabkhani, Jonathan RG Etnel, Mirjam t’Mannetje, Richard van Valen,
Tanja van Essen, Emmanuel Lansac, Rob de Lind van Wijngaarden, Isabelle Di Centa, 
Ad JJC Bogers, Johanna JM Takkenberg
Submitted
103
14570-arabkhani-layout.indd   7 10/05/2017   10:39
7. Allografts In Aortic Position: Insights From A 27-Year, Single-Center Prospective 
Study
Arabkhani B, Bekkers JA, Andrinopoulou ER, Roos-Hesselink JW, Takkenberg JJ, 
Bogers AJ
J Thorac Cardiovasc Surg. 2016 Dec;152(6):1572-1579
129
8. Pregnancy Outcomes In Women With Aortic Valve Substitutes
Heuvelman HJ, Arabkhani B, Cornette JM, Pieper PG, Bogers AJ, Takkenberg JJ, 
Roos-Hesselink JW
Am J Cardiol. 2013 Feb 1;111(3):382-7
157
9. Does Pregnancy Influence The Durability Of Human Aortic Valve Substitutes?
Arabkhani B, Heuvelman HJ, Bogers AJ, Mokhles MM, Roos-Hesselink JW, Takkenberg JJ 
J Am Coll Cardiol. 2012 Nov 6;60(19):1991-2
175
10. Therapeutic Decisions For Patients With Symptomatic Severe Aortic Stenosis:
Room For Improvement?
van Geldorp MW, van Gameren M, Kappetein AP, Arabkhani B, de Groot-de Laat LE, 
Takkenberg JJ, Bogers AJ
Eur J Cardiothorac Surg. 2009 Jun;35(6):953-7
183
11. Operation Outcome, Valve Durability And Quality Of Life After Valve Sparing 
Aortic Root Reimplantation (David Procedure): A Single-Center Study
B Arabkhani, CM Kievit, WG Morshuis, ML Geleijnse, JJM Takkenberg, AJJC Bogers, 
JA Bekkers
Submitted
197
12. General Discussion and Future Perspectives 217
13. Summary / Samenvatting    241
Acknowledgements / Dankwoord 249
PhD Portfolio 255
List of Publications 259
About the author 263
14570-arabkhani-layout.indd   8 10/05/2017   10:39
14570-arabkhani-layout.indd   9 10/05/2017   10:39
14570-arabkhani-layout.indd   10 10/05/2017   10:39
Chapter 1
Introduction
14570-arabkhani-layout.indd   11 10/05/2017   10:39
14570-arabkhani-layout.indd   12 10/05/2017   10:39
13
1
Cl
in
ica
l o
ut
co
m
e a
nd
 Q
oL
 af
te
r v
al
ve
 sp
ar
in
g 
ro
ot
 re
pl
ac
em
en
t
There are several surgical techniques and various valve prostheses available for the 
treatment of diseased aortic valve and root. The decision-making on the most suitable 
treatment strategy is a challenging and dynamic process. It depends not only on the 
technical complexity of the surgical treatment, but on specific characteristics and 
preferences of the individual patient as well. This thesis intends to evaluate these issues 
and addresses the surgical options currently available. 
THE AORTIC ROOT
The aortic root consists of the three leaflets that form the aortic valve, sinuses of Valsalva. 
The line of closure of the valve is just below the free edge. At the center of the free edge a 
nodular thickening is present, called the nodule of Arantius. The root also includes the left 
and the right ostium from where the coronary arteries arise, as well the three commissures 
(i.e. areas where attachments of two adjacent cusps meet). The normal aortic valve 
contains three cusps and corresponding sinuses of Valsalva (the aortic sinuses). The aortic 
valve is in continuity with the anterior leaflet of the mitral valve and the membranous 
septum, where it is a fibrous layer. The junction where the aortic root continues into the 
tubular aorta is known as the sinotubular junction. 
The aortic valve has a passive movement mechanism, unlike the atrioventricular valves. 
During closure this mechanism ideally prevents backflow of blood by aligning the cusps 
accurately, withstanding systemic blood pressures. The components of the aortic root 
provide the ability for the valve to close during the diastole and to open during the systole, 
thus taking part in the hemodynamic changes of the cardiac cycle.  
Any change in the aortic root that may cause dysfunctional opening of the aortic valve (in 
case of aortic stenosis) and/or closure (in aortic regurgitation) may cause symptoms and 
may be associated with decreased survival, increased morbidity and decreased quality of 
life for the patients involved. 
14570-arabkhani-layout.indd   13 10/05/2017   10:39
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Aortic valve and root disease
Aortic valve dysfunction includes aortic stenosis and aortic regurgitation. 
The etiology of aortic stenosis may be subdivided three categories:  
1) congenital aortic disease, like bicuspid aortic valves, which is associated with a higher 
calcification rate [1], 2) degenerative (calcific) aortic valves, and 3) rheumatic valve disease, 
which is less frequent in the developed countries nowadays. The prevalence of aortic 
stenosis varies from 0.2 percent at 50 to 59 years, to 1.3 percent at 60 to 69,  3.9 percent at 
70 to 79 years, and 9.8 percent at ages 80 to 89 years [2]. The progression of aortic stenosis 
is associated with symptoms of dyspnea on exertion or mostly with exercise intolerance, 
exertional dizziness and/or syncope, and exertional angina pectoris. Aortic valve stenosis 
is the most common heart valve disease with an increasing incidence with age, which has 
a great impact on our health and health care. Patients with symptomatic severe aortic 
stenosis who have not been treated surgically, or, in selected patients, percutaneously, 
have a poor prognosis, with reduced survival [3-5]. Thus, surgical treatment of aortic 
stenosis is recommended in patients with severe, symptomatic aortic stenosis, by 
European and U.S. guideline on valvular heart disease [6, 7]. Percutaneous treatment with 
valve implantation is rapidly developing [8].
Aortic regurgitation of the aortic valve is less common and may or may not be due to a 
dilated aortic root.  Aortic regurgitation accounts for approximately 10% of aortic valve 
surgery and occurs typically at a younger age than aortic stenosis. The etiology of  aortic 
regurgitation is more diverse : 1. congenital disease (bicuspid valves), 2. perforation 
due to (infective) endocarditis, 3. rheumatic disease, 4. root aneurysm (idiopathic or 
associated with connective tissue disease) with deformation of the symmetrical hanging 
points of the valve, and 5. (acute) dissection of the ascending aorta. While sudden aortic 
regurgitation is associated with acute ascending dissection and endocarditis of the aortic 
valve, the more common causes of isolated aortic regurgitation are congenital, bicuspid 
valves and aortic root aneurysm. Patients may not have any symptoms at the beginning 
of aortic regurgitation, but often progressively experience shortness of breath, dyspnea 
on exercise, chronic chest pain, and syncope. The natural history of aortic regurgitation 
depends predominantly on the severity of regurgitation [9]. After onset of symptoms in 
acute severe aortic regurgitation, first year survival is only about 10 to 30 percent [10], 
and could be higher in endocarditis and acute dissection patients. Therefore, guidelines 
on valvular heart disease recommend surgical treatment in case of severe, symptomatic 
aortic regurgitation, and in case of aortic root aneurysm with a root diameter above 
14570-arabkhani-layout.indd   14 10/05/2017   10:39
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55mm in most connective tissue disease and bicuspid aortic valves, or above 50mm with 
additional risk factors (e.g., family history of aortic dissection or aortic growth rate ≥0.5 cm 
per year). In addition, replacement of the ascending aorta of 45mm or greater is reasonable 
in asymptomatic patients with bicuspid aortic valve undergoing aortic valve surgery [11]. 
Additionally, patients with connective tissue disease (e.g. Marfan syndrome) with risk 
factors like; family history of aortic dissection and/or aortic size increase .2 mm/year, 
severe AR or mitral regurgitation, desire of pregnancy; have a lower threshold (≥45mm) in 
favor of operation [6, 7].  
Treatment of aortic root disease 
There are several surgical options to treat aortic valve or root aneurysm. Depending on the 
presence and extent of aortic root dilatation (like in connective tissue disease or in bicuspid 
aortic valves), the valve can be replaced with or without aortic root replacement. Valve 
replacement may be performed with either a mechanical or biological valve substitute. In 
case of aortic root replacement the “gold standard” has been composite valve replacement 
(the Bentall procedure; i.e. tube graft with mechanical valve prosthesis) [12]. Biological 
valve substitutes include stented and stentless bioprostheses, allografts (i.e. aortic root 
replacement by a human donor aortic root) [13], and the pulmonary autograft procedure 
(i.e. Ross procedure; replacement of the aortic root with patients’ own pulmonary valve 
and implantation of a biological conduit in pulmonary position) [14]. In addition, in 
case of aortic regurgitation with or without root aneurysm, aortic valve repair or a valve 
sparing aortic root replacement is possible, where the patients native valve is preserved 
and a (partial) prosthetic tube graft replaces the aortic root [15, 16]. Young female patients 
with a child wish require special attention, since the type of therapy used in these patients 
is associated with both mother and fetal outcome [17], as the physiological adaptations 
to pregnancy influence the cardiac function and clinical status (e.g., an increased risk of 
thrombo-embolism and alternated pharmacokinetics with increased intravascular blood 
volume). In addition, in the last decade transcatheter aortic valve implantation (TAVI) has 
become available as an alternative to surgical aortic valve replacement (SAVR). TAVI was 
intended for those patients who are not surgical candidates due to comorbidity [18, 19] 
and frailty,  but, at present TAVI is associated with a relatively higher incidence of valve 
related complications than conventional surgical valve replacement [20]. However, the 
use of TAVI is expected to increase in the next years as indications for the use of this 
therapeutic strategy widen [21]. Chapter 2 will discuss the surgical options for aortic valve 
and root disease in further detail.
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FIGURE 1. Different types of valve prosthesis. A: Mechanical valve; B: Stented bio-prosthesis; C: Stentless bio-prosthesis
 
FIGURE 2. Different prosthesis/techniques for aortic root replacement. A: Bentall (mechanical) valve prosthesis; B: 
Allograft; C: Pulmonary autograft (Ross); D: Valve sparing root replacement (a: Yacoub procedure; b: David procedure)
Quality of life after aortic valve surgery and choice of surgical treatment
Apart from clinical results, an important outcome after aortic valve surgery is patient 
quality of life. In this regard a technically well performed operation is a prerequisite for 
good outcome.  However, individual patient-preference and specific life expectation after 
aortic valve surgery must be taken into account while choosing the optimal treatment. It is 
obvious that a young patient with contraindication for anticoagulation therapy is not a good 
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candidate for mechanical valve prosthesis. Nevertheless, relatively young patients with a 
very active lifestyle may have a better quality of life with a biological valve, although at cost 
of a reoperation later in life [22]. An important tool for measuring quality of life experienced 
by patients is the Short Form Health Survey (SF-36) questionnaire, where both physical and 
mental health of patients is assessed and may be compared to the general population [23]. 
Evidence on quality of life after aortic valve and root surgery may help the clinicians and 
patients to further tailor an individual treatment to the individual patient taking into 
account clinical outcome as well as patient preference. Quality of life after aortic valve 
surgery is addressed in Chapter 11. 
Objectives of this thesis
This thesis aims to provide insight into clinical outcome after surgery on the aortic valve 
and root for a variety of indications (valve stenosis, regurgitation, infective endocarditis, 
root aneurysm). Early and late clinical outcome, as well as quality of life will be addressed, 
with special attention to young adult patients after aortic valve or root surgery. 
Various types of surgical treatment; valve replacement with biological and mechanical 
prosthesis, and valve sparing root replacement techniques will be presented. Moreover, 
echocardiographic parameters and patient characteristics associated with valve related 
outcome are investigated. In addition, quality of life after aortic valve or root surgery and 
decision making and patient selection is addressed.
OUTLINE
Chapter 2 provides an overview of indications for surgery in aortic regurgitation, surgical 
options, and subsequent outcomes after aortic valve repair and replacement.
In Chapter 3 a systematic review of literature and a meta-analysis was performed to 
outline the occurrence rate of valve related outcome after composite valve replacement 
in patients with aortic root disease.
Chapter 4 is a systematic review and microsimulation after mechanical aortic valve 
replacement in young adolescents estimating the occurrence rate of valve related 
outcome in time.
14570-arabkhani-layout.indd   17 10/05/2017   10:39
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In Chapter 5 a systematic review of literature and a meta-analysis was undertaken on 
outcome after valve sparing aortic root replacement (both David and Yacoub procedure) 
in relatively young patients, presenting an overview and testing surgical technique as well 
as variables associated with valve related outcome. 
In Chapter 6 a systematic review and meta-analysis with microsimulation modeling 
provides an overview on outcome after aortic root replacement with biological valve 
prosthesis in elderly.
Chapter 7 provides insight into long-term outcome after aortic valve replacement with 
allografts in a prospective single center study and studies potential echocardiographic 
factors for the prediction of reoperation and death in a joint model.
In Chapter 8 and Chapter 9 the use of allografts in the setting of pregnancy is studied: 
Chapter 8 studies the association between pregnancy and allograft durability while 
chapter 9 addresses challenges and complications that heart valve recipients may 
experience during pregnancy.  
Chapter 10 describes the difference between conservative treatment and surgery 
regarding symptomatic patients with severe aortic stenosis and timing of the operation.
Chapter 11 describes early and late outcome (reimplantation technique), 
echocardiographic changes in valve function during follow-up, and the reported quality 
of life after valve sparing aortic root replacement.
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Chapter 2
The long term results of aortic valve repair 
and replacement (Chapter 10, pages 
473-491, from “Aortic Regurgitation”)
 
B. Arabkhani , J.J.M. Takkenberg
Vojáček J., Žáček P. and Dominik J., October 2016, Aortic Regurgitation, 
Skladem, Czech Republic, GRADA (ISBN: 978-80-247-5685-1) 
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INTRODUCTION
The gold standard for surgical treatment of aortic regurgitation is aortic valve or root 
replacement with either a mechanical or biological valve substitute. However, in the 
past decades several surgical approaches aimed at preserving the aortic valve have been 
introduced, and gain popularity. This chapter aims to describe the long-term results of 
aortic valve repair and replacement in the setting of aortic regurgitation. In order to 
adequately understand long-term results of aortic valve repair it is important to realize that 
patient outcome after surgical treatment of aortic regurgitation is determined by patient 
related factors, timing of surgery and procedural factors which are often interrelated. 
This makes prognostication challenging. Nevertheless in this chapter we attempt to take 
all these factors into account in describing indications for surgery, surgical options, and 
subsequent outcomes after aortic valve repair and replacement.
Indications for surgery in aortic regurgitation
According to 2012 ESC/EACTS guidelines on the management of valvular heart disease 
all patients with severe aortic regurgitation who are experiencing symptoms have an 
indication for aortic valve surgery, as do asymptomatic patients with a resting LVEF < 
50% and patients who require CABG or surgery of the ascending aorta or another valve. 
In addition, surgery should be considered in asymptomatic patients with a resting EF > 
50% with severe LV dilatation [1]. The 2014 AHA/ACC guidelines for the management of 
patients with valvular heart disease echo most of these recommendations, and add that 
surgery is reasonable in patients with moderate aortic regurgitation while undergoing 
surgery on the ascending aorta, CABG, or mitral valve surgery [2] 
According to the ESC/EACTS guidelines in Marfan patients with a a maximal ascending 
aorta diameter ≥ 50 mm, regardless of the severity of aortic valve regurgitation, surgery 
is indicated with. Surgery should be considered in patients who have aortic root disease 
with maximal ascending aortic diameter of ≥45 mm for patients with Marfan syndrome 
with risk factors (family history of aortic dissection and/or aortic size increase .2 mm/year, 
severe AR or mitral regurgitation, desire of pregnancy), ≥50 mm for patients with bicuspid 
valve with risk factor (coarctation of the aorta, systemic hypertension, family history of 
dissection or increase in aortic diameter .2 mm/year), and ≥55 mm for other patients. The 
AHA/ACC guidelines slightly deviate from the European guidelines regarding intervention 
in patients with bicuspid valve and ascending aortic dilatation by stating that an operative 
14570-arabkhani-layout.indd   25 10/05/2017   10:39
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intervention to repair the aortic sinuses or replace the ascending aorta is indicated in 
patients with a bicuspid aortic valve if the diameter of the aortic sinuses or ascending 
aorta is greater than 5.5 cm. In addition, they state that an operative intervention to repair 
the aortic sinuses or replace the ascending aorta is reasonable in patients with bicuspid 
aortic valves if the diameter of the aortic sinuses or ascending aorta is greater than 5.0 cm 
and a risk factor for dissection is present (family history of aortic dissection or if the rate 
of increase in diameter is ≥0.5 cm per year), and that replacement of the ascending aorta 
is reasonable in patients with a bicuspid aortic valve who are undergoing aortic valve 
surgery because of severe AS or AR if the diameter of the ascending aorta is greater than 
4.5 cm.
Surgical options
There are several surgical options to treat AR. The gold standard is valve replacement 
with or without aortic root replacement, depending on the presence and extent of aortic 
root dilatation. Valve replacement can be done with either a mechanical or biological 
valve substitute. Biological valve substitutes include stented and stentless bioprostheses, 
homografts, and the Ross procedure. In addition, AR can be treated by repairing the 
valve or by valve sparing aortic root replacement. All surgical options carry a number of 
advantages and disadvantages that are detailed in Table 1. Both the European and the 
US guidelines state that when it comes to choosing any of these options, this should be 
a shared decision-making process that accounts for the patient’s values and preferences, 
with full disclosure of the indications for and risks of anticoagulant therapy and the 
potential need for and risk of reoperation [1, 2].
Mechanical valve prostheses 
Since the first successful mechanical valve (i.e. the so called caged-ball valves) was 
designed in the mid-1960s by pioneers M. Lowell Edwards and Albert Starr [3, 4] 
tremendous improvements have been made in the design of mechanical valves. Nowadays 
the most popular mechanical valve prostheses are bileaflet mechanical valves. The main 
advantage of mechanical valve prostheses is their outstanding durability, and therefore 
low -although not absent- risk of reoperation. On the downside, because of the increased 
thrombogenicity of mechanical valve prostheses life-long use of anti-coagulation therapy 
is necessary in order to prevent valve thrombosis and other thromboembolic events. 
Anticoagulation therapy is associated with an increased bleeding risk, and currently 
available anticoagulants require frequent monitoring of the level of anticoagulation and 
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if necessary adjustment of anticoagulation dose. Another feature of mechanical valve 
prostheses is the characteristic ticking closing sound of the valve that may be heard by 
the patient and/or others. This sound can be perceived anywhere between very positive 
(“knowing that the valve is working well”) and very negative (“the sound is driving me crazy”). 
When aortic valve regurgitation and aortic root dilatation are both present, the “gold 
standard” surgical treatment is composite valve graft replacement, better known as the 
Bentall procedure that involves complete replacement of the aortic valve and ascending 
aorta with a tube graft containing a mechanical valve prosthesis [5, 6]. It is also possible 
to use a bioprosthesis when performing a Bentall procedure, the so-called bio-Bentall 
procedure.
TABLE 1. Surgical options for the treatment of AR: advantages and disadvantages
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expertise required
- - +/- + ++ ++
Durability Excellent Limited Limited Limited Limited Limited
AC required? Yes No No No No No
Valve sound Yes No No No No No
Hemodynamics Adequate Adequate Good Good Excellent Excellent
According to current ESC/EACTS guidelines on the management of valvular heart disease, 
a mechanical valve prosthesis is recommended according to the desire of the informed 
patient and if there are no contraindications for long-term anticoagulation, in patients at 
risk of accelerated structural valve deterioration (SVD) or those already on anticoagulation 
therapy as a result of having a mechanical prosthesis in another valve position. A 
mechanical prosthesis should be considered in patients aged younger than 60 years, in 
patients with a reasonable life expectancy for whom future redo valve surgery would be 
of high risk. Finally, a mechanical prosthesis may be considered in patients already on 
long-term anticoagulation due to high risk of thromboembolism [1]. The US AHA/ACC 
guidelines are in agreement with the European guidelines.
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Biological valve substitutes
Biological valve substitutes include stented and stentless bioprostheses, homografts, and 
the Ross procedure. The main advantage of biological valve substitutes as depicted in 
Table 1 is their absent need for anticoagulation therapy and thus the avoidance of bleeding 
complications associated with anticoagulant use. On the downside, all biological valves 
have a limited durability that may necessitate a re-intervention later in life. Nowadays 
biological valves are increasingly being used in patients under the age of 65 years. In 2004, 
30% of patients aged 60-65 years who underwent AVR in the United Kingdom received 
a biological valve; this has increased to 60% in 2008  and this number is increasing [7, 8].  
Stented bioprostheses are the most commonly used biological valve substitutes. This 
prosthesis type is composed of a sewing ring and an artificial frame in which porcine, 
bovine or equine pericardial leaflets are suspended. The prosthesis is relatively easy to 
implant and since its introduction in 1965 by Carpentier et al [9], it is widely used in mainly 
older adults [10].
Stentless bioprostheses form good alternative to stented bioprostheses as they have better 
hemodynamics and may also be used to replace the aortic root. They are especially useful 
in patients with a relatively small aortic annulus to avoid prosthesis-patient mismatch as 
stentless bioprostheses have a larger effective orifice area (EOA) which provides lower 
transvalvular gradients resulting in improved reduction of left ventricular hypertrophy 
[11]. However, a disadvantage of stentless bioprostheses is that they require some surgical 
expertise and are more time-consuming to implant. 
Homografts or human donor valves were introduced in the early 1980’s a good alternative 
for bioprostheses, expecting they would have better hemodynamics, increase infection 
resistance and superior durability compared to bioprostheses. Due to their favorable 
tissue characteristics they can be either implanted using a subcoronary technique, 
replacing only the valve, or as a root replacement. In more recent years it has become 
apparent that homograft durability is comparable to bioprostheses [12]. This, and the 
fact that homografts are not readily available “of the shelf”, has resulted in that nowadays 
homografts account for less than 1% of AVRs and are used almost exclusively in case of 
active endocarditis with complex root pathology [13], where excess homograft tissue can 
be used to repair tissue defects caused by endocarditis. 
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Pulmonary autograft valve replacement, better known as the Ross procedure, was 
introduced by Donald Ross in 1967 and entails replacement of the diseased aortic valve 
by the patient’s own pulmonary valve with concomitant pulmonary valve replacement 
usually with a homograft or bovine jugular vein [14]. Being the only living biological valve 
substitute it has become an alternative option for aortic valve replacement in children 
and young adult patients [14-16]. As with other biological valves, the advantage of the 
autografts lies in the absent need for anticoagulation therapy and the related complications. 
In addition, the hemodynamic performance of pulmonary autograft valves is superior to 
other biological and mechanical valve substitutes, and in the growing child the autograft 
increases in size proportional to the growth of the child [17]. On the downside, the Ross 
procedure is a complex procedure that should only be performed by trained surgeons in 
specialized centers. In addition, when performed as a root replacement the neo-aortic 
root tends to dilate over time with an increasing need for reintervention in the second 
postoperative decade. Finally, the valve substitute in pulmonary position may degenerate 
and require reintervention, although less common in adults [18]. The Ross procedure is 
discussed more comprehensively in a dedicated chapter in this book.
According to the European ECS/EACTS guidelines a bioprosthesis is recommended 
according to the desire of the informed patient, when good quality anticoagulation is 
unlikely (compliance problems; not readily available) or contraindicated because of high 
bleeding risk (prior major bleed; comorbidities; unwillingness; compliance problems; 
lifestyle; occupation), and for reoperation for mechanical valve thrombosis despite good 
long-term anticoagulant control. In addition, a bioprosthesis should be considered 
in patients for whom future redo valve surgery would be at low risk, in young women 
contemplating pregnancy, and in patients aged >65 years or those with life expectancy 
lower than the presumed durability of the bioprosthesis. The AHA/ACC guidelines 
agree mostly, and add that a bioprosthesis is reasonable in patients >70 yrs, and both a 
mechanical and bioprosthesis are reasonable between ages 60-70 years [2].
The ESC/EACTS guidelines do not give specific recommendations for the use of homografts 
but state that, although under debate, the main indication for homografts is acute 
infective endocarditis with perivalvular lesions [1]. With regard to the Ross procedure the 
ESC/EACTS guidelines do not give specific recommendations either, but the AHA/ACC 
guidelines recommend that replacement of the aortic valve by a pulmonary autograft 
valve, when performed by an experienced surgeon, may be considered in young patients 
when VKA anticoagulation is contraindicated or undesirable. [1, 2]. 
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Aortic valve repair and valve preserving aortic root replacement
Although outcome after AVR has improved over the past decades, the concerns about 
prosthetic valve-related complications such as SVD, thromboembolism and valve 
thrombosis, bleeding, and endocarditis remain. In this light several reconstructive 
methods have been developed to treat AR and/or preserve the aortic valve in the setting 
of aortic root dilatation, mainly based on repairing the native aortic valve, and/or sparing 
the valve while replacing or stabilizing the other components of the aortic root [19-21]. 
These different surgical techniques are discussed extensively in other chapters of this 
book. 
As with biological prostheses, the main advantages of aortic valve repair and valve 
preserving aortic root replacement are the absent need for anticoagulation. In addition, 
hemodynamic function is excellent. On the downside, specific surgical expertise is required 
as these procedures are technically more demanding compared to standard aortic valve 
replacement. Also, durability is limited, and patients may need a reoperation later in life. 
Neither the ESC/EACTS not the AHA/ACC guidelines provide recommendations for the 
reconstructive methods that have been developed to treat AR and/or preserve the aortic 
valve in the setting of aortic root dilatation
Reported outcome after aortic valve replacement and valve repair
In order to adequately understand long-term results of aortic valve replacement and 
repair it is important to realize that patient outcome after surgical treatment of aortic 
regurgitation is not only determined by valve replacement or repair approach but also 
by patient related factors, timing of surgery and procedural factors which are often 
interrelated. This makes prognostication challenging.
Patient related factors that play a prominent role in the outcome after aortic valve surgery 
include patient age, preoperative NYHA class, hemodynamic diagnosis, the need for 
concomitant CABG, and heart rhythm. In the landmark paper by Kvidal et al. [22] it was 
shown that although older patient age seems to be associated with increased observed 
late mortality, younger patient age is associated with increased relative late mortality 
compared to the age-matched population: in AVR patients younger than 50 years 
observed mortality was 4.5 times higher than would be expected in the age-matched 
general population, while AVR patients over the age of 70 years showed a life expectancy 
comparable to the general population. These observations can be explained by the more 
severe phenotype of valve disease in younger patients, and at the same time by the more 
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stringent selection that takes place for AVR in the elderly. The same paper showed that a 
higher preoperative NYHA class, the presence of atrial fibrillation, and the hemodynamic 
diagnosis of aortic regurgitation versus aortic stenosis were all important determinants 
of increased late mortality. It should be noted that survival after aortic valve replacement 
in non-elderly adult patients has improved significantly over the past few decades [23], 
and this also applies to patients with aortic regurgitation, even for those with severe left 
ventricular dysfunction [24].
Timing of surgery is another crucial determinant of both early and late outcome after 
aortic valve surgery. Patients who present urgently and patients who present late in their 
disease process do worse than elective patients with relatively early symptoms and signs 
of disease. The question is: how early should we treat? Earlier surgery on the one hand will 
deal with some of the patient related factors mentioned above. However, on the other 
hand all surgery carries early operative risks, and in the setting of aortic valve surgery 
late (prosthetic) valve related complications.  Procedural factors may also have an impact 
on outcome after aortic valve surgery: for example concomitant cardiac surgery carries a 
higher operative risk than isolated aortic valve surgery, while the need for multiple valve 
surgery and/or CABG will increase both early and late morbidity and mortality.
Outcome after valve replacement and repair is defined by the 2008 AATS/STS/EACTS 
guidelines for reporting morbidity and mortality after cardiac valvular interventions [25]. 
These guidelines help us to uniformly report on outcome after valve surgery and provide 
us a tool to compare the results after valve surgery in a structural manner. 
Reported outcomes after mechanical valve implantation and Bentall procedure
Early mortality after mechanical AVR is on average below 2% in non-elderly adults [26] 
while early mortality after a mechanical Bentall procedure is considerably higher, on 
average 6% [27]. In patients after mechanical valve AVR reported annual occurrence 
rates of major bleeding, thromboembolism, and valve thrombosis are 1.6%, 1.6% and 
0.16% per patient-year respectively; endocarditis rates are 3.9% per patient-year in the 
first 6 postoperative months and  0.66% per patient-year after the first 6 postoperative 
months; reoperation rates (due to non-structural valve deterioration) are 0.29% per 
patient-year [26]. Using microsimulation these annual occurrence rates can be translated 
to life time risks of complications for patients of different ages. These life time risks for the 
most commonly occurring complications after mechanical AVR, bleeding and thrombo-
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embolism, are detailed in Figure 1. This Figure illustrates that although annual occurrence 
rates appear low, they translate to considerable lifetime risks of bleeding and thrombo-
embolism.
FIGURE 1. Lifetime risk of major bleeding and thrombo-embolism after mechanical aortic valve replacement for 
different patient ages at the time of valve implantation (From Puvimanasinghe et al. Heart, 2004) [26] 
In patients after the Bentall procedure an average aortic root reoperation rate of 0.46% 
per patient-year and an aortic valve reoperation rate of 0.30% per patient-year is reported. 
Reported bleeding and thrombo-embolic event rates are 0.64%, and 0.77% per patient-
year respectively, while endocarditis rates are 0.39%, [27]. Although bleeding and 
thrombo-embolic event rates appear lower after Bentall compared with mechanical AVR, 
a direct comparison of the groups is hampered by differences in patient age, etiology, and 
by potential bias caused by the predominantly retrospective study designs of the reports 
that were combined to obtain these estimates. Nevertheless, bleeding and thrombo-
embolism also represent the most common complications after the Bentall procedure, 
and result in considerable lifetime risks of major bleeding and thrombo-embolism for 
these predominantly young adult patients.
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Reported outcomes after stented bioprosthetic aortic valve replacement
As would be expected, compared to mechanical prostheses reported major bleeding event 
rates are lower (although not absent) after stented bioprosthetic valve implantation, but 
interestingly thrombo-embolic event rates appear comparable at first sight. A systematic 
review of reported outcome after AVR with two common stented bioprostheses (Carpentier 
Edwards (CE) pericardial and supra-annular bioprostheses) report major bleeding event 
rates of  0.43 and 0.46% per patient year respectively, major thrombo-embolic event rates 
of 1.35 and 1.76% per patient-year and valve thrombosis event rates of 0.03 and 0.02%/
patient year respectively. When interpreting these event rates one should realize that 
bioprosthetic valve recipients are on average approximately 15 year older compared to 
mechanical valve recipients, more often have atrial fibrillation requiring anticoagulation, 
and a higher baseline bleeding and thrombo-embolic event hazard as this is observed to 
increase with age in the general population.  Endocarditis and reoperation rates for non-
structural valve failure are reportedly 0.62 and 0.39%/patient year and 0.13 and 0.61%/
patient year respectively for CE pericardial and supra-annular bioprostheses.  SVD is the 
major downside of stented bioprostheses; it cannot simply be depicted in an annual event 
rate as the hazard of SVD increased with the time since the operation and is inversely 
related to patient age at the time of operation: in particular younger patients have a very 
high lifetime risk of reoperation for SVD which can be explained by the fact that they live 
longer than older patients but also by the observation that older patients are less likely to 
be referred for redo surgery. Figure 2 illustrates the lifetime risks of reoperation for SVD for 
male stented bioprosthetic valve recipients of different ages at implantation.
Reported outcomes after stentless bioprosthesis aortic valve replacement
SVD of stentless bioprostheses is age-dependent and comparable to stented aortic 
bioprostheses, as depicted in Figure 3. Estimated annual occurrence rates of major 
bleeding, thrombo-embolism and valve thrombosis for one of the most commonly used 
stentless bioprostheses (Medtronic Freestyle stentless bioprosthesis) are 0.28%, 2.9% and 
0.04% per patient year respectively, while endocarditis and reoperation for non-structural 
valve failure have an annual hazard of 0.45%  and 0.28% per patient year [28].
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FIGURE 2. Lifetime risk of reoperation for SVD with CE pericardial (CEP) and supra-annular bioprostheses (CESA) for 
male patients of different ages at implantation.
 
FIGURE 3. Weibull estimates of freedom from reoperation for SVD for a 65-year-old male after implantation with an 
allograft valve, a Carpentier Edwards pericardial valve, a Carpentier Edwards supra-annular valve or a stentless Freestyle 
valve (From Kappetein et al. Interact Cardiovasc Thorac Surg., 2006) [28]. 
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Reported outcomes after homograft aortic valve and root replacement
The latest report of the Rotterdam prospective cohort study [13] shows an early mortality 
of 5.8% after homograft implantation in 353 patients with a mean age of 45 years. This 
is considerably higher than in standard aortic valve replacement with mechanical or 
bioprosthetic valves, but can be explained by the high proportion of complex patients 
(endocarditis, aneurysm, dissection, often urgent operations). Estimated annual 
occurrence rates of major bleeding, thrombo-embolism and valve thrombosis are 
reportedly 0.1%, 0.5% and 0% per patient year respectively, while endocarditis rates of 
0.33% per patient year illustrate the resistance of homografts to infection. The SVD pattern 
of homografts appears comparable to stented and stentless bioprostheses, as illustrated 
in Figure 3, and younger patient age is associated with a shorter time to reoperation for 
SVD. However, the only randomized controlled trial comparing homografts with Freestyle 
stentless bioprostheses shows significantly less progressive aortic valve dysfunction and 
reoperations with the Freestyle valve [30]. 
Reported outcomes after the Ross procedure 
Although initially there was concern about high early operative mortality after the Ross 
procedure, several short and mid-term studies have proven that in experienced hands in 
dedicated centers this procedure can be performed with low operative risk and survival 
rates comparable to the general population [31-33]. A comprehensive systematic review 
(12 observational studies in 1749 adult patients, mean age ranging from 28-51 years) 
showed an early mortality risk of 3.04% and a late mortality rate of 0.48% per year[34]. 
The excellent observed survival rates may be explained by the excellent hemodynamic 
characteristics of the only living valve substitute available today [33]. On the other hand, 
there is also evidence that through optimization of anticoagulation management in 
mechanical valve prosthesis recipients, a survival pattern comparable to Ross patients 
can be achieved [35]. Freedom from autograft reoperation has been reported to range 
between 69% and 99% after 10 to 13 years of follow-up, depending on which surgical 
technique has been used[31, 33, 36, 37]. The results of the comprehensive systematic 
review showed a linearized rate of 1.15%/patient year for structural and nonstructural 
autograft failure leading to reoperation [34]. Application of proven durable autograft 
implantation techniques are crucial for the durability results after the Ross procedure. In 
addition, patient characteristics may also play a role: younger patient age [32], congenital 
aortic valve disease [38], rheumatic valve disease[39], and preoperative AR [40] and 
dilatation [32] are the most commonly reported patient-related determinants of durability 
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of the autograft valve. However, even if the durability of autografts is less in patients with 
preoperative AR, the decision whether to perform the Ross procedures depends also on 
technical considerations and informed patient preferences, and the option of the Ross 
procedure should not upfront be discarded [41]. Freedom from pulmonary allograft 
reoperation is reported to range between 87% and 96% after 10 to 13 years of follow-
up [31, 33]. The pooled structural or non-structural pulmonary allograft failure has been 
shown to be 0.91% per year [34]. Autograft endocarditis occurs with a rate of 0.32% 
per year, ranging between 0.04% and 0.70% between different studies [34]. Pulmonary 
allograft endocarditis has been reported to range between 0.04% and 0.69% per year for 
different studies with a pooled estimate of 0.32% per year [34].
Further details on the autograft operation is given elsewhere in this book. 
Reported outcomes after valve sparing aortic root replacement 
A recently published systematic review and meta-analyses of 31 articles published 
between 2000 and 2014 on valve sparing aortic root replacement [42] showed a pooled 
early mortality of 2%, and a late mortality rate of 1.53% per patient-year. Additionally 
a reoperation rate of 1.32% per patient-year was reported. Thromboembolism and 
hemorrhagic event rates were estimated to be 0.23% and 0.41% per patient-year, 
respectively. Reported pooled endocarditis rates were 0.21% per patient-year. Importantly, 
preoperative severe aortic valve regurgitation showed a trend toward higher reoperation 
rates, while remodeling and reimplantation techniques show comparable survival and 
valve durability results. Obviously, given the limited follow-up duration of studies in this 
review, these results can only be applied to the first postoperative decade, and longer 
follow-up studies are needed to assess durability in the longer term.
Another systematic review (11 publications) in 1385 Marfan patients that compared total 
root replacement with valve sparing root replacement, has shown a reintervention rate 
of 0.3%/year versus 1.3%/year while thromboembolic events rate was 0.7%/year versus 
0.3%/y, respectively. Among patients undergoing valve sparing aortic root replacement, 
the reimplantation technique was associated with a reduced rate of reintervention 
compared with the remodeling technique (0.7%/year vs 2.4%/year) [43].
Aortic valve preservation and repair in the setting of acute type A dissection has been 
nicely summarized in a systematic review of  19 observational studies concerning 2402 
patients (median age 59 years) with a median follow-up of 4.1 years. AV resuspension 
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was performed in 95% of the patients and the remainder underwent valve-sparing root 
replacement. Pooled early mortality rate was expectedly considerable, 18.7%, as was 
the late mortality rate of 4.7%/pt-yr. Aortic valve reintervention rate was 2.1%/year. The 
composite rate of thromboembolism and bleeding was 1.4%/year [44].
Reported outcomes after aortic valve repair
Aortic valve repair is currently in transition from surgical improvisation to a reproducible 
operation and an option for many patients with aortic regurgitation [45]. It is therefore not 
surprising that reports on outcomes are small, of limited follow-up duration and usually 
concern specific patient subcategories and varying surgical repair techniques. A few 
reports are worth mentioning. 
A large series from Germany reports on 640 patients undergoing aortic valve repair 
for regurgitation of a unicuspid, bicuspid, tricuspid or quadricuspid aortic valve. The 
mechanism of regurgitation included prolapse, cusp retraction, and/or root dilatation. 
Treatment consisted of cusp repair (n=529), root repair (n=323) or a combination of both 
(n=208). Hospital mortality was 3.4% in the total patient cohort and 0.8% for isolated 
aortic valve repair. Thrombo-embolism rate was 0.2% per patient year, endocarditis rates 
0.16%per patient year. Freedom from re-operation at 10 years was 81% in bicuspid and 
93% in tricuspid aortic valves (p<0.001), showing an impaired durability in bicuspid 
versus tricuspid valves [46]. This case series nevertheless nicely shows that reconstructive 
surgery of the aortic valve is feasible with low mortality in many individuals with aortic 
regurgitation. 
A more recent report from the same group that focused on bicuspid aortic valve repair it 
was shown that preservation of the bicuspid aortic valve results in good long-term stability 
of the repaired valves, and that the negative impact of a dilated atrioventricular junction 
can be reduced by suture annuloplasty [47]. This group has also shown that in patients 
with a unicuspid aortic valve the concept of valve bicuspidization and root remodeling 
can be applied with satisfactory hemodynamic results [48].
Finally, a multicenter European collaboration recently showed that neo-aortic valve sparing 
reoperations after the Ross procedure may be performed with limited early morbidity and 
mortality in most patients. This approach provides patients with the continued benefit of 
a functioning autograft valve. However, the need for reintervention after valve-sparing 
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reoperation is common in the first 2 postoperative years in patients with isolated and/
or severe autograft regurgitation; careful consideration of the surgical approach in these 
patients is warranted [49].
The observed lack of standardization in data reporting concerning outcomes after 
valve sparing aortic root replacement, and the sparsity of available outcome data after 
aortic valve repair have led to an international prospective multicenter registry for 
aortic valve-sparing/repair and replacement surgical procedures called AVIATOR (www.
heartvalvesociety.org). AVIATOR aims to provide sufficient patient numbers to address key 
epidemiological and therapeutic issues and standardize indications for surgery as well as 
the place of repair versus replacement in aortic valve surgery.
Quality of life after aortic valve surgery
The main goal of aortic valve surgery is not only optimizing clinical outcomes but also 
patient quality of life. It is therefore important in choosing a particular surgical strategy 
to consider the available evidence on quality of life after aortic valve surgery. Koch et 
al showed an improved quality of life after aortic valve surgery in particular in patients 
with an impaired quality of life before surgery. Interestingly, patients with relatively 
high preoperative quality of life had little quality of life to gain after surgery, and more 
importantly: a lot to lose [46, 50]. Quality of life may differ between the different valve 
surgery options: Ruel et al observed in young adult patients with mechanical valve 
substitutes a lower physical capacity; a higher prevalence of disability; and poorer 
disease perception compared to bioprosthetic valve recipients [51]. In their landmark 
study concerning mechanical valve recipients, Ross procedure patients and patients 
who underwent aortic valve repair, Aicher et al have demonstrated that Ross procedure 
patients and aortic valve repair patients have better physical functioning, general health 
and mental health, and less cardiac anxiety compared to mechanical valve recipients [52]. 
These observations underline the importance of considering patient preferences and 
quality of life when choosing a surgical strategy.
Selecting the optimal treatment for the individual patient with AR
Unfortunately, the ideal non-thrombogenic, infection-resistant, living autologous 
valve substitute with excellent hemodynamics and an unlimited durability is not yet 
available. In real life, the available aortic valve substitutes are associated with one or 
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more disadvantages. Valve repair or preservation offers an attractive biological solution 
in selected patients with aortic regurgitation and/or aortic root disease, but also have 
limitations as detailed above. 
In selecting the optimal treatment for the individual patient one needs to consider 
evidence on outcome after the different available treatment options, individual patient 
characteristics, and importantly informed patient preferences. The choice between a 
mechanical or a biological surgical strategy is ideally driven by the anticipated valve-
related morbidity of each strategy, and patient valuation of this morbidity:  some patients 
may highly value a life without anticoagulation therapy, while others may wish to avoid 
a potential reoperation due to valve failure at any cost. The failure to consider patient 
preferences may negatively affect patient quality of life. Of course, there are patients in 
whom objective assessment of their clinical condition leaves little room for alternative 
treatment strategies. However, in the majority of patients there are multiple options 
that should ideally be discussed with the patient, informing the patient and allowing 
the patient to participate in the decision. Ideally, a choice is made in a process of shared 
decision making that allows patients to be informed about their options, weigh these 
options in their own context, invited them to participate in decision making, and finally 
come to a decision together with their treating physician [53].
The continuous improvement of heart valve prostheses and aortic valve repair and 
valve sparing aortic root replacement techniques will certainly help to optimize patient 
outcome after aortic valve surgery. In particular for patients with aortic regurgitation 
the recently established international AVIATOR registry (www.heartvalvesociety.org) 
that aims to collect and share real life data on the characteristics and outcomes of valve 
preserving and valve replacement strategies in the setting of aortic regurgitation and/or 
aortic root dilatation, will provide an important knowledge platform concerning optimal 
individualized patient tailored surgical strategies to treat aortic regurgitation.
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Chapter 3
Bentall Procedure:
a Systematic Review and Meta-Analysis
Aart Mookhoek, Nelleke M Korteland, Bardia Arabkhani, Isabelle Di Centa, 
Emmanuel Lansac, Jos A Bekkers, Ad JJC Bogers, Johanna JM Takkenberg
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ABSTRACT
Background. The Bentall procedure is considered the gold standard in treatment of 
patients requiring aortic root replacement. An up-to-date overview of outcome following 
the Bentall procedure is lacking.
Methods. We conducted a systematic review and meta-analysis of characteristics of 
and long-term outcome after the Bentall procedure with a mechanical valve prosthesis. 
Pooling was performed using the inverse variance method within a random-effect model. 
Outcome events are reported as linearized occurrence rates (percentage per patient year) 
with 95% confidence intervals.
Results. In total, 46 studies with 7629 patients (mean age 50 years, 76% males) were 
selected. Pooled early mortality was 6% (422 patients). During a mean follow-up of 6 
years (49,175 patient years), the annual linearized occurrence rate for late mortality was 
2.02% (1.77% - 2.31%; 892 patients), for aortic root reoperation 0.46% (0.36% - 0.59%), 
for hemorrhage 0.64% (0.47% - 0.87%), for thromboemboli 0.77% (0.60% - 1.00%), for 
endocarditis 0.39% (0.33% - 0.46%) and for major adverse valve-related events 2.66% 
(2.17% - 3.24%). Operations performed in more recent years were associated with lower 
rates of aortic root reoperation (beta = -0.452, P=0.015).
Conclusion. This systematic review illustrates that rates of aortic root reoperation after 
the Bentall procedure have decreased over the years. However, late mortality, major 
bleeding and thromboembolic complications remain a concern. This report may be used 
to benchmark the potential therapeutic benefit of novel surgical approaches, such as 
valve-sparing aortic root replacement.
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INTRODUCTION
The Bentall procedure is considered the gold standard in treatment of patients requiring 
aortic root replacement. Since its introduction, novel surgical techniques and approaches 
have changed the Bentall procedure considerably [1]. While the original procedure was 
associated with a high incidence of coronary button complications, several modifications 
have been proposed to tackle this problem [2, 3]. The vast majority of Bentall procedures 
concerns replacement of the aortic root with a mechanical valved conduit. The use of 
a mechanical valve provides a durable solution, but requires life-long anticoagulation 
associated with increased bleeding risk.
Surprisingly, an up-to-date overview of outcome following the Bentall procedure is 
lacking, as most reports are single center and usually concern limited numbers of patients. 
Pooling data from the literature will allow individual centers or surgeons to benchmark 
their experience. More importantly, it is key to allow for assessment of the potential 
therapeutic benefit of novel techniques such as valve-sparing aortic root replacement 
[4]. This study comprises a systematic review and meta-analysis of published evidence 
on characteristics of and outcome after the Bentall procedure using a mechanical valve 
prosthesis.
METHODS
Search Strategy
On July 20th 2015, a systematic literature search was conducted in Embase, MEDLINE, 
The Cochrane Collaboration and Web of Science (Appendix 1). All studies published from 
January 1998 onwards were screened by two independent reviewers (AM and NMK) using 
the following inclusion criteria: morbidity and mortality after the Bentall procedure with 
a mechanical valve prosthesis, cohorts ≥ 30 patients and mean age ≥ 18 years. Exclusion 
criteria were: studies limited to patients with acute type A aortic dissection, studies limited 
to reoperations or to patients receiving a biological valve prosthesis, studies with mean 
follow < 4 years and studies reporting state of the art, case reports, experimental studies 
and reviews. In case of multiple publications on the same patient cohort, the most recent 
and complete study was selected. All selected studies were cross-referenced to identify 
additional publications. In case of disagreement between the reviewers about inclusion 
of a publication, consensus was reached.
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Data Extraction
Data extraction was performed in duplicate with Microsoft Excel (Microsoft Office 2010, 
Microsoft, Redmond, WA, USA) by two of the authors (AM and NMK) according to the 
guidelines for reporting mortality and morbidity after cardiac valve interventions [5]. 
Events were not included in our database when adherence to the reporting guidelines 
could not be ascertained. For each article with missing information on important variables, 
the corresponding author was requested to provide the missing data. An overview of 
extracted variables is presented in Appendix 2.
Data Analysis
Data analysis was performed with Microsoft Excel (Microsoft Office 2010, Microsoft, 
Redmond, WA, USA) and IBM SPSS version 21.0 (IBM, Somers, NY, USA). Reported study 
characteristics are quoted as mean ± standard deviation for continuous variables and 
percentages for discrete variables. To study the association between surgical period 
and outcome after the Bentall procedure, the continuous variable “surgical period” was 
defined as the year of first patient inclusion in each cohort.
Outcome events are reported as linearized occurrence rates (percentage per patient year). 
The rate for each event, calculated by dividing the number of events by the total follow-up 
in patient years, was calculated for each individual study and then pooled on a logarithmic 
scale using the inverse variance method within a random-effect model. When a certain 
event did not occur in an individual study, we set the number of events to 0.5 to allow for 
inclusion of the study in pooling of the linearized occurrence rate for that particular event. 
When a certain event was not reported according to the guidelines for reporting mortality 
and morbidity after cardiac valve interventions (5) in an individual study, this study was 
excluded from the analysis of that particular event.
To assess the association of five variables (age, surgical period, proportion of patients with 
Marfan’s disease, proportion of patients with acute type A aortic dissection, proportion 
of patients receiving a mechanical valve prosthesis with the Bentall procedure) with four 
important outcome events (late mortality, reoperation, major bleeding, major adverse 
valve-related events), linear regression was performed with correction for age as a possible 
confounder. Regression analysis was weighted by study size according to the inverse 
variance method. To better characterize the patient population with Marfan’s disease 
or other connective tissue disorders, Pearson’s correlation coefficient was calculated to 
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analyze whether the proportion of patients with connective tissue disorder was correlated 
to age, proportion of patients with acute type A aortic dissection or proportion of patients 
receiving a mechanical valve prosthesis with the Bentall procedure.
Statistical heterogeneity between studies was assessed for each outcome event using the 
I2 test. Publication bias was assessed for each outcome event by inspection of Funnel plots.
RESULTS
The systematic literature search identified 1,403 articles. Figure 1 illustrates the selection 
process that resulted in the inclusion of 46 articles in the systematic review and meta-
analysis. Missing data was provided by the authors of the article by Van Duffel et al [6]. 
Characteristics of the included studies are summarized in Appendix 3 [2, 6-50].
FIGURE 1. Flowchart of systematic literature search.
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Pooled pre-operative and peri-operative characteristics are displayed in Table 1. Early 
mortality occurred in 422 patients (pooled early mortality 5.6%), there was no trend 
toward reduced operative mortality in more recent years. The article by Milano et al. was 
not included in this analysis because it only concerned hospital survivors [30].
TABLE 1. Pooled pre-operative and peri-operative characteristics
Variable
Pooled 
data
Range
Included 
studies (N)
Total patient number 7629 40 - 675 46
Surgical period 1968 - 2012 45
Mean age 49.8 years 29 – 65 years 44
Gender Male 76.3% 55 – 91% 45
Comorbidity
Connective tissue disease 22.6% 0 – 100% 38
Bicuspid aortic valve 24.9% 4 – 100% 17
Prior surgery
 
Cardiac 16.2% 1 – 37% 22
Aortic valve 11.8% 0 – 30% 14
Other indications *
Acute type A dissection 15.3% 0 – 39% 43
Active endocarditis 2.0% 0 – 15% 25
Emergency surgery 15.8% 0 – 43% 35
Other surgery types †
Homograft 0.4% 0 – 5% 43
Valve-sparing 2.2% 0 – 27% 45
Other 0.9% 0 – 41% 45
Valve type
Mechanical 93.2% 43 – 100% 40
Biological 6.8% 0 – 57% 40
Reexploration for bleeding 6.7% 0 – 23% 28
Concomitant
Aortic hemiarch repair 11.6% 0 – 39% 28
Aortic arch repair 5.9% 0 – 18% 26
CABG 11.9% 0 – 31% 36
Mitral valve surgery 6.1% 0 – 18% 36
Early mortality 5.6% 1 – 20% 46
Causes of early mortality ‡
Low cardiac output 29.4%
Hemorrhage 8.5%
Multiorgan failure 7.8%
Myocardial infarction 5.9%
Cardiac arrhythmias 5.7%
Unknown / unreported 20.4%
CABG indicates coronary artery bypass grafting. * majority of patients underwent Bentall procedure for aortic root aneurysm 
with or without aortic valve insufficiency; † majority of patients received Bentall procedure; ‡ major causes of early mortality.
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Mean follow-up after the Bentall procedure was 6.4 years (range 3.0 – 10.4 years) resulting 
in a total of 49,175 patient years. From four articles, it proved impossible to ascertain the 
exact number of late deaths [8, 20, 36, 45]. Although unknown or unreported in 47.9% 
of cases, the main causes of late mortality were low cardiac output (9.9%), distal aortic 
dissection or rupture (8.9%), hemorrhage (4.1%), stroke (3.8%), endocarditis (3.7%), 
cardiac arrhythmias (3.3%), other cardiac-related deaths (9.6%) and other non cardiac-
related deaths (8.9%). The linearized occurrence rates of late mortality, reoperation on 
the aortic root, hemorrhage, thromboembolism, endocarditis and major adverse valve-
related events are presented along with a measure of statistical heterogeneity in Table 2 
and Appendix 4.
TABLE 2. Linearized occurrence rates of late outcome events
Pooled late outcome events LOR + 95% CI
Heterogeneity 
(I2)
Included 
studies (N)
Events 
(N)
Patient 
years (N)
Late mortality * 2.02 (1.77 – 2.31) 70.60 42 892 41803
Valve-related mortality 0.46 (0.36 – 0.59) 49.49 43 172 42845
Root reoperation † 0.46 (0.36 – 0.59) 50.79 40 161 37231
Valve reoperation 0.30 (0.22 – 0.41) 37.27 35 87 32423
Hemorrhage 0.64 (0.47 – 0.87) 67.91 31 174 29234
Thromboembolism 0.77 (0.60 – 1.00) 72.08 30 291 36318
Endocarditis 0.39 (0.33 – 0.46) 0.00 31 125 35638
MAVRE 2.66 (2.17 – 3.24) 79.35 20 531 19839
*Including valve-related mortality. † Including valve reoperation. LOR indicates linearized occurrence rates; CI, confidence 
interval; MAVRE, major adverse valve-related events.
The proportion of patients with a connective tissue disorder was correlated with age 
(coefficient -0.671, P<0.001), proportion of patients with a BAV (coefficient -0.482, P=0.069) 
and proportion of patients with acute aortic dissection (coefficient 0.370, P=0.024).
A more recent surgical period was associated with a decreased hazard of reoperation on 
the aortic root (beta = -0.452, P=0.015). Use of a mechanical valve prosthesis was also 
associated with a decreased hazard of reoperation on the aortic root (beta = -0.425, 
P=0.011). The other analyses did not show significant associations.
Inspection of funnel plots revealed asymmetry, with smaller studies showing consistently 
lower event rates than studies with large patient numbers.
14570-arabkhani-layout.indd   51 10/05/2017   10:39
52
Comment
This systematic review offers cardiologists and cardiac surgeons a unique and up-to-
date overview of long-term outcome following the Bentall procedure. We have shown 
that surgical centers worldwide have performed the Bentall procedure in a highly 
heterogeneous patient population with respect to patient age, indication for surgery, 
comorbidities and concomitant procedures. This is corroborated by the demonstration of 
substantial statistical heterogeneity.
The findings of the systematic review and meta-analysis, which represent the real-world 
experience with the Bentall procedure, may be used by individual surgeons or surgical 
centers to benchmark their experience with the procedure. In addition, the meta-analysis 
will allow comparison of the gold standard in aortic root aneurysm surgery with novel 
therapeutic approaches such as valve-sparing aortic root replacement and personalized 
external aortic root support (PEARS) [51]. 
In the Society of Thoracic Surgeons database, early mortality in adult patients receiving 
root reconstruction with a valved conduit, including patients with acute endocarditis and 
those operated non-electively, operated between 2000 and 2011 was 8.9% [52]. Therefore, 
our finding of pooled early mortality of 5.6% appears excellent, especially when taking 
into account that many of our patients were operated several decades ago. However, 
while the Society of Thoracic Surgeons database represents daily clinical practice, our 
finding of pooled early mortality may have been influenced by publication bias and/or 
selective outcome reporting.
Given the mean age and comorbidities of the patient population, pooled late mortality 
is acceptable. The reported incidence of both major bleeding and thromboembolic 
complications is substantial accounting for a combined cumulative incidence of 14.1% 
at ten years. The reported low incidence of prosthetic valve endocarditis following the 
Bentall procedure is encouraging. However, major adverse valve-related events are 
common after the Bentall procedure with a cumulative incidence of 26.6% at ten years. 
Despite the lower linearized occurrence rates of reoperation in patients operated in more 
recent years, no such trend is apparent for late mortality, major bleeding, thromboembolic 
complications and endocarditis. Major bleeding and thromboembolic complications are 
strongly correlated with use of oral anticoagulation and mechanical valve implantation, 
respectively. Therefore, it may prudent to advise a different surgical approach in selected 
patients.
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In this systematic review and meta-analysis, patients with Marfan’s disease or other 
connective tissue disorders were on average younger and more often presented with acute 
aortic dissection. Interestingly, hazards of late mortality, reoperation, major bleeding and 
major adverse valve-related events were not associated with the presence of connective 
tissue disease. Five studies in this systematic review focused specifically on aortic root 
surgery in patients with connective tissue disease [7, 10, 15, 20, 53]. The pooled linearized 
occurrence event rates from these studies were comparable to the rates reported in Table 
2, except for reoperation (1.01% versus 0.46% per year). In contrast, in a meta-analysis 
from Benedetto et al. focusing on Marfan’s disease, the linearized occurrence rate for 
reoperation after the Bentall procedure is reported as 0,3% per year [54]. Our reported 
high reoperation rate in the studies focused on connective tissue disease can be attributed 
to poor results from one study with an estimated freedom from reoperation of only 67.1% 
at ten years. This study was not included in the meta-analysis from Benedetto et al. [15].
According to the recent American Heart Association / American College of Cardiology 
valvular heart disease guidelines, a mechanical valve prosthesis is not recommended in 
patients in whom use of oral anticoagulation is either contraindicated or not desired [55]. 
For instance, use of oral anticoagulation may not be desired in women who may wish 
to become pregnant in the future or in high performance athletes. In this meta-analysis, 
no association was shown between implantation of a mechanical valve prosthesis and 
occurrence of major valve-related events, including major bleeding and thromboembolic 
complications. Implantation of a mechanical valve prosthesis was associated with lower 
hazard of reoperation. In one study included in this meta-analysis with 57% of patients 
receiving a biological valve substitute, the authors described a higher freedom from 
thromboembolic complications at ten years in these patients [40]. Interestingly, the 
majority of manuscripts included in this meta-analysis that reported on a substantial 
proportion of patients (>10%) receiving a biological valve substitute did not analyze the 
association between the choice of valve substitute and outcome measures. The only other 
study to do so, showed similar late survival in both groups [6].
The guidelines also state that choice of both valve intervention and prosthesis type should 
be an informed, shared decision. This is especially important in aortic valve disease, as 
the choice between available options is often highly value-sensitive. Therefore, patients 
and surgeons should discuss and explore all available options, including implantation of a 
bioprosthesis, valve-sparing aortic root replacement and perhaps even considering novel 
therapeutic approaches in selected patients such as PEARS [51].
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In this light, we compared our findings to those from a systematic review and meta-
analysis on outcome after valve-sparing aortic root replacement published by Arabkhani 
et al. [56]. Pooled data from 4,777 patients with a follow-up of 21,716 patient years show 
that reinterventions are more common after valve-sparing aortic root replacement 
than after the Bentall procedure. Interestingly, rates of early and late mortality as well 
as late hemorrhage and thromboembolic complications were substantially lower after 
valve-sparing aortic root replacement. Patient characteristics, such as age at the time of 
operation, proportion of patients with connective tissue disease and aortic arch repair 
were similar between the two studies. However, differences in surgical era between 
the studies may explain why differences in early and late mortality were so striking. 
Nonetheless, the comparison clearly illustrates that valve-sparing aortic root replacement 
offers a great promise for the future.
To improve decision making, detailed and up-to-date information on long-term outcome 
of the available techniques is required. In this light, we strongly support projects such 
as the recently initiated AVIATOR registry; a prospective international registry of patients 
undergoing surgery, including the Bentall procedure and valve-sparing root replacement, 
for ascending aorta aneurysm and/or isolated aortic regurgitation.
Limitations
Statistical heterogeneity limits application of our findings for use in individual patients 
and precluded use of meta-regression. Heterogeneity is likely the result of large diversity 
in patient characteristics as well as the large time period in which surgery was performed.
When interpreting the findings, it is important to realize that the presented pooled outcome 
measures may underestimate the actual occurrence of late mortality and morbidity 
following the Bentall procedure as most included studies were of a retrospective nature. 
In addition, publication bias may have contributed to lower mean linearized occurrence 
rates.
Several studies included in the systematic review did not adhere to the available guidelines 
on reporting after heart valve interventions [5]. Therefore, it was not always possible to 
extract (reliable) information on the important outcome measures. 
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Lack of access to individual patient data precluded use of more robust outcome measures 
than the linearized occurrence rate. The main concern with linearized occurrence rates is 
that many biological events occur in a non-linear fashion.
CONCLUSIONS
Published experience with the Bentall procedure with a mechanical valve prosthesis is 
extensive in a diverse patient population. Over the years, rates of aortic root reoperation 
have decreased. However, rates of late mortality, major bleeding and thromboembolic 
complications, associated with the use of a mechanical valve prosthesis, remain a concern. 
In this light, we encourage using this report as a benchmark to assess the potential 
therapeutic benefit of novel surgical approaches, such as valve-sparing aortic root 
replacement.
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APPENDIX 1
Embase
(bentall:ab,ti OR (((‘aorta valve’/de OR ‘aorta valve replacement’/de OR ‘aorta valve prosthesis’/de OR 
‘aorta valve disease’/exp OR (aort* NEAR/3 valv*):ab,ti) AND (‘aorta root’/de OR ‘aortic root surgery’/
de OR (aort* NEAR/3 root*):ab,ti) AND (‘ascending aorta’/de OR ‘ascending aorta surgery’/de OR 
(ascend* NEAR/3 aort*):ab,ti)) AND (surgery/exp OR surgery:lnk OR (surg* OR graft* OR homograft* 
OR replace* OR composit* OR operat* OR postoperat*):ab,ti))) AND (survival/exp OR mortality/exp 
OR (surviv* OR mortal* OR ‘death rate’):ab,ti) NOT (‘case report’/de OR (‘case report’):ab,ti) 
MEDLINE
(bentall.ab,ti. OR (((“aortic valve”/ OR (aort* ADJ3 valv*).ab,ti.) AND ((aort* ADJ3 root*).ab,ti.) AND 
((ascend* ADJ3 aort*).ab,ti.)) AND (“Surgical Procedures, Operative”/ OR surgery.xs. OR (surg* OR 
graft* OR homograft* OR replace* OR composit* OR operat* OR postoperat*).ab,ti.))) AND (survival/ 
OR exp mortality/ OR mortality.xs. OR (surviv* OR mortal* OR “death rate”).ab,ti.) NOT (“case reports”.
pt. OR (“case report”).ab,ti.) 
PubMed as supplied by publisher
(bentall[tiab] OR ((((aort*[tiab] AND valv*[tiab])) AND ((aort*[tiab] AND root*[tiab])) AND 
((ascend*[tiab] AND aort*[tiab]))) AND ((surg*[tiab] OR graft*[tiab] OR homograft*[tiab] OR 
replace*[tiab] OR composit*[tiab] OR operat*[tiab] OR postoperat*[tiab])))) AND ((surviv*[tiab] OR 
mortal*[tiab] OR death rate*[tiab])) NOT (case reports[pt] OR (case report[tiab])) AND publisher[sb]
The Cochrane Collaboration
(bentall:ab,ti OR ((((aort* NEAR/3 valv*):ab,ti) AND ((aort* NEAR/3 root*):ab,ti) AND ((ascend* 
NEAR/3 aort*):ab,ti)) AND ((surg* OR graft* OR homograft* OR replace* OR composit* OR operat* 
OR postoperat*):ab,ti))) AND ((surviv* OR mortal* OR ‘death rate’):ab,ti) NOT ((‘case report’):ab,ti) 
Web of Science 
TS=((bentall OR ((((aort* NEAR/3 valv*)) AND ((aort* NEAR/3 root*)) AND ((ascend* NEAR/3 aort*))) 
AND ((surg* OR graft* OR homograft* OR replace* OR composit* OR operat* OR postoperat*)))) AND 
((surviv* OR mortal* OR “death rate”)) NOT ((“case report”)))
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APPENDIX 2
Variables Description
First author
Publication Year
Journal
Country Country where patients were operated in
Operative period
Patient Number
Follow-up
Mean in years; calculated from median and interquartile range 
when mean was not given
Age
Mean in years; calculated from median and interquartile range 
when mean was not given
Sex
CTD
BAV
Prior cardiac surgery
Prior aortic valve surgery
Acute type A dissection As indication for Bentall procedure
Acute infective endocarditis As indication for Bentall procedure
Emergency surgery Within 24 hours after diagnosis
Homograft surgery Patients with non-Bentall procedures
Valve-sparing surgery Patients with non-Bentall procedures
Other surgery Patients with non-Bentall procedures
Mechanical prosthesis Valve choice for Bentall procedure
Bioprosthesis Valve choice for Bentall procedure
Aortic hemiarch repair
Aortic arch repair
CABG
Mitral valve surgery
Reexploration for bleeding In-hospital or within 30 days post-operatively
Early mortality In-hospital mortality and 30 days mortality
Late mortality According to guidelines (5)
Root reoperation According to guidelines (5)
Hemorrhage According to guidelines (5)
Thromboembolism According to guidelines (5)
Endocarditis According to guidelines (5)
MAVRE
Composite of late valve-related mortality, reoperation, 
hemorrhage, thromboembolism and endocarditis
CTD indicates connective disease; BAV, bicuspid aortic valve; CABG, coronary artery bypass grafting; MAVRE, major adverse 
valve-related events.
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CHAPTER 4
Mechanical aortic valve replacement in non-
elderly adults: meta-analysis and Microsimulation
Nelleke M. Korteland; Jonathan R.G. Etnel; Bardia Arabkhani; M. Mostafa Mokhles;
Arezo Mohamad; Jolien W. Roos-Hesselink; Ad J.J.C. Bogers; Johanna J.M. Takkenberg
European Heart Journal, article in Press
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ABSTRACT
Aims. To support decision-making regarding prosthetic valve selection in non-elderly 
adults, we aim to provide a detailed overview of outcome after contemporary mechanical 
aortic valve replacement (AVR).
Methods and Results. A systematic review was conducted for papers reporting clinical 
outcome after AVR with bileaflet mechanical valves with a mean patient age ≥18 and ≤55 
years, published between 1/1/1995 and 31/12/2015. Through meta-analysis outcomes 
were pooled and entered into a microsimulation model to calculate (event-free) life 
expectancy and lifetime event risk.
Twenty-nine publications, encompassing a total of 5728 patients with 32515 patient-
years of follow-up (pooled mean follow-up: 5.7 years), were included. Pooled mean age 
at surgery was 48.0 years. Pooled early mortality risk was 3.15%(95%CI:2.37-4.23), late 
mortality rate was 1.55%/year(95%CI:1.25-1.92); 38.7% of late deaths were valve-related. 
Pooled thromboembolism rate was 0.90%/year(95%CI:0.68-1.21), major bleeding 0.85%/
year(95%CI:0.65-1.12), nonstructural valve dysfunction 0.39%/year(95%CI:0.21-0.76), 
endocarditis 0.41%/year(95%CI:0.29-0.57), valve thrombosis 0.14%/year(95%CI:0.08-0.25), 
structural valve deterioration 0.00%/year(zero events observed), and reintervention 0.51%/
year(95%CI:0.37-0.71), mostly due to nonstructural valve dysfunction and endocarditis. 
For a 45-year-old, for example, this translated to an estimated life expectancy of 19 years 
(general population: 34 years) and lifetime risks of thromboembolism, bleeding and 
reintervention of 18%, 15% and 10%, respectively.
Conclusions. This study demonstrates that outcome after mechanical AVR in non-
elderly adults is characterized by suboptimal survival and considerable lifetime risk of 
anticoagulation-related complications, but also reoperation. Non-elderly adult patients 
who are facing prosthetic valve selection are entitled to conveyance of evidence-based 
estimates of the risks and benefits of both mechanical and biological valve options in a 
shared decision-making process. 
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INTRODUCTION
Aortic valve replacement (AVR) is the most widely used surgical treatment for aortic 
valve disease in non-elderly adults. When valve repair is not possible, two types of valve 
substitutes are available: mechanical and biological valves. The primary advantage of 
mechanical valves is their durability. They do, however, require lifelong anticoagulation 
due to their increased thrombogenicity, which gives rise to a substantial risk of 
thromboembolic and bleeding complications that may have an important impact on 
quality of life.1 Furthermore, patients are faced with the hassle of INR regulation, the valve 
sound and, in the case of a woman with pregnancy wishes, the hazards of anticoagulation 
during pregnancy. Biological valves do not require long-term anticoagulation unless 
another indication is present. However, they are subject to valve deterioration over time 
and young patients, in particular, may require a reoperation later in life.2 
Since all currently available valve substitutes have important limitations, younger patients 
who require AVR are facing a difficult choice. A mechanical valve is often recommended 
in non-elderly adult patients due to the lower, though not absent, rate of reoperation 
compared with biological valves. Subsequently, most non-elderly adult patients will face 
a lifelong risk of bleeding and thromboembolic events after their mechanical AVR. To 
improve decision-making with regard to prosthetic valve selection in non-elderly adults, 
detailed and up-to-date information on mechanical valve-related mortality and morbidity 
is required. To gain insight in morbidity and mortality after contemporary mechanical AVR 
in non-elderly adults, we aim to provide an overview of published evidence by conducting 
a systematic review and meta-analysis of reported outcome. Furthermore, we aim to 
estimate age-specific life expectancy and lifetime risk of valve-related events with the use 
of a microsimulation model based on the results of our meta-analysis. 
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METHODS
This systematic review was conducted according to the PRISMA guidelines.3 This study 
was approved by the institutional review board and informed consent was waived (MEC-
2015-170).
Literature search
On December 7, 2015, a systematic literature search was conducted in Embase, MEDLINE, 
The Cochrane Collaboration and Web of Science by a biomedical information specialist 
(Supplement 1). All studies were screened by two independent reviewers (NMK, JRGE). 
Studies reporting survival after contemporary AVR with a mechanical valve in patients 
with a mean age ≥18 and ≤55 years published in English after 1/1/1995 were considered 
for inclusion. Studies were included if >90% of the cohort received bileaflet prostheses. 
Studies limited to patients with preexisting comorbidities or patients with a history of 
previous AVR were excluded. Studies with a study size ≤20 patients or focusing only on 
certain prosthetic valve sizes or multiple valve replacement were also excluded.   
In case of overlapping study populations, only the most recent or most complete study was 
included. In case of disagreement between the reviewers, a consensus was negotiated. 
In case a full text publication was not available or information was missing the author was 
contacted by e-mail. 
Data Extraction
Microsoft Office Excel (details in Supplement 5) was used for data extraction. The same 
pair of reviewers (NMK, JRGE) extracted the data independently. After data extraction, 
each reviewer verified the other reviewer’s data entries. Recorded study characteristics, 
baseline patient and operative characteristics and outcome events are listed in Supplement 
5. Morbidity and mortality were documented according to the guidelines.4 Early outcome 
events were defined as occurring within the first 30 postoperative days, regardless of the 
patient’s location, and late outcome events were defined as occurring after the first 30 
postoperative days. If the total follow-up was not reported, it was calculated by multiplying 
the number of patients with the mean follow-up of that study.
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Meta-analysis
Continuous variables are presented as mean ± standard deviation. Categorical variables 
are presented as counts and percentages. Linearized event occurrence rates are presented 
as percentages per year. 
Pooled baseline patient characteristics were calculated with the use of sample size 
weighting. Early mortality risk and linearized occurrence rates of late mortality, 
reoperations and complications after AVR were calculated and pooled with the use of 
inverse variance weighting on a logarithmic scale, as the Shapiro-Wilk test revealed a 
significantly skewed distribution among the included studies in the majority of outcome 
measures. Inverse variance weighting was conducted according to the number of patients 
for early mortality and according to the number of patient-years of follow-up for late 
events. In case a particular event was reported not to occur in an individual study, then for 
the purpose of inverse variance weighting it was assumed that 0.5 patient experienced 
that event. A random-effects model was used to estimate pooled effects. 
The Cochran Q statistic and the I2 test were used to assess heterogeneity. Potential causes 
of heterogeneity were explored by investigating the effect of year of first inclusion, 
mean follow-up duration, case mix and study design (retrospective versus prospective/
randomized controlled trial) by means of univariable random-effects meta-regression. 
Funnel plots were used to investigate publication bias. To investigate the potential 
influence of publication bias on pooled outcome, sensitivity analyses were conducted by 
temporarily excluding the smallest quartile (by sample size) of included studies. Statistical 
analyses were performed in Microsoft Office Excel, IBM SPSS Statistics and R (software 
details are listed in Supplement 5).
Microsimulation
A microsimulation model based on the pooled outcome estimates of our meta-analysis 
was used to calculate age-specific life expectancy and lifetime risk of valve-related 
morbidity.5,6 The microsimulation model iteratively simulates individual patient lives 
after surgery, taking into account the morbidity and mortality events that the patient 
may experience. The simulated individual patient life histories are then aggregated to 
obtain estimates of population level outcome. The mortality of a patient is composed of 
the background mortality of the general population, operative mortality, mortality due 
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to valve-related events and an additional excess mortality component that is not a direct 
result of valve-related events, but is associated with underlying valve pathology, left 
ventricular function and other associated pathology.
The operative mortality risk, the occurrence rate of each valve-related event and the risk 
of mortality and reintervention as a direct result of each of these valve-related events 
were obtained from our meta-analysis. The occurrence rates of all events were assumed to 
be linear and non-age-dependent. The hazard ratios of the additional excess mortality not 
directly resulting from valve-related events have been previously estimated.6 For patients 
aged 25, 35, 45 and 55, these hazard ratios were 5.5, 4.4, 2.9 and 1.8 for males and 7.0, 7.0, 
4.2 and 2.8 for females, respectively. The background mortality of the general population 
was obtained from the 1996 United States Life Tables, as 1996 was the pooled median 
year of intervention (assuming a constant incidence rate over time in each study) and 
the majority of the included study population originated from, or was comparable to the 
United States population.7
To obtain age-specific estimates of life expectancy and lifetime risk of valve-related 
morbidity, the microsimulation model was run for the ages 25, 35, 45 and 55 years for 
10,000 iterations each and separately for males and females. The age-specific outcomes of 
both genders were then pooled at the male/female ratio obtained from our meta-analysis 
(72.0% male). 
For the purposes of internal validation, the model was additionally run for 10,000 iterations 
at the pooled mean age (48 years) and pooled male/female ratio of the included studies 
(72.0% male). The actuarial survival curve obtained from this model was then plotted 
against the pooled overall mortality observed in our meta-analysis.
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FIGURE 1. Flowchart of systematic literature search.
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RESULTS
The systematic literature search identified 3100 publications, of which 29 were included 
in the meta-analysis, encompassing a total of 5728 patients with 32515 patient-years of 
follow-up (pooled mean follow-up: 5.7 years) (Figure 1).  Supplement 2 represents the 
characteristics of the included studies (references listed in Supplement 6). Pooled baseline 
patient characteristics are shown in Table 1. 
Pooled risks of early mortality and early complications and pooled linearized occurrence 
rates of late mortality and late morbid events are presented in Table 2 (individual study 
estimates are presented in Supplement 3).
TABLE 1. Pooled pre-operative and peri-operative characteristics. 
Variable
Pooled 
data
Range
Included 
studies (N)
Total number of patients 5728 20–865 29
Mean age (years) 48.0 33.0–54.9 29
Gender Male 72.0% 50.0–91.0% 23
Etiology
Degenerative 21.5% 0.0–78.0% 12
Endocarditis 10.0% 0.0–100% 19
Rheumatic 36.4% 0.0–77.8% 12
Congenital 16.5% 0.0–57.0% 10
Prosthetic valve dysfunction 3.8% 0.0–22.0% 14
Other/unknown 11.7% 0.0–66.0% 13
Aortic valve hemodynamics
Stenosis 43.5% 0.0–100% 13
Regurgitation 40.4% 0.0–70.0% 13
Combined 16.2% 0.0–30.0% 12
Bicuspid aortic valve 24.5% 1.4–100% 4
Previous cardiac intervention 8.4% 0.0–26.0% 13
Emergency surgery 3.4% 0.0–35.0% 10
Prosthetic valve type
Bileaflet 99.9% 96.5–100% 29
Tilting-disc 0.1% 0.0–3.5% 29
Caged-ball 0.0% 0.0–0.0% 29
Concomitant procedures 22.2% 0.0–52.2% 11
CABG 7.1% 0.0–17.5% 21
Aortic surgery 8.6% 0.0–33.0% 11
Multiple valve replacement 2.6% 0.0–24.6% 17
CABG=coronary artery bypass grafting.
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TABLE 2. Pooled risk of early outcome events and linearized occurrence rates of late outcome events obtained from 
the meta-analysis. 
Outcome events
Overall
Pooled estimate Heterogeneity*
Included 
studies (N)
Early(<30 days)
Early mortality(%) 3.15(2.37-4.21) I2=70%(p<0.001) 25
Re-exploration for bleeding(%) 5.15(2.57-11.81) I2=87%(p<0.001) 7
Pacemaker implantation(%) 3.53(2.47-5.05) I2=20%(p=0.289) 4
Deep sternal infection/mediastinitis(%) 2.48(1.56-3.94) I2=0%(p=0.409) 5
Endocarditis(%) 0.43(0.16-1.13) I2=0%(p=0.853) 7
Stroke(%) 1.55(0.98-2.46) I2=15%(p=0.312) 8
Transient ischemic attack(%) 0.81(0.38-1.72) I2=1%(p=0.400) 5
Myocardial infarction(%) 0.87(0.40-1.87) I2=0%(p=0.687) 5
Valve thrombosis(%) 0.30(0.09-1.05) I2=0%(p=0.782) 5
Peripheral bleeding(%) 0.41(0.15-1.09) I2=0%(p=0.756) 7
Late(>30 days)
Late mortality(%/year) 1.55(1.25-1.92)~ I2=83%(p<0.001) 29
     -Cardiac death(%/year) 0.95(0.71-1.27) I2=70%(p<0.001) 22
          -Valve-related death(%/year) 0.60(0.44-0.81) I2=64%(p<0.001) 24
               -SUD(%/year) 0.37(0.26-0.54) I2=47%(p=0.011) 19
Reintervention(%/year) 0.51(0.37-0.71) I2=47%(p=0.011) 20
Thromboembolism(%/year) 0.90(0.68-1.21)# I2=79%(p<0.001) 25
Valve thrombosis(%/year) 0.14(0.08-0.25) I2=62%(p<0.001) 18
Bleeding(%/year) 0.85(0.65-1.12)# I2=67%(p<0.001) 26
SVD(%/year) 0.00† - 15
NSVD(%/year) 0.39(0.21-0.76) I2=83%(p<0.001) 17
Endocarditis(%/year) 0.41(0.29-0.57)  I2=34%(p=0.072) 19
*The reported p-values are the p-values of Cochran’s Q test for heterogeneity. †There were zero events of SVD in the 15 
studies that reported this outcome. ∼ The background mortality rate in the age- and gender-matched United States general 
population for the pooled year of surgery and length of follow-up of our cohort was 0.55%/year. #The background rates of 
thromboembolism and bleeding events in the age- and gender-matched general population were 0.12%/year and 0.03%/
year, respectively (based on the Oxford Vascular Study28). Pooled estimates presented as “percentage (95% confidence 
interval)”. SUD=sudden, unexplained death;SVD=structural valve deterioration;NSVD=nonstructural valve dysfunction. 
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Microsimulation-based age-specific estimates of (event-free) life expectancy and lifetime 
risk of valve-related morbidity are shown in Figure 2. The microsimulation model calibrated 
well with the pooled mortality observed in our meta-analysis over the first postoperative 
decade (Supplement 7). For a 45-year-old, for example, microsimulation-based estimated 
life expectancy was 19 years (general population: 34 years) and lifetime risks of thrombo-
embolism, bleeding and reintervention were 18%, 15% and 10%, respectively.
The funnel plots showed evidence of possible publication bias in early mortality, late 
mortality, thromboembolism, and bleeding (Supplement 8). Sensitivity analyses showed 
that this potential publication bias did not substantially influence our pooled outcomes, 
as pooled outcomes remained largely unchanged after temporary exclusion of the 
smallest quartile of studies (before vs. after exclusion: early mortality [3.15% vs. 3.03%], 
late mortality [1.55%/year vs. 1.55%/year], thromboembolism [0.90%/year vs. 0.88%/
year], bleeding rates [0.85%/year vs. 0.87%/year]).
Heterogeneity
There was substantial heterogeneity in early mortality, re-exploration for bleeding and 
all late outcome measures with the exception of structural valve deterioration (SVD) and 
endocarditis. Univariable random-effects meta-regression (Supplement 4) showed that 
studies with a longer mean follow-up reported lower early mortality (p<0.001), lower 
reintervention rates (p=0.010) and lower bleeding rates (p=0.042), although follow-up 
duration was moderately negatively correlated with concomitant CABG (r=-0.37) and 
earlier year of first inclusion (r=-0.31). 
Etiology was another important factor associated with heterogeneity as a higher 
proportion of preoperative endocarditis appeared to be correlated with higher rates of 
late mortality (p=0.008) and NSVD (p=0.002), while a higher proportion of rheumatic 
etiology was associated with lower rates of NSVD (p=0.004). Bleeding and nonstructural 
valve dysfunction (NSVD) rates were higher in cohorts with a higher proportion of aortic 
stenosis (bleeding p=0.026; NSVD p<0.001) and, consequently, a lower proportion of 
aortic regurgitation (bleeding p=0.003; NSVD p<0.001), although there was a moderate-
to-strong negative correlation between preoperative aortic valve stenosis (as opposed 
to regurgitation) and etiology (endocarditis r=-0.71; rheumatic r=-0.37). Lastly, higher 
proportions of emergency surgeries (p=0.007) and concomitant CABG (p=0.046) were 
associated with higher rates of NSVD and a higher proportion of concomitant procedures 
was associated with higher reported early mortality risk (p=0.045). We were unable to 
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find any explanatory variables for the heterogeneity in thromboembolism and valve 
thrombosis rates. Differences in study design, year of first inclusion and previous cardiac 
interventions were not associated with heterogeneity in any of the outcome measures. 
Meta-regression was not conducted for re-exploration for bleeding due to limited sample 
size.
Figure 2.
0%
5%
10%
15%
20%
25%
30%
25 35 45 55
Lif
et
im
e 
ris
k 
(%
)
Age at surgery (years)
Thromboembolism
Valve thrombosis
Hemorrhage
Reintervention
Non-structural dysfunction
Endocarditis
0
10
20
30
40
50
60
25 35 45 55
M
ea
n 
lif
e 
ex
pe
ct
an
cy
 (y
ea
rs
)
Age at surgery (years)
General Population - Life
expectancy
Mechanical AVR - Life
expectancy
Mechanical AVR - Event-free
life expectancy
FIGURE 2. Microsimulation-based age-specific life expectancy and lifetime risk of valve-related morbidity. AVR=aortic 
valve replacement.
14570-arabkhani-layout.indd   77 10/05/2017   10:39
78
DISCUSSION
This study offers an overview of reported mortality and morbidity after single mechanical 
AVR in non-elderly adult patients and microsimulation-based age-specific estimates of 
expected lifetime outcome. It confirms the excellent long-term durability of mechanical 
valves in these patients, but also underlines the substantial late cardiovascular death and 
anticoagulation-related complication hazards after mechanical AVR. Although no cases of 
SVD were observed after contemporary AVR with currently available mechanical valves, 
microsimulation revealed a considerable lifetime risk of reintervention in this subgroup 
that ranged from 15% for patients aged 25 years at surgery to 8% for 55-year-olds, mostly 
due to NSVD and endocarditis. Most notably however, the combined lifetime risk of 
thromboembolism, valve thrombosis and bleeding ranged from 53% for patients aged 
25 years at surgery to 30% for 55-year-olds. Life expectancy is substantially impaired in 
these patients compared with the general population and about 40% of deaths are valve-
related.
Mortality
Elective, isolated mechanical AVR has been previously shown to be associated with 
significant excess mortality when compared with the general age-matched population.8 
In our meta-analysis we found a 3.15% early mortality risk and a substantial late mortality 
rate of 1.55%/year in patients with a pooled mean age of 48.0 years at the time of surgery. 
Microsimulation-based mean life expectancy after contemporary mechanical AVR ranged 
from 28 years for patients aged 25 years at surgery to 16 years for 55-year-olds, which is 
little over half the life expectancy of the age-matched general population. When taking 
the absent risk of SVD and subsequent reintervention associated with contemporary 
mechanical AVR into account, this mortality rate appears to be relatively high in 
comparison with other valve substitutes in non-elderly adults, such as the Ross procedure, 
which has been reported to be associated with lower late mortality in non-elderly adults 
compared with our pooled results after contemporary mechanical AVR (0.64%/year vs. 
1.55%/year), while early mortality risk was comparable (3.24% vs. 3.15%).9 Prosthetic 
valve-associated hemodynamic factors, such as prosthesis-patient mismatch, may play 
a role in this observed excess mortality.10,11 Furthermore, the higher mortality after 
mechanical AVR may be attributable in part to the required anticoagulation treatment. In 
this regard, optimization of the anticoagulation therapy after mechanical AVR may offer 
a survival benefit in these patients. This is supported by a recent study by Mokhles et 
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al., which found that, with optimal self-management anticoagulation, mechanical AVR 
offers excellent late survival, comparable to the general age-matched population and to 
patients undergoing the Ross procedure.12 
The survival differences between mechanical valves and other valve substitutes may be 
further explained by possible differences in patient characteristics, surgical technique and 
concomitant procedures performed at the time of AVR. Rheumatic valve disease being 
the most common etiology in present study (34% of our patients) may represent evidence 
of this possible selection bias.
Thromboembolism and bleeding
Present study underlines the burden of thromboembolism and bleeding after mechanical 
AVR in non-elderly patients as approximately half of patients aged 25 and 1 out of 3 patients 
aged 55 at the time of surgery are estimated to experience thromboembolism, valve 
thrombosis or bleeding events during their lifetime. This is most likely an underestimate 
as the included studies were largely retrospective in design, which may have given rise 
to recall bias.  Anticoagulation related complications remain an important limitation of 
mechanical valve prostheses, especially in the young patients in which they are generally 
used, as there are serious implications for life-, career- and pregnancy-planning in these 
patients. However, optimizations of the required anticoagulation therapy such as self-
management and lower dosing may be promising methods of reducing complication 
rates after mechanical AVR. There is increasing evidence that patients with contemporary 
mechanical valves and no comorbidities may be safely managed at a lower INR than 
currently recommended, subsequently reducing bleeding complications without 
increasing the risk of thromboembolic events.13-15 Furthermore, advances in the design of 
mechanical valves may lead to reduced thrombogenicity. Mechanical valves specifically 
designed with this in mind have emerged, one of which has recently received FDA-
approval for anticoagulation management at a lower INR than recommended by the 
guidelines.15 Nevertheless, we did not find any evidence in this systematic review that 
thromboembolism and bleeding hazard has decreased in more recent years. 
Pharmacological advances that provide more stable INR management may further reduce 
complication rates as studies have shown that, in patients treated with currently available 
anticoagulants, 25% of periodically measured INR values lie outside of the target range.13
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Reintervention, (N)SVD and Endocarditis
Our results underline excellent long-term durability as the main advantage of mechanical 
valves, with negligible SVD rates. Although SVD remains a rare complication in mechanical 
valve recipients, depending on age at surgery, approximately 8%-15% of patients require 
reintervention during their lifetime, mostly due to NSVD (pannus formation, paravalvular 
leakage, etc.), valve thrombosis or prosthetic valve endocarditis. Although this risk of 
reintervention is very low compared with other valve substitutes in non-elderly adults, it is 
not absent and should always be taken into consideration and discussed with the patient 
when prosthetic valve selection is addressed.
Prosthetic valve selection
In prosthetic valve selection, mechanical valve-associated thromboembolism and 
bleeding risk is generally weighed against the risk of SVD and subsequent reintervention 
associated with biological valve substitutes. In non-elderly patients a mechanical valve 
is often recommended due to the limited durability of biological alternatives. However, 
the durability of modern bioprostheses is improving. These improvements as well as 
improved outcomes in reoperative aortic valve surgery and the prospect of transcatheter 
valve-in-valve replacement of failing bioprostheses has led to an increase in their use in 
younger patients.16-21 Additionally, the Ross procedure represents another valuable option 
in these patients that avoids the need for long-term anticoagulation and provides superior 
long-term survival, excellent hemodynamic performance and a low risk of endocarditis 
in selected patients when performed in centers of expertise. Due to the continued 
improvements in bioprosthetic AVR and the option of the Ross procedure, the substantial 
risk of mechanical valve-related complications, as delineated by our results, will become 
more prominent in the process of prosthetic valve selection. Furthermore, although the 
risk of reintervention after mechanical AVR is low, it is certainly not absent and should also 
be taken into consideration in the process of prosthetic valve selection. This also applies to 
the risk of thromboembolism and bleeding after AVR with biological alternatives. Besides 
clinical factors, the benefits and limitations of each option have substantial implications 
for life-, career- and pregnancy planning in these patients. Therefore, conveyance of 
patient-tailored evidence-based risks and benefits of both mechanical and biological 
valve options in a shared decision-making process is of great importance.2,22 Innovative 
solutions such as patient information portals and decision aids may prove useful in this 
setting.23
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Heterogeneity
Although heterogeneity was considerable in our meta-analysis and may have potentially 
influenced the results, we pursued a thorough examination of possible sources of 
heterogeneity. Etiology and concomitant procedures appear to be important factors 
of influence on the reported outcomes, which is in line with expectations based on the 
literature.24,25 Furthermore, we found aortic regurgitation vs. stenosis to be associated 
with more favorable reported outcome with regard to bleeding and NSVD rates, while 
regurgitation has been previously described to be associated with less favorable 
outcome. 24 This discrepancy may be explained by the strong correlation we found in our 
meta-regression between aortic valve hemodynamics and etiology (studies with a higher 
proportion of stenosis had lower proportions of endocarditis and rheumatic etiology), 
which may have confounded the results.
Lastly, although there were no consistent evidence thereof in our analyses, the year of 
operation, ranging from 1977-2014 among the included studies, may still have affected 
the results, as case-mix may have changed over the years and evolution of operative 
techniques may have led to lower operative risk. 
Although this observed heterogeneity might have introduced uncertainty in our meta-
analysis, with the use of a random-effects model, this uncertainty is incorporated in the 
reported pooled outcome estimates.
The asymmetry we found in our funnel plots may represent evidence of possible 
publication bias. However, assessment of publication bias in absolute risk outcomes, as 
were all of our outcomes, is associated with substantial methodological limitations which 
may in itself give rise to funnel plot asymmetry.26 Our funnel plots should therefore be 
interpreted with caution. Although a conclusive investigation of publication bias may 
not be possible, our sensitivity analyses show that any potential publication bias did not 
substantially influence our pooled outcomes.
Limitations
The present study is a systematic review and meta-analysis of observational studies, most 
of which are retrospective in design. As such, the inherent limitations of meta-analyses 
and combining data from retrospective observational studies should be taken into 
consideration.27 Selection bias may have affected the observed outcomes, as unpublished 
data, abstracts and presentations were not included. Among the included studies, baseline 
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and surgical characteristics were not reported in sufficient detail and consistently enough 
for us to fully account for all baseline covariates in our meta-analyses. Direct comparisons 
with alternative valve prostheses is hampered by the lack of published comparative data. 
Setting a time limit to systematic literature searches may introduce potential bias, but we 
chose to do so in our aim to provide an overview of contemporary outcome. Finally, there 
are some limitations to the microsimulation model that should be taken into account. 
The relationship of the occurrence rates of valve-related events after mechanical AVR 
with age, follow-up duration and history of previous valve-related events remains poorly 
defined and could, thus, not be incorporated into our microsimulation model. Uncertainty 
in the parameters within the model (second order uncertainty) was also not incorporated 
in our microsimulation model. The model requires assumptions to be made about the 
evolution of event occurrence rates beyond the observed follow-up period, which may 
have introduced uncertainty. Our United States general population-based background 
mortality estimate should be regarded as merely a reference point, as it may not be an 
ideal reflection of the general population mortality of the different countries that are 
represented in the individual studies in the review.
CONCLUSIONS
This review shows that the use of mechanical valves in non-elderly adult patients is 
associated with substantial excess mortality over time and considerable lifetime risk 
of anticoagulation-related complications, but also reoperation. This confirms the fact 
that non-elderly adult patients who require AVR are facing a difficult choice between 
mechanical and biological valves and, therefore, conveyance of patient-tailored evidence-
based risks and benefits of both mechanical and biological valve options in a shared 
decision-making process is of great importance in the setting of prosthetic valve selection. 
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CHAPTER 5
Reported Outcome After Valve-Sparing Aortic 
Root Replacement for Aortic Root Aneurysm: 
A Systematic Review and Meta-Analysis
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ABSTRACT
Background. Valve-sparing aortic root techniques have progressively gained ground in 
the treatment of aortic root aneurysm and aortic insufficiency. By avoiding anticoagulation 
therapy it offers a good alternative to composite graft replacement. This systematic review 
describes the reported outcome of valve-sparing aortic root replacement focusing on the 
remodeling and reimplantation technique. 
Methods. A systematic literature search on characteristics of and outcome after valve-
sparing aortic root replacement revealed 1.659 articles. Inclusion criteria: focus on valve-
sparing aortic root replacement in adults with aortic root aneurysm, presenting survival 
data, including at least 30 patients. Data were pooled by inverse variance weighting and 
analyzed by linear regression.
Results. Of 1.659 articles published between 01/01/2000 and 01/01/2014, 31 were 
included (N = 4.777 patients). Mean age at operation was 51 ± 14.7 years, 14% had 
bicuspid aortic valve. The reimplantation technique was used in 72%, remodeling in 27% 
(1% other).  No clinical advantage in terms of survival and reoperation of one technique 
over the other was found. Cusp repair was performed in 33%. Pooled early mortality was 
2% (N=103). During follow-up (21.716 patient-years), 262 patients died (survival 92%) and 
228 (5%) were reoperated, mainly valve replacement. Major adverse valve related events 
was  low (1.66% patient-years). Preoperative severe aortic valve regurgitation showed a 
trend toward higher reoperation rate. 
Conclusions. Remodeling and reimplantation techniques show comparable survival 
and valve durability results providing a valid alternative to composite valve replacement. 
The  heterogeneity in data underlines the need for a collaborative effort to standardize 
outcome reporting.
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INTRODUCTION
There are no comprehensive recommendations in the literature regarding  the surgical 
treatment of aortic root aneurysms other than that it should be concentrated in those 
centers with proven expertise with the procedure[1]. Various valve sparing aortic root 
replacement techniques have been developed in the last decades to preserve the native 
aortic valve and to avoid anticoagulation therapy, as is needed with the standard composite 
aortic root replacement (Bentall procedure) [2]. The two most widely used techniques 
are the remodeling and the reimplantation technique. In the Yacoub procedure, the 
aortic root is reduced and neo-sinuses of Valsalva are created using synthetic tube graft, 
thereby  producing a nearly physiological reconstruction of the aortic root. However, 
the aortic annulus remains untreated [3]. The David procedure (the most widely used 
reimplantation technique) involves reimplantation of the aortic valve within a synthetic 
tube, whereby the sino-tubular junction as well as the annulus are reduced but includes 
the interleaflet triangles thus impairing root expansibility and possibly valve dynamics 
[4]. Over the years numerous modifications to these techniques have been described, 
such as a standardized  and physiological approach of valve sparing procedure with the 
association of a remodeling root reconstruction to an aortic ring annuloplasty in order to 
combine advantages of both original techniques [5-7]. 
To contribute to the debate on which type of valve surgery is most appropriate in patients 
with aortic root aneurysms, we conducted a systematic review of observational reports on 
characteristics of, and mortality and morbidity after valve sparing aortic root replacement 
(VSARR), and explored factors potentially influencing outcome.
METHODS 
This systematic review and meta-analysis was conducted using the guidelines of the 
Meta-analysis Of Observational Studies in Epidemiology, proposed by Stroup et al. [8].
Search Strategy
On 10 January 2014, a search was executed in Embase, MEDLINE, Cochrane database and 
Web of Science (Appendix 1). All studies published from 1 January 2000 to 10 January 
2014 were screened by two reviewers (BA and AM) using the following inclusion criteria: 
reporting on mortality and morbidity after VSARR, study size N≥ 30 patients, mean age ≥ 
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18 years. Exclusion criteria were: solely acute aortic dissections, more than 50% children 
included, studies reporting state of the art, case reports, experimental studies and 
reviews. In case of disagreement, studies were assessed by a third, independent reviewer 
(RLW) and agreement was negotiated. In case of multiple publications on the same 
patient cohort, the most complete study in terms of outcome with the greatest number 
of patients included was selected. All selected studies were used for cross-referencing. 
Data Extraction
Microsoft Office Excel (Microsoft, l. Redmond, Washington) was used for data extraction. 
Data extraction was performed in duplicate by two of the authors (BA and AM). 
Outcome events in individual studies were registered according to the 2008 American 
Association for Thoracic Surgery/Society of Thoracic Surgeons/European Association for 
Cardiothoracic Surgery guidelines for reporting mortality and morbidity after cardiac 
valve interventions[9]. Events were not included in our database when adherence to the 
reporting guidelines could not be ascertained. For each article with missing information 
on important variables, the corresponding author was requested to provide the missing 
data. An overview of extracted variables is presented in Appendix 2 [5, 10-39].
Statistical Analysis
Data analysis was performed with Microsoft Excel (Microsoft Office 2010, Microsoft, 
Redmond, WA, USA) and IBM SPSS version 21.0 (IBM, Somers, NY, USA). Linearized 
occurrence rates of valve-related complications were calculated as number of events 
divided by number of patient-years for each study and pooled on a logarithmic scale 
with the use of the inverse variance method in a random-effect model, to minimize 
the  variance  of the weighted average. Each random variable is weighted in  inverse 
proportion to its variance. Reported study characteristics are quoted as mean ± standard 
deviation for continuous variables and percentages for discrete variables. Baseline 
characteristics are reported as means. For dichotomous or ordinal outcomes, individual 
and pooled statistics were calculated as occurrence  rates  and 95% CI. When the total 
number of patient-years was not reported, it was calculated by multiplying number of 
patients with mean follow-up. In case a certain event did not occur in an individual study, 
then we assumed that 0.5 events occurred for that particular outcome, to allow calculation 
of pooled occurrence rates. When a particular event was not reported in a study, this study 
was excluded from the analysis of that particular event. 
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Subgroup analyses of outcome were performed for surgical technique (reimplantation 
versus remodeling), preoperative AR severity, bicuspid valve disease, connective tissue 
disease and cusp repair. To assess the association of these variables with late mortality 
and reoperation, linear regression was performed with correction for age as a possible 
confounder. Regression analysis was weighted by study size according to the inverse 
variance method.
Heterogeneity between the studies was assessed with the use of the I2 test in Excel. 
Funnels plots were used to study publication bias.
RESULTS
Study characteristics and outcome
 
The initial literature search yielded 1.659 publications. The selection procedure of this 
systematic review is depicted in Figure 1. A total of 31 studies were included in this 
systematic review with a total number of 4.777 patients and 21.716 patient-years. An 
overview of the included publications and study characteristics is given in Appendix 3.
FIGURE 1. Selection procedure.
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Pooled pre-operative and peri-operative characteristics are displayed in Table 1. Early 
mortality occurred in 103 patients (pooled early mortality 2.2%). 
Mean follow-up after VSARR was 4.4 years (range 1.5-13.2 years).  Late mortality occurred 
in 262 cases and was unknown or unreported in 19% of deaths. The main causes of late 
mortality were non-cardiac (39%). Cardiac valve-related and cardiac non-valve related 
death occurred in 37% and 5% of deaths respectively.  
TABLE 1. Pooled pre-operative and peri-operative characteristics.
Variable Pooled data Range
Included 
studies (N)
Total patient number 4.777 32 - 430 31
Surgical period 1988 - 2012 31
Mean age 51.0 years 29 – 63 years 30
Gender Male 71.0% 57 – 85% 30
Comorbidity
Connective tissue disease 23.9% 0 – 100% 35
Severe aortic regurgitation 46.1% 6.4 – 100% 25
Bicuspid aortic valve 14.1% 0 – 33% 28
Prior surgery Cardiac 4.49% 2 – 12% 14
Other indications Acute type A dissection 10.5% 0 – 33% 28
Reexploration for bleeding 6.4% 0 – 23% 27
Concomitant
Aortic (hemi)arch repair 22.1% 0 – 68% 26
Cusp repair† 33.2% 0 – 76% 30
CABG 9.1% 0 – 19% 25
Mitral valve surgery 5.3% 0 – 12% 25
Extracorporeal circulation Time in minutes 157 66-281 22
Aortic cross-clamping Time in minutes 122 36-223 22
Early mortality 2.2% 0 – 7% 31
Causes of early mortality ‡
Low cardiac output 29.6% 0 – 60%
Hemorrhage 1.0% 0 – 33%
Multiorgan failure 12.6% 0 – 40%
Stroke 1.0% 0 – 25%
Unknown / unreported 55.8%
CABG indicates coronary artery bypass grafting; † Peroperative cusp repair in order to tailor the aortic valve; ‡ major causes 
of early mortality.
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Pooled outcome
The linearized occurrence rates of late mortality, reoperation on the aortic root, 
hemorrhage, thromboembolism, endocarditis and major adverse valve-related events are 
presented along with a measure of statistical heterogeneity in Table 2 and Appendix 3.
TABLE 2. Linearized occurrence rates of late outcome events.
Pooled late outcome 
events
LOR + 95%
CI*
Heterogeneity 
(I2)
Included 
studies (N)
Events
(N)
Patient years 
(N)
Late mortality 1.53 ( 1.19 – 1.96) 82.6 31 262 21274
Reoperation on aortic 
valve
1.32 (1.0 – 1.74 ) 72.3 31 228 21274
Hemorrhage 0.23 ( 0.13 – 0.42 ) 78.7 26 15 19158
Thromboembolism 0.41 (0.22 – 0.77 ) 27.6 26 42 19158
Endocarditis 0.23 ( 0.11 – 0.51) 0.00 30 29 20930
MAVRE 1.66 (1.24  – 2.23 ) 100 20 300 19158
LOR indicates linearized occurrence rates; CI, confidence interval; MAVRE, major adverse valve-related events.
Publication Bias 
Analysis of the funnel plots revealed evidence of underreporting of late mortality in 
studies with smaller patient numbers. For other parameters, no evidence of publication 
bias was found.
Subgroup Analyses
A total of 12 studies reported using both the remodeling and the reimplantation technique. 
Four studies reported using solely the remodeling technique and 15 studies solely the 
reimplantation technique. Data about severity of post-procedural AR was mentioned in 9 
studies and further specified in AR grade II or more in 6 of these studies, with a total of 41 
patients (3.5% of these studies). Additionally, there were no data regarding leaflet heights 
and coaptation surfaces of the repaired valves.
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Surgical technique was not associated with higher survival or reoperation rates. Figure 
2 represents the association between preoperative AR severity and reoperation hazard 
based on pooled LOR. Correcting for age we found a trend (p = 0.07) toward preoperative 
severe AR being associated with a higher reoperation risk. Other analyses did not show 
any significant associations. No other factors were found to be associated with survival 
and/or reoperation rates. 
FIGURE 2. Association of reoperation rate and preoperative severe AR, based on LOR’s. 
Dots represent studies (the larger the study the greater the dots), p-value is derived from regression analysis (according to the 
weighted, inverse variance method). 
COMMENT
This systematic review and meta-analysis gives an overview of published contemporary 
evidence on characteristics and outcome after valve sparing aortic root replacement. It 
shows acceptable outcomes in terms of survival and freedom from both reoperation and 
valve-related events in the first 5 postoperative years, regardless of the surgical technique 
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employed (remodeling or reimplantation). Moreover, it illustrates that current evidence 
is fragmented and heterogeneous, and does not allow for furthermore exploration of 
potential determinants of outcome. 
Early and late outcomes
The observed pooled early and late mortality in this systematic review is low. Additionally, 
there is a low incidence of thromboembolism, endocarditis and hemorrhagic events 
after valve sparing aortic root replacement. Previous reports, including a less exhaustive 
review conducted by Rahnavardi et al. [40], confirm our observation of low early mortality 
and 4 year reoperation hazard, and that  bicuspid aortic valves are not associated with a 
significant higher reoperation rate.  The  rate of bicuspid repair is low (14%)  in this meta-
analysis, as confirmed by Badiu et al. that BAV is not associated with a higher reoperation 
hazard, but there is a trend toward higher reoperation hazard for patients with preoperative 
severe AR [17]. Only 9 studies in our  systematic review describe their direct postoperative 
echocardiographic aortic valve regurgitation data. Thus, based on our systematic review it 
is not possible to make assumptions about the association between direct postoperative 
AR and reoperation hazard. Although there are no large reports on VSARR and cusp 
prolapse, a report by Schäfers et al. emphasized that symmetric cusp prolapse should be 
corrected during VSARR to avoid AR by the measurement of cusp effective Height using 
a dedicated caliper [41]. This was confirmed by Lansac et al. defining the absence of cusp 
effective height resuspension as an independent risk factor for AR grade 2 or higher and 
for reoperation  [21]. There were no reports about leaflet heights and cusp anatomy, 
therefore we are not able to test any assumption about their possible association with 
reoperation or other valve-related complications.  Of course, given the limited follow-up 
duration of most studies in this review, the reported late outcomes cannot be extended 
beyond the first postoperative decade.
Surgical technique: remodeling versus reimplantation
No clinical advantages in terms of survival and reoperation of one technique over the 
other is evident from our meta-analysis of the literature. Although the remodeling 
technique provides physiological cusp movements within the three reconstructed neo 
sinuses, thus preserving root expansibility through the interleaflet triangles, it does not 
address annulus dilation which has been identify as a risk factor of failure (>25-28mm) [7-
8, 13-15]. The reimplantation procedure as an inclusion technique performs a subvalvular 
annuloplasty through the proximal suture of the graft but withdraws the sinuses of 
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Valsalva and includes the interleaflet triangles within the non-compliant prosthesis, thus 
impairing root dynamics [8, 14].  Therefore, since annulus dilation has been identified  as 
a risk factor for repair failure for dystrophic aortic roots with bicuspid and tricuspid valves, 
there is a consensus among authors to favor valve sparing root replacement  providing an 
aortic annuloplasty through either a proximal suture using the reimplantation technique 
or an annuloplasty ring device in combination with the remodeling technique.  
VSARR versus Bentall
VSARR offers patients with aneurysms of the ascending aorta several advantages over 
composite graft replacement (Bentall), such as no need for oral anticoagulation, thereby 
avoiding increased bleeding risk, INR monitoring, and lifestyle adjustments (e.g. sports, 
alcohol intake etc.). In addition, there is evidence that patients receiving a VSARR may 
experience a better overall quality of life compared to patients with a mechanical valve 
[42]. On the downside, after VSARR more reoperations are expected compared to the 
Bentall procedure.
Although the Bentall procedure yields a lower risk of reoperation, especially in longer 
follow up, there is a lower hemorrhagic risk and thromboembolism seems to occur less 
often in patients receiving a VSARR because of anti-coagulation therapy needed after 
the Bentall [43, 44]. This is particularly important in patients with an active lifestyle as 
well as in female patients with the desire of a pregnancy after the operation [45, 46]. 
Patient characteristics, such as age at the time of operation, proportion of patients with 
connective tissue disease and aortic arch repair are similar between the two studies. 
Need for standardized data 
Given the observed heterogeneity, it is obvious from this systematic review that there is a 
need for uniform standardized reporting of VSARR procedures and their outcomes. Also, 
there is a need for collaboration between centers in their reporting of VSARR procedures, 
as it will accelerate our knowledge building of this complex surgical procedure and its 
outcomes. Within the Heart Valve Society the AVIATOR registry was initiated: a multicenter, 
prospective registration with the goal to combine forces and share experience in order 
to advance knowledge in the field of surgical treatment of patients with aortic root 
dilatation and/or aortic valve regurgitation (www.researchonline.org/link/study/aviator). 
This initiative will hopefully provide an evidence base to tailor the most suitable surgical 
treatment, such as valve sparing procedures, to the individual patient.
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Limitations
The available guidelines on reporting after heart valve interventions were not 
applied in several studies included in our systematic review and may have resulted in 
misinterpretation of the available data. It is obvious that the included studies represent a 
heterogeneous population of patients in their thirties through sixties, with varying aortic 
aneurysm, bicuspid valve, and aortic regurgitation prevalence. These patients of various 
cohorts were operated between 1988 and 2011, spanning over 20 years. In this light, 
the observed outcomes should be weighted carefully. Additionally, the limited follow 
up duration of the included studies does not allow for conclusions beyond the first five 
postoperative years. 
The pooled linearized occurrence rates for reoperation and mortality data were based 
on heterogeneous data, under the linearity assumption, and should be treated with 
considerable caution. We included only studies with cohorts greater than 30 patients 
were included and in addition, where available, selecting the largest series of published 
data from a center was included, thus selecting more experienced surgeons and centers. 
This may have led to selection bias.
Finally, due to the retrospective nature of the available and included studies, underreporting 
of – in particular nonfatal – events is likely.   
CONCLUSION
Valve sparing aortic root replacement is an acceptable option for the treatment of aortic 
root aneurysm, with or without aortic regurgitation, especially in young active patients, 
and patients in whom anticoagulation therapy is less desirable due to lifestyle or medical 
history. Severe preoperative aortic valve regurgitation is associated with a trend towards 
a higher reoperation rate. Therefore, in order to improve the results, valve sparing aortic 
root replacement would benefit from a technical standardization that resuspends cusp 
effective height and reduces the dilated  aortic annulus (either by an annuloplasty 
device in case of remodeling or a proximal suture when using the reimplantation 
technique)  and restores proper valve coaptation. The observed lack of standardization 
in data reporting has led to the proposition of an international prospective multicenter 
registry for aortic valve sparing/repair and replacement surgery (AVIATOR registry). 
In addition, the most suitable surgical procedure should be determined on an individual 
basis, also taking into account patient preference. 
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ABBREVIATIONS
AR  =  Aortic Regurgitation
AS  =  Aortic Stenosis
CTD  =  Connective Tissue Disease
BAV  =  Bicuspid Aortic Valve
MAVRE  =  Major Adverse Valve Related Events
TE  =  Thromboembolism
VSARR  =  Valve Sparing Aortic Root Replacement
LOR  = Linearized occurrence rates
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ABSTRACT
Background. For middle-aged patients, aortic root replacement with biological valve 
prostheses offers a good alternative to the “gold standard” mechanical Bentall-procedure, 
avoiding anticoagulation therapy. Evidence on outcome after bioprosthetic aortic root 
replacement remains limited and fragmented. 
Methods. A systematic literature search on this subject revealed 2,105 publications 
between January 2000 and July 2016. Inclusion criteria: aortic root replacement in adults 
with root aneurysm, presenting survival, and ≥50 patients. Data were pooled by inverse-
variance weighting and entered into a microsimulation model to calculate lifetime event-
risk and (event-free) life expectancy.
Results. Of 2,105 publications, 29 were included (N = 4,623 patients, 74% stentless valves). 
Mean age at operation was 65.9 years (68% male), 14% had prior cardiac surgery. Pooled 
early mortality was 5.9% (N= 220: 95% CI: 4.7-7.3%). During follow-up (mean 4.1 years, 
total 18,675 patient-years), 742 patients died (4.6%/patient-year) and 140 were reoperated 
(0.7%/patient-year). Linearized-occurrence-rates for thromboembolism, endocarditis, 
and hemorrhagic events were 1.4%/patient-year, 1.0%/patient-year and 0.6%/patient-
year, respectively. Estimated life-time event risk of bleeding and thromboembolism were 
21% and 8%, respectively.
Conclusions. The meta-analysis and microsimulation model suggest acceptable results 
in terms of freedom from reintervention and valve-related events after bioprosthetic 
aortic root replacement, regardless of the prosthesis type (stented or stentless). The 
relatively high thromboembolic event hazard may be explained by older patient age. 
The age threshold for bioprosthetic root replacement remains debatable, as prosthetic 
valve selection is value-sensitive. The observed heterogeneity among studies underlines 
the need for international collaboration to obtain reliable data on the characteristics and 
outcomes after bioprosthetic aortic root replacement.
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INTRODUCTION
There are several surgical techniques to treat aortic root aneurysm when the valve is not 
eligible for sparing or repair procedure. In younger patients, i.e. patients under the age 
of 60-65 [2], mechanical composite valve replacement (the “Bentall” procedure(1)) is a 
widely used prosthesis, due to its long-term durability (2). In older patients, aortic root 
replacement with biological valve prosthesis is more common, because reoperations are 
less prominent because of the shorter life expectancy and because of avoiding the higher 
anticoagulation-related hemorrhagic complication rate associated with mechanical 
valve implantation. While structural valve deterioration (SVD) is associated with higher 
reintervention risk in younger patients (3, 4), there are no large, long follow-up  studies 
presenting outcome after bioprosthetic aortic root replacement in middle-aged patients, 
and most published studies have limited follow-up duration which is a limitation for 
the interpretation of the results, in particular regarding SVD and reoperation hazard 
(5). Nevertheless, biological valve prostheses are increasingly implanted in middle-
aged patients. Another topic of debate remains the most appropriate type of biological 
valve prosthesis (i.e. stented or stentless) in patients with aortic valve and root disease 
(6).  Although stentless valves may have better hemodynamics, advantages in terms of 
patient survival and long-term durability have not yet been demonstrated (7). To assess 
the current body of evidence on bioprosthetic aortic root replacement we conducted 
a systematic review of observational reports on patient characteristics and outcome ∼
valve related morbidity, mortality and reintervention rates∼ after bioprosthetic aortic root 
replacement with stented or stentless prostheses, and explored potential determinants 
of outcome.
MATERIAL AND METHODS
Search Strategy
On 30 July 2016, a systematic literature search was conducted in MEDLINE, Embase, The 
Cochrane Collaboration and Web of Science, and Google Scholar (Appendix 1). Studies 
published from January 2000 onwards were screened by three independent reviewers 
(BA, MM, RvV) using the following inclusion criteria: reporting morbidity and mortality 
after bioprosthetic aortic root replacement with stentless or stented prosthesis, cohorts 
≥ 50 patients (in order to prevent including early experience reports highlighting the 
learning curve), and mean age at surgery ≥ 18 years. Exclusion criteria were: > 50% acute 
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type A aortic dissection included, studies limited to reintervention or to patients receiving 
a mechanical valve prosthesis (i.e. Bentall-procedure), studies reporting only on early 
results, > 10% use of subcoronary technique, > 50% children included (aged <18 years), 
and state of the art publications, case reports, experimental studies and reviews. In case 
the same cohort was published more than once, the most complete publication was 
selected. All included studies were cross-referenced to identify additional publications. In 
case of disagreement, studies were assessed by another, independent reviewer (RLW) and 
agreement was negotiated until consensus was reached.
Data Extraction
Data extraction was performed in duplicate with Microsoft Excel (Microsoft Office 
2010, Microsoft, Redmond, WA, USA) by two of the authors (BA and JE) according to the 
guidelines for reporting mortality and morbidity after cardiac valve interventions (8). 
Events were not included in our database when adherence to the reporting guidelines 
could not be ascertained. For each article with missing information on important variables, 
the corresponding author was requested to provide the missing data. An overview of 
extracted variables is presented in Appendix 2.
Data Analysis
Data analysis was performed with Microsoft Excel (Microsoft Office 2010, Microsoft, 
Redmond, WA, USA) and IBM SPSS version 21.0 (IBM, Somers, NY, USA) and in the R statistical 
software (version 3.1.0. R Development Core Team, R Foundation for Statistical Computing, 
Vienna, Austria) using the metafor package. Pooled baseline patient characteristics were 
calculated with the use of sample size weighting.  Early mortality and linearized occurrence 
rates of late valve-related complications were pooled on a logarithmic scale with the use of 
inverse variance weighting in a random-effects model. Reported study characteristics and 
pre- and peri-operative patient characteristics are presented as mean ± standard deviation 
for continuous variables and percentages for discrete variables. For outcome variables, 
individual and pooled statistics are presented as linearized occurrence rates and 95% 
confidence interval (CI). In studies where median and ranges instead of mean and variance 
were reported, the method described by Hozo et al. (9) was used to calculate the mean. 
In case of absence of total number of patient-years, this was calculated by multiplying the 
number of patients with the mean follow-up duration in years. In case a certain event did 
not occur in an individual study, we assumed that 0.5 events occurred for that particular 
outcome for the purpose of inverse variance weighting. When a particular event was not 
14570-arabkhani-layout.indd   106 10/05/2017   10:39
107
6
Bi
op
ro
st
he
tic
 ao
rt
ic 
ro
ot
 re
pl
ac
em
en
t
reported in a study, this study was excluded from the analysis of that particular event. 
 
For late mortality and reintervention, subgroup analyses were performed stratifying the 
root replacement by prosthesis type (stented vs. stentless), follow-up duration (individual 
study mean follow-up less than pooled mean follow-up versus individual study mean 
follow-up more than pooled mean follow-up), and age at surgery. To assess the association 
of these variables with late mortality and reintervention rates, linear regression analyses 
were performed with weighting the studies according to the inverse variance of the 
occurrence rate.  Heterogeneity between the studies was assessed using the I2 test. 
Funnels plots were used to investigate publication bias. This systematic review and meta-
analysis was conducted according to the PRISMA guidelines (10).
Microsimulation
In order to estimate the age-specific life expectancy and an additional lifetime risk of 
valve-related morbidity, a microsimulation model was used based on the pooled outcome 
estimates of our meta-analysis. 
 
Microsimulation model: the concept
The microsimulation model is a computer application that simulates the life of a patient 
after aortic valve replacement, taking into account the morbidity and mortality events 
that the patient could experience. The calculated mortality of a patient is composed of 
the background mortality of the general population, operative mortality, mortality due to 
valve-related events and an additional “excess mortality”. This so called excess mortality 
in the patient compared to a matched person in the general population reflects mortality 
associated with the underlying left ventricular function, valve pathology, and the root 
replacement procedure.
All pooled and weighted occurrence rates of (operative) mortality risk, the occurrence 
rate of valve-related events together with the risk of mortality and reintervention directly 
due to valve-related events were obtained from the meta-analysis. The occurrence rates 
of all events were assumed to be linear and non-age-dependent. The hazard ratios of 
the additional excess mortality not directly resulting from valve-related events have 
been previously estimated (11). A more detailed account of the microsimulation and the 
methodology has been supplied previously (12).
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For patients aged 61-70 and > 70 years, these “excess mortality“ hazard ratios were 1.2 
and 0.8 for males and 2.2 and 1.3 for females, respectively. The background mortality of 
the general population was obtained from the 2004 United States Life Tables, as 2004 was 
the pooled median year of intervention, assuming a constant incidence rate over time in 
each study (13).
To obtain age-specific estimates of life expectancy and lifetime risk of valve-related 
morbidity, the microsimulation model was run for the ages of 60, 65 and 70 years for 10,000 
iterations each and separately for males and females. The age-specific outcomes of both 
genders were then pooled at the male/female ratio obtained from our meta-analysis. For 
the internal validation of the model, we performed an additional run for 10,000 iterations 
at the pooled mean age (65.9 years) and male/female ratio (67.6%) of the meta-analysis. 
The actuarial survival obtained from the microsimulation model for these data was then 
plotted against the pooled (overall) mortality observed in the meta-analysis.
RESULTS
Study and baseline patient characteristics
The initial literature search exposed 2,105 publications. The selection procedure is 
illustrated in Figure 1. Cross-referencing did not result in additional papers. A total of 
29 studies were finally included in this systematic review with a total number of 4,623 
patients, a mean follow-p of 4.1 yea rs (range 1-10 years), and a total follow-up of 17,725 
patient-years. 
Of these root replacements 26% were with stented and 74% with stentless valve prostheses. 
In one of the studies the implantation period was missing, which was provided by the 
authors (14). This study by Melina et al. was also the only prospective randomized trial; all 
others were retrospective, observational studies. Excluding this study from the analysis 
did not result in any inference and therefore this study was included in the analysis. 
Appendix 3 shows an overview of the included publications and study characteristics. 
Pooled pre- and peri-operative characteristics are presented in Table 1.
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408 
2105 
29 
Embase, MEDLINE, Web of Science, Goole Scholar 
from 
January 2000 to July 2016 
No survival/reoperation data 10 
More than 50% children 6 
Review/case-report/experimental 125 
Mostly acute dissection 34 
N < 50 cases 122 
Different subject/focus   1697 
Overlapping cohorts 
Conference abstract        82 
Full-text not available  
111 
FIGURE 1. Flowchart of systematic search and included articles.
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TABLE 1. Pooled pre-operative and peri-operative characteristics.
Variable Pooled data Range
Included 
studies (N)
Total patient number 4623 50 - 421 29
Surgical period 1992 - 2014 28
Mean age 64.2 years 47 – 73 years 28
Gender Male 67.6% 30 – 85% 29
Etiology
Valve pathology 17
   Aortic stenosis 49.8% 3 – 100%
   Aortic regurgitation 37.7% 0 – 92%
   Stenosis & regurgitation 17.9%
Connective tissue disease 2.9% 0 – 32% 12
Bicuspid aortic valve 28.0% 0 – 42.6% 14
Prior surgery Cardiac 14.2% 0 – 39% 22
Other indications 
Acute type A dissection 7.2% 0 – 24% 19
Acute endocarditis 9.1% 1 – 11% 8
Valve type
Stentless 99.7% 95 – 100% 21
Stented 92.8% 84 – 100% 5
Mixed 50% 50 – 50% 2
Concomitant 
procedures
Aortic hemiarch repair 18.2% 0 – 44% 19
Aortic arch repair 5.9% 3 – 21% 19
CABG 28.9% 0 – 44% 19
Mitral valve surgery 3.3% 0 – 17% 19
Reexploration for bleeding 10.8% 1 – 28% 14
Early mortality 5.9% 0 – 16% 29
Causes of early 
mortality *
Low cardiac output 22.7% 1 – 44%
Multi-organ failure Hemorrhage
18.1%
7.5%
13 – 100%
0 – 13%
Sepsis 
Myocardial infarction
5.0% 
4.0%
6 – 25%
0 – 100%
Unknown / unreported 9.6% 10 – 55%
CABG indicates coronary artery bypass grafting. * major causes of early mortality. Data indicate the pooled mean % of 
occurrence and the pooled range of occurrence. Included studies are publications reporting on the specific characteristic. 
The percentages mentioned are means of the reported variables in the studies that provided these variable numbers. The 
range indicates the lowest and the highest reported % of that specific variable within all studies, and N indicates the number 
of studies reporting on that specific variable.
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Pooled outcome 
Early (30 day) mortality occurred in 220 patients, corresponding to a weighted early 
mortality of 5.9% (95% CI: 4.7 – 7.3%). The linearized occurrence rates of mortality, 
reintervention on the aortic root, hemorrhage, thromboembolism, endocarditis and 
major adverse valve-related events are presented along with a measure of statistical 
heterogeneity in Table 2.
TABLE 2. Linearized occurrence rates of late outcome events.
Pooled late 
outcome events
LOR (%/yr) + 95% 
CI*
Heterogeneity 
(I2)
Included
studies (N)
Events
(N)
Patient years of 
follow-up (N)
Late mortality 4.61 (3.98 – 5.36) 71 29 742 18675
Root reintervention 0.72 (0.47 – 1.10) 73 29 140 118675
Hemorrhage 0.56 (0.33 – 0.94) 68 24 75 13743
Thromboembolism 1.41 (0.96 – 2.06) 73 24 141 13911
Endocarditis 1.00 (0.69 – 1.44) 69 26 134 15694
SVD* 0.32 (0.16 – 0.62) 76 25 63 14405
NSVD* 0.21 (0.13 – 0.35) 49 23 15 12438
LOR indicates linearized occurrence rates; CI, confidence interval; SVD, structural valve degeneration; MAVRE, major adverse 
valve-related events.* not all (N)SVD led to reintervention
Late mortality occurred in 742 patients (4.6%/patient-year); in 41% the cause was 
unknown or not reported. The main causes of late mortality were cardiac (52%). Cardiac 
valve-related and cardiac non valve-related death occurred in 51% and 49% of all cardiac 
deaths, respectively.  
Publication Bias 
Analysis of the funnel plots revealed evidence of underreporting of late mortality, 
reintervention on the aortic root, and thromboembolism in studies with smaller patient 
numbers. For other variables, no evidence of publication bias was found (Appendix 3).
Subgroup Analyses 
A total of 21 studies reported using solely a biological valve-containing vascular 
prosthesis (14-34), of which 14 studies with Freestyle bioprosthesis, 2 studies solely Bio-
Valsalva prosthesis, 2 Shelhigh bioconduit, 1 Edwards S prima Plus, 2 with mixed stentless 
prosthesis. In and one study the type of the biological valve was unspecified (35). Two 
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studies included both stentless and stented bioprostheses (36, 37). Four studies used 
(nearly) exclusively self-made aortic root prosthesis using a stented bioprosthesis (38-
41). No associations were found between late mortality or reintervention and the type 
of prosthesis used. Moreover, mean follow-up time, age at operation, with a sub-analysis 
of studies with a mean follow-up of more than 4.1 years versus less than 4.1 years, and 
use of the Freestyle bioprosthesis were not associated with mortality or reintervention. 
Of 8 studies that explicitly tested age as a potential predictor for reoperation, 3 found an 
association between younger age and reoperation hazard.
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FIGURE 2. Microsimulation-based life expectancy and lifetime risk of valve-related morbidity for 60, 65 and 70 years 
old patients.
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Microsimulation-based estimates of (event-free) life expectancy and lifetime risk of 
valve-related morbidity for 60, 65 and 70 years old patients are shown in Figure 2. The 
microsimulation model calibration with the pooled mortality is shown is Appendix 4.
COMMENT
This systematic review and meta-analysis provides an overview of contemporary published 
evidence on outcome after aortic root replacement with biological valve prostheses. It 
shows acceptable outcomes in terms of patient survival and freedom from reintervention 
irrespective of the type of valve prosthesis used (stented or stentless). Although stentless 
valves may have better hemodynamics (6), no improvement in terms of patient survival 
or long-term durability were observed in this review. In addition, thromboembolic events 
occur relatively frequently. The observed heterogeneity of the compiled outcome data 
does not allow for accurate exploration of potential risk factors associated with outcome.
Early outcome
The observed pooled early mortality was 5.9%. This is in accordance with earlier published 
review  on aortic root replacement with the Freestyle prosthesis (4.5 to 5.3%) and in the 
recent report of the Society of Thoracic Surgeons database from the U.S. that estimates early 
mortality after bioprosthetic aortic root replacement to be 6.2% (42, 43). Early mortality 
was mainly due to low cardiac output (22.7%) and multi-organ failure (18.1%). Although 
surgical indication was endocarditis in 9.2% of patients and type A aortic dissection in 
7.2%, no further details on early mortality in these subgroups could be extracted from 
the individual studies. Thus further inferences on comorbidity and early mortality were 
not possible. Additionally, there was a 1.8% risk of re-exploration for excessive bleeding 
or cardiac tamponade. The 16 studies that reported on re-exploration for bleeding and 
tamponade did not assess potential risk factors for this complication, and did not specify 
the postoperative anticoagulation regime, which precluded any further inferences.
Late mortality and reintervention outcome
There was a high mortality rate of 4.6%/pt-year for a pooled mean age of 65.9 years in 
our meta-analysis, which is higher than the general population mortality. Translated 
to our microsimulation-based life expectancy, there is a life expectancy of 14.3 year 
for a 60 year old patient receiving a bioprosthetic root replacement, while there is a 
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life expectancy of 22.5 years for the 60 year old U.S. “healthy” population (13). From 
previous research there is evidence of significant “excess mortality” in (elective) isolated 
aortic valve replacement and in case of prosthesis-patient mismatch, compared to 
the age-matched general population (44). Additionally, patients in this meta-analysis 
were diagnosed with a diseased aortic root as well, with some 13% suffering from a 
dissection of the root and/or connective tissue disease, which are conditions that may 
have an effect on patient survival due to complication other than valve-related events. 
Nevertheless, the calibration of the microsimulation model seems to underestimate the 
mortality hazard over time (appendix 4). This could be explained by the excess mortality 
data that was based on data from studies in de 1990’s  which may not be representative 
for our patients and this underestimation of the “excess mortality” probably led to 
overestimating the life time event risks observed. More accurate data on more recent 
mortality in the general population will probably lead to better calibration of our data.  
Our microsimulation model shows a life time reintervention risk of 9% for a patients older 
than 60 years, which is comparable to previous predictions on biological aortic valve 
prostheses (3). From the literature it is known that younger patient age is associated with 
higher reintervention hazard after aortic valve replacement, especially in patients younger 
than 60 years old, mainly due to higher, progressive SVD in these younger patients (3, 45). 
However, we could not confirm this association between age and reintervention hazard. 
Notably, mean age at inclusion in the individual studies was  higher than 60 years, except 
for 2 studies (Desai et al.[18] and LeMaire et al.[14]), which may explain this discordance 
in findings between younger age and reintervention outcome. Although, LeMaire et al. 
with a mean age at inclusion of 55 years reported lower reintervention hazard (0.23%/
pt-year) compared to Desai et al. (2.72%/pt-year), with a mean age of 47 at inclusion 
[14, 18]. Moreover, out of 8 studies that explicitly tested association between age and 
reintervention, 3 found indeed that older age is associated with lower reintervention 
hazard. More studies on bioprosthetic aortic root replacement in younger patients are 
needed in order to investigate this presumed association. 
Thromboembolic events
In this study, there is a high incidence of thromboembolic events, with a life time risk of TE 
more than >20%, after bioprosthetic aortic root replacement. The data in our meta-analysis 
on TE events are not comprehensive, thus the impact of the TE and e.g. discriminating 
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between TIA and disabling ischemic CVA is not possible. However, a previous systematic 
review and microsimulation study on aortic valve replacement with isolated biological 
(stented) valve, published by Puvimanasinghe et al. (3), report similar TE event rates 
(1.4%/patient-year). Additionally, the incidence of a thromboembolic event is known 
to increase with age (46, 47) and this may, at least partly, explain the high incidence of 
thromboembolic events in these patients with a pooled mean age of 65.9 years.
Subsequently the question arises whether there may be a difference with patients 
receiving a mechanical valve prosthesis. Although comparing patients receiving 
biological aortic valve prostheses and mechanical valve prostheses is hampered by the 
differences in patient characteristics, mainly due to the younger age in patient receiving 
mechanical valves; a recently published systematic review and meta-analysis on Bentall 
procedure in patients with mean age of 50 years, shows lower thromboembolic event 
rates  (0.77%/patient-year) (48). Anticoagulation therapy that is required after mechanical 
valve implantation in these patients may also play a protective role in prevention of 
thromboembolic events, as TE events occur irrespective of the aortic valve replacement 
due to the aging process and higher atrial fibrillation incidence in the older population 
(47).  
According to the current US and European guidelines on the management of valvular 
heart disease antiplatelet therapy is reasonable/may be considered for the first 3 months 
after biological valve replacement (2, 49). Additionally, the European guidelines state 
that the need for a 3 months postoperative period of anticoagulation therapy has been 
challenged in patients with bioprostheses, with the use of low-dose aspirin being favored 
as an alternative. According to our findings, with high incidence rate of TE events, it is 
questionable whether the proposed anticoagulation therapy is appropriate in patient 
receiving a bioprosthetic aortic root replacement. Further studies are needed to determine 
the most optimal anticoagulation therapy after biological aortic valve replacement. 
Endocarditis
Although the rate of endocarditis after bioprosthetic aortic root replacement varies widely 
in the literature (50), our findings are comparable to a systematic review and microsimulation 
study on biological (stented) aortic valve replacement by Puvimanasinghe et al. [3]. 
Additionally, in our systematic review there are 3 large studies with an endocarditis rate 
of  >2.8%/patient-year (22, 26, 51), with all 3 including only stentless valve prostheses. 
However, these studies included a relatively high proportion of patients with active 
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endocarditis which may explain the higher re-endocarditis rate. Moreover, we did not 
find an association between the type of prostheses used (stentless or stented valves) and 
endocarditis, neither is there to our knowledge any association reported in the literature. 
Hence, both stented and stentless bioprosthetic valve prostheses are good alternatives to 
be used in case of endocarditis. Notably, the severity of endocarditis was not included in 
the analysis.
The place of bioprosthetic aortic root replacement on the surgical menu
There is no perfect valve substitute for the individual patient with aortic valve 
or root disease as all valve prostheses are associated with certain valve-related 
events of varying nature. Careful weighting of the advantages and disadvantages 
of biological and mechanical valve substitutes tailored to the patient’s unique 
clinical characteristics as well as patient preference, is the current golden standard. 
Interestingly, there is a trend toward using a biological valve in younger patients than 
recommended in the mentioned guidelines (5, 52). Although evidence is lacking, perhaps 
this is emerging due to the potential prospect of transcatheter valve-in-valve therapy in 
younger patients. However, it remains debatable which option is the most appropriate for 
the individual patient.
According to the ESC/EACTS guidelines on valvular heart disease, age limits contain an 
arbitrary element, and the choice of prostheses type should be individualized in a joint 
decision between the informed patient, cardiologist and surgeon. Although SVD is known 
to occur earlier in younger patients (53), mechanical valve prostheses are not desirable in 
all young patients. Moreover, quality of life and patient preferences must also be taken 
into account when choosing the most suitable valve prosthesis. Briefly, these relatively 
young patients (below 60-65 ) with a life expectancy exceeding the mean durability of 
a bioprosthetic valve should be aware of the prospect and risks of a reintervention later 
in life, but also the profits gained for not receiving a mechanical valve prostheses (e.g. 
avoid the use of anticoagulation therapy). Nevertheless, as individual patient norms, 
values and goals in life vary widely, the decision for a particular valve prosthesis should be 
individualized in a shared decision making process, and together with surgical experience, 
the most suitable surgical approach should be determined (2, 49). Our systematic review 
adds to the body of evidence by showing in a middle-aged patient population undergoing 
bioprosthetic ARR acceptable reintervention rates and valve-related event occurrence.
14570-arabkhani-layout.indd   116 10/05/2017   10:39
117
6
Bi
op
ro
st
he
tic
 ao
rt
ic 
ro
ot
 re
pl
ac
em
en
t
Limitations
This is a systematic review and meta-analysis of retrospective observational studies. 
Hence, inherent (known) limitations of a meta-analysis of this type should be taken into 
consideration (54)  Furthermore, recall bias inherent to the retrospective design of all but 
one study and publication bias may have affected the observed outcome. In addition, 
the included studies represent a heterogeneous population of patients with differing 
patient characteristics between these populations, with patients operated in different 
era spanning over 20 years, and considering improvements in anticoagulation strategies, 
medical management of valvular heart disease and surgical techniques over the past 
decades, which may have influenced outcome. Moreover, a lack of uniform data reporting 
as proposed by the guidelines (8) may have influenced the uniformity of the pooled data. 
The pooled late outcome estimates are based on the linearity assumption, while occurrence 
of outcome events may not be linear in nature. However, due to the lack of randomized 
trials where homogeneous data are present, this meta-analysis was performed to provide 
an overview of published outcomes after bioprosthetic aortic root replacement.
CONCLUSION
This systematic review and meta-analysis provides an overview of contemporary outcome 
after bioprosthetic aortic root replacement and demonstrates acceptable outcome 
in terms of survival and freedom from reintervention, irrespective of the type of valve 
prosthesis used (stented or stentless). Thromboembolic events occur relatively frequent 
and may reflect the higher thromboembolic risk in the middle aged and older patients. 
Given the observed heterogeneity of the pooled study results, in-depth analysis of 
potential risk factors remains challenging. It requires a collective international effort such 
as the recently started AVIATOR registry (55) employing uniform data definitions and high 
quality data collection, to push forward the knowledge on outcomes and provide clues 
toward optimization of treatment selection for patients requiring aortic root replacement.
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APPENDIX 1
Embase
((bio* NEAR/3 (bentall* OR valsalva*)) OR biobentall* OR Biovalsalva* OR (Freestyle NEAR/3 
(bioprosthe* OR ‘aortic valve’ OR ‘aortic valves’ OR ‘aorta valve’ OR ‘aorta valves’ OR xenograft OR 
‘aortic root’ OR ‘aortic roots’ OR ‘aorta root’ OR ‘aorta roots’ ))):ab,ti OR (‘aorta valve prosthesis’/de OR 
‘aorta valve replacement’/de OR ‘aorta valve’/de OR (aort* NEAR/3 valve*):ab,ti) AND (‘aorta root’/de 
OR ‘aortic root surgery’/de OR (aort* NEAR/3 root*):ab,ti) AND (‘aorta valve prosthesis’/de OR ‘aorta 
valve replacement’/de OR ‘aortic root surgery’/de OR ‘aorta valve prosthesis’/exp OR  ((root* OR valve* 
OR aort*) NEAR/3 (replace* OR conduit* OR prosthe* OR bioprosthe*)):ab,ti) AND (bioprosthesis/
de OR ‘heart valve bioprosthesis’/exp OR xenograft/de OR (freestyle* OR bioprosth* OR biologic* 
OR (bio NEXT/1 prosth*) OR porcine* OR xenograft* OR (xeno*  NEXT/1 (graft* OR transplant*)) 
OR xenotransplant* OR ‘Tissue-valved’):ab,ti) NOT (‘mitral valve’/de  OR ‘Ross procedure’/de OR 
(mitral OR (Ross NEXT/1 (procedure* OR operat*)) OR (pulmonar* NEXT/1 autograft*)):ab,ti) NOT 
([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Conference Paper]/lim OR [Editorial]/
lim)
Medline (OvidSP)  
((bio* ADJ3 (bentall* OR valsalva*)) OR biobentall* OR Biovalsalva* OR (Freestyle ADJ3 (bioprosthe* 
OR “aortic valve” OR “aortic valves” OR “aorta valve” OR “aorta valves” OR xenograft OR “aortic root” 
OR “aortic roots” OR “aorta root” OR “aorta roots” ))).ab,ti. OR (“aortic valve”/ OR (aort* ADJ3 valve*).
ab,ti.) AND ((aort* ADJ3 root*).ab,ti.) AND (“Heart Valve Prosthesis”/ OR “Heart Valve Prosthesis 
Implantation”/ OR  ((root* OR valve* OR aort*) ADJ3 (replace* OR conduit* OR prosthe* OR 
bioprosthe*)).ab,ti.) AND (bioprosthesis/ OR (freestyle* OR bioprosth* OR biologic* OR (bio ADJ 
prosth*) OR porcine* OR xenograft* OR (xeno*  ADJ (graft* OR transplant*)) OR xenotransplant* OR 
“Tissue-valved”).ab,ti.) NOT (“mitral valve”/  OR (mitral OR (Ross ADJ (procedure* OR operat*)) OR 
(pulmonar* ADJ autograft*)).ab,ti.) NOT (letter OR news OR comment OR editorial OR congresses 
OR abstracts).pt.
Cochrane  
((bio* NEAR/3 (bentall* OR valsalva*)) OR biobentall* OR Biovalsalva* OR (Freestyle NEAR/3 
(bioprosthe* OR ‘aortic valve’ OR ‘aortic valves’ OR ‘aorta valve’ OR ‘aorta valves’ OR xenograft OR 
‘aortic root’ OR ‘aortic roots’ OR ‘aorta root’ OR ‘aorta roots’ ))):ab,ti OR ((aort* NEAR/3 valve*):ab,ti) 
AND ((aort* NEAR/3 root*):ab,ti) AND (((root* OR valve* OR aort*) NEAR/3 (replace* OR conduit* 
OR prosthe* OR bioprosthe*)):ab,ti) AND ((freestyle* OR bioprosth* OR biologic* OR (bio NEXT/1 
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prosth*) OR porcine* OR xenograft* OR (xeno*  NEXT/1 (graft* OR transplant*)) OR xenotransplant* 
OR ‘Tissue-valved’):ab,ti) NOT ((mitral OR (Ross NEXT/1 (procedure* OR operat*)) OR (pulmonar* 
NEXT/1 autograft*)):ab,ti)
Web-of-science   
TS=(((bio* NEAR/3 (bentall* OR valsalva*)) OR biobentall* OR Biovalsalva* OR (Freestyle NEAR/3 
(bioprosthe* OR “aortic valve” OR “aortic valves” OR “aorta valve” OR “aorta valves” OR xenograft OR 
“aortic root” OR “aortic roots” OR “aorta root” OR “aorta roots” ))) OR ((aort* NEAR/3 valve*)) AND 
((aort* NEAR/3 root*)) AND (((root* OR valve* OR aort*) NEAR/3 (replace* OR conduit* OR prosthe* 
OR bioprosthe*))) AND ((freestyle* OR bioprosth* OR biologic* OR (bio NEAR/1 prosth*) OR porcine* 
OR xenograft* OR (xeno*  NEAR/1 (graft* OR transplant*)) OR xenotransplant* OR “Tissue-valved”)) 
NOT ((mitral OR (Ross NEAR/1 (procedure* OR operat*)) OR (pulmonar* NEAR/1 autograft*)))) AND 
DT=(Article)
Scopus    
TITLE-ABS-KEY(((bio* W/3 (bentall* OR valsalva*)) OR biobentall* OR Biovalsalva* OR (Freestyle W/3 
(bioprosthe* OR “aortic valve” OR “aortic valves” OR “aorta valve” OR “aorta valves” OR xenograft OR 
“aortic root” OR “aortic roots” OR “aorta root” OR “aorta roots” ))) OR ((aort* W/3 valve*)) AND ((aort* 
W/3 root*)) AND (((root* OR valve* OR aort*) W/3 (replace* OR conduit* OR prosthe* OR bioprosthe*))) 
AND ((freestyle* OR bioprosth* OR biologic* OR (bio W/1 prosth*) OR porcine* OR xenograft* OR 
(xeno*  W/1 (graft* OR transplant*)) OR xenotransplant* OR “Tissue-valved”)) AND NOT ((mitral OR 
(Ross W/1 (procedure* OR operat*)) OR (pulmonar* W/1 autograft*)))) AND DOCTYPE(ar)
PubMed publihser   
((bio*[tiab] AND (bentall*[tiab] OR valsalva*[tiab])) OR biobentall*[tiab] OR Biovalsalva*[tiab] 
OR (Freestyle AND (bioprosthe*[tiab] OR aortic valve*[tiab] OR aorta valve*[tiab]OR xenograft 
OR aortic root*[tiab] OR aorta root*[tiab]))) OR ((aort*[tiab] AND valve*[tiab])) AND ((aort*[tiab] 
AND root*[tiab])) AND (((root*[tiab] OR valve*[tiab] OR aort*[tiab]) AND (replace*[tiab] OR 
conduit*[tiab] OR prosthe*[tiab] OR bioprosthe*[tiab]))) AND ((freestyle*[tiab] OR bioprosth*[tiab] 
OR biologic*[tiab] OR bio prosth*[tiab] OR porcine*[tiab] OR xenograft*[tiab] OR xeno graft*[tiab] 
OR xeno transplant*[tiab] OR xenotransplant*[tiab] OR Tissue-valved*[tiab])) NOT ((mitral[tiab] OR 
Ross procedure*[tiab] OR ross operat*[tiab] OR pulmonary autograft*[tiab])) AND publisher[sb]
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APPENDIX 2
Study characteristics of included publications
First 
Author
Publi-
cation 
Year
Implantation 
Period
Patients 
(N)
Mean 
Age 
(yrs)
Type of 
prosthesis
Mean 
FU 
(yrs)
BAV
(%)
AD
(%)
CTD 
(%)
Kon 2002 1992-1997 104 72 Stentless 6 - - -
Gleason 2004 2001-2003 176 63 Mixed 1 37 8 12
Melina 2004  1993-2003 80 66 Stentless 4 - - -
Auriemma 2006 1993-2004 318 69 Stentless 3 - 20 -
Dapunt 2008 1999-2007 317 70.2 Stentless 2 - 14 -
LeMaire 2009 2001-2007 132 54.8 Stentless 3 34 10 20
Zannis 2009 1997-2008 55 71 Stentless 2 18 9 -
Baraki 2010 2007-2009 50 65 Stentless 8 - 4 -
El- Hamamsy 2010 1997-2005 90 66 Stentless 7 - - -
Etz 2010 1995-2008 307 71 Stented 7 27 48 1
Desai 2011 1997-2007 138 47,4 Stentless 5 - 8 -
Ennker 2011 1996-2007 301 72 Stentless 10 - - -
Galinanes 2011 1999-2008 67 67.9 Stentless 7 - 9 -
Kaya 2011 1998-2007 175 71.1 Stentless 3 9 11 3
Lehr 2011 1998-2007 93 60.9 Stentless 3 - 11 5
Pagni 2011 1998-2009 170 67.4 Stentless 3 21 9 -
Kaya 2012 2008-2011 102 70.9 Stentless 1 16 4 2
Mazzola 2012 2001-2010 79 73 Stented 4 18 0 0
Yang 2013 2004-2010 150 66.3 Mixed 1 - - 1
Bach 2014 1992-1997 178 71.7 Stentless 6 - - -
Badiu 2014 2000-2011 91 65 Stented 4 - 22 2
Benetis 2014 1997-2012 51 72.5 Stentless 5 12 - -
Meszaros 2014 2005-2011 201 66 Stentless 2 0 21 0
Mohammadi 2014 1993-2013 101 65.2 Stentless 10 43 0 0
Urbanski 2015 1998-2008 79 - Stented 6 - 1 -
Sherrah 2015 2004-2014 237 63.2 Stentless 2 - 9 -
Sahin 2016 2001-2005 63 62 Stentless 10 - - -
Svensson 2016 1995-2011 297 66 Unspecified 6 24 - -
Gaudino 2016 1997-2014 421 63.3 Stented 2 52 0 3.1
AD = Acute Dissection, BAV = Bicuspid Aortic Valve, CTD = Connective Tissue Disease, FU = Follow-up
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APPENDIX 3
Funnel plots for estimating publication bias.
SE = standard error.
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APPENDIX 4
The actuarial survival curve obtained from the microsimulation model run for 10,000 
iterations at the pooled mean age (66 years) and male/female ratio (67.6% male) observed 
in the meta-analysis compared to the pooled overall mortality observed in the meta-
analysis.
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Chapter 7
Allografts in aortic position:
Insights from a 27-year,
single-center prospective study
Arabkhani B, Bekkers JA, Andrinopoulou ER, Roos-Hesselink JW, Takkenberg JJ, Bogers AJ
J Thorac Cardiovasc Surg. 2016 Dec;152(6):1572-1579
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ABSTRACT
Objective. Over the past decades the indication for allograft implantation in aortic 
position has evolved. The purpose of this study is to report long-term survival, allograft 
durability, and potential risk factors. 
Methods. Between 1987 and 2010, 353 patients underwent aortic valve replacements 
using allograft (92 subcoronary, 261 root replacement; 98% aortic allografts). Patient 
characteristics, survival, valve durability, and valve-related events were analyzed. 
Additionally, patients were followed with standardized echocardiography. A joint 
modeling approach was used to detect the effect of (echocardiographic) variables on 
mortality and reoperation hazard. 
Results. Mean age was 45 years (range 1 month to 84 years); 71% males. Etiology: 
endocarditis 32% (active 22%), congenital 31%, degenerative 9%, aneurysm/dissection 
12%, rheumatic 6%, and prosthetic valve failure 10%. Hospital mortality: 5.9% (N = 21). 
During follow-up (mean 12 years, range 0-24, 99% complete), 113 patients died. Twenty-
year cumulative survival was 41% (95% CI: 32-50). Valve-related reoperations occurred in 
117 patients:  100 SVD, 9 NSVD, and 8 endocarditis. Competing-risk analysis predicted 
that at 20 years 31% died, and 30% were alive without reoperation. Younger patient-age 
was associated with increased reoperation. During follow-up left ventricular dilatation 
and severe aortic regurgitation were associated with mortality (p= 0.006 and 0.005 
respectively), and ≥ grade 3 aortic regurgitation during follow-up was associated with 
reoperation risk (p= 0.001). 
Conclusions. After almost 3 decades of experience with allografts in aortic position, the 
indication for use has become selective, mainly because of progressive SVD over time. 
In case of complex aortic root pathology and active endocarditis allografts may still be 
useful. 
Ultramini abstract. Allografts have excellent clinical results in the first postoperative 
decade. However, from the second postoperative decade SVD becomes more apparent 
and a reoperation hazard will increase. Infective endocarditis (reinfection) hazard after 
allograft implantation is low. Allograft may be used in case of endocarditis and complex 
aortic root pathology.   
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INTRODUCTION
The indication for implantation of allografts in aortic position has changed over the last 
decades. Initially allografts were regarded as a good alternative to biological and mechanical 
valve substitutes because of the excellent hemodynamics, low thrombo-embolic 
complications, good resistance to endocarditis, and no need for anticoagulation therapy. 
In addition, aortic allografts were found very useful in complex aortic root pathology with 
aortic annular destruction because of the flexible allograft tissue properties that allow for 
reconstruction of destructed tissue. However, the durability of the allografts showed to be 
limited and  age dependent and the advantages of the allografts must be weighed against 
the risk of a possible reoperation due to structural valve deterioration (SVD) over time [1, 2]. 
 
In 1987 we started a prospective cohort study in our institution, using cryopreserved 
allografts for aortic valve and root disease. The allografts were used as a simple valve 
substitute, using a sub-coronary implantation technique, as well as full root replacement with 
reimplantation of the coronary arteries. Our earlier reports described the mid-term clinical 
outcome [3-5]. After almost 3 decades we are now able to present the long-term results of this 
prospective cohort. Comparable long-term follow-up has not frequently been reported on. 
The aim of our study is to describe the long term clinical outcome after aortic valve and/or 
root replacement with allografts. In addition, the associations of several echocardiographic 
variables with survival and reintervention on implanted allograft are displayed. 
MATERIALS AND METHODS
Between April 1987 and March 2013, 353 consecutive patients underwent allograft aortic 
valve or root replacement at Erasmus University Medical Center. All patients receiving an 
allograft in the aortic position are part of this prospective follow up study in our center 
[3, 6]. Institutional Review Board approval was obtained for this study (MEC 12-477), and 
informed consent was waived. 
Operation technique
Cardiopulmonary bypass with moderate hypothermia was used in all surgical procedures. 
Crystalloid cardioplegia and topical cooling were used for myocardial protection. 
In addition, deep hypothermia and circulatory arrest were used in 37 patients with 
ascending aorta and/or arch pathology. Initially the subcoronary technique was the 
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preferred technique for aortic valve replacement, while from 1998 the root replacement 
technique was performed (Appendix 1). A subcoronary technique was initially performed 
with scalloping of the sinuses of Valsalva (N=32), while later on the non-coronary cusp 
was preserved (N=63). Root replacement was performed as a freestanding root with 
reimplantation of the coronary arteries. 
Follow-up
All patients who received an allograft (98% aortic) at Erasmus University Medical Center 
were followed up prospectively through their visits to their cardiologist and by annual 
telephone interviews. Additionally, echocardiographic follow-up was obtained at 6 
months, 1 year postoperative, and thereafter biennially by means of serial standardized 
echocardiography. Valve-related events were registered according to the 2008 American 
Association for Thoracic Surgery/Society of Thoracic Surgeons/European Association for 
Cardiothoracic Surgery guidelines for reporting mortality and morbidity after cardiac 
valve interventions [7]. The study database was frozen on December 31, 2014. Follow-up 
was 98% completed: eight patients were lost to follow-up because of emigration. 
Statistical methods       
Continuous data are presented as means (standard deviation; range). Comparison 
between groups was performed using the unpaired t-test unless data were not normally 
distributed (Mann-Whitney U-test in these cases). Categorical data are presented as 
proportions. Comparison was done by chi-square test or the Fisher-exact test, where 
appropriate. The study started at the time of allograft implantation and ended at the time 
of event (death/reoperation) or at the last follow-up date. Univariable logistic regression 
analysis was used to study potential variables affecting early mortality (hospital and/or 
30 day mortality).The Cox proportional hazards model was used for univariable analyses 
of time-related events. Survival was analyzed using the Kaplan-Meier method (Appendix 
2). Survival and freedom from overall re-operation were presented using the cumulative 
incidence function, from a competing risk analysis. Tests were performed two-sided and 
a p-value of 0.05 was considered statistically significant. Variables that were tested as 
potential risk factors for hospital mortality, late mortality, and reoperation are displayed 
in Appendix 3. For the analyses mentioned above, Statistical Package for Social Sciences 
(SPSS) 21.0 for Windows statistical software (SPSS, Chicago, IL, USA) was used. Advanced 
statistical linear mixed-effects model was used to assess changes in echocardiographic 
measurements of hemodynamic variables while accounting for the correlation between 
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repeated measurements in each patient. Residuals plot was used to test the assumption 
of homoscedasticity in the model. Details of how the mixed-effects models were built 
are presented in Appendix 4. Furthermore, joint models of longitudinal and survival data 
were used to test whether echocardiographic variables were associated with survival or 
reoperation hazard. Specifically, this approach accounts for the biological variation in 
repeated (echocardiographic) measured variables within patients  [8]. The association of 
the following variables (which are of clinical interest) with survival and reoperation were 
tested: LVEDD (in mm), LEVSD (in mm), STJ (in mm), Annulus diameter (in mm), Aortic 
regurgitation (grade), and Aortic gradient (in mmHg). For the advanced joint modeling 
R (version 3.1.3, available at: www.r-project.org) was used. A more detailed specification 
of the mixed-effects model and the joint model together with the syntax is provided in 
Appendix 4.
RESULTS
The mean follow-up was 11.5 years (range 0-24.5 years), with a total follow-up of 4188 
patient years. There were several differences in characteristics between the subcoronary 
implantation and the full root replacement recipients. Table 1 displays patient 
characteristics and the preoperative data. Coronary artery bypass grafting (CABG) due 
to complications related to reimplantation of the coronary arteries was necessary in six 
patients, of which two subsequently died.
Indication for allograft implantation
The indication for implantation of an allograft has changed over the years.  Between 
1987 and 2005 334 patients received an allograft in aortic position. The etiology of 
disease was: 33% endocarditis; 23% prosthetic valve/allograft failure; 24% bicuspid valve 
disease; 7% rheumatic disease; 8% senile valve dysfunction; and 6% congenital disease. 
Between 2006 and 2014 the etiology of disease was (N= 26): 41% bicuspid valve disease; 
35% endocarditis; 12% senile valve dysfunction; 8% prosthetic valve/allograft failure; 4% 
rheumatic disease. Figure 1 displays the etiology of disease, thus indication for allograft 
implantation over the years. Allograft characteristics are displayed in appendix 5.
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TABLE 1. Patient characteristics and perioperative data.
All patients 
(N= 353)
Subcor technique 
(N = 92)
Root replacement
(N = 261)
Mean age (yrs (SD; range)) 45 (16; 0.1-84) 46 (16; 14-84) 44 (17; 0.1-77)
Male 72% 75% 71%
Creatinin (µmol/l; (SD; range)) 102 (85; 22-930) 113 (107; 48-930) 99 (76; 22-900) ª
Prior cardiac surgery 26.3% (N = 93) 17.4% (N = 16) 29.5% (N = 77)
Hypertension 14.0 % (N = 49) 14.1% (N = 13) 13.8% (N = 36)
Ischemic heart disease 8,5% (N = 30) 10.8% (N = 10) 7.6% (N = 20)
Connective tissue disease 5% (N = 18) 0 6.8% (N = 18) ª
Diabetes mellitus 3.4% (N = 12) 4.3% (N = 4) 3.0% (N = 8)
Prior CVA 5,1% (N = 18) 8.6% (N = 8) 3.8% (N  = 10)
Ventilation support 5,9% (N = 21) 0 8% (N = 21) ª
Urgent operation (< 24 h) 11% (N = 39) 2.1% (N = 2) 14.2% (N = 37) ª
Diagnosis      
   Aortic valve regurgitation (AR) 79.4% (N = 201) 56.7% (N = 52) 57.1% (N = 149)
   Aortic valve stenosis (AS) 18.4 % (N = 65) 27.2% (N = 25) 15.3% (N = 40)
   Combined AR + AS 17.5% (N = 62) 16.1% (N = 15) 18.0% (N = 47)
   Other 6.2% (N = 22) 0 8.4% (N = 22)
Etiology      
   Endocarditis 32.5% (N = 115) 33.6% (N = 31) 32.2% (N = 84)
      Active N = 80 N = 13 N = 67
   Congenital (incl. bicuspid*) 31.1% (N = 111) 32.6 % (N = 30) 30.0% (N = 81)
   Degenerative 8.8% (N = 31) 11.9% (N = 11) 7.6% (N = 20)
   Aneurysm 7.1% (N= 25) 0 9.5% (N = 25) ª
   Rheumatic 6.2% (N = 22) 15.2% (N = 14) 3.1% (N = 8)
   Dissection 5.1% (N = 18) 0 6.9% (N = 18)
   Other (prosthetic  valves) 7.9% (N = 28) 6.5% (N = 6) 8.4% (N = 22)
Systolic LVF      
   Good 74.2% (N = 267) 78.9% (N = 75) 72.5% (N = 192)
   Impaired 18.3% (N = 66) 16.8% (N =16) 18.9% (N = 50)
   Moderate/Severe 6.6% (N = 24) 4.3% (N = 4) 7.5% (N = 20)
Preoperative NYHA class      
   I 25.8% (N = 92) 12,6% (N= 12) 30.5% (N = 80)
   II 26.9% (N = 96) 27.4% (N = 26) 26.7% (N = 70)
   III 29.7% (N = 106) 48.4% (N = 46) 22.9% (N = 60)
   IV 17.7% (N = 63) 11.6% (N = 11) 19.8% (N = 52)
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Perioperative characteristics Valve requiring operation
   Bicuspid 36% (N = 130) 44% (N = 42) 33% (N = 88)
   Tricuspid 48% (N = 174) 47% (N = 45) 49% (N = 129)
   Quadricuspid 1% (N = 2) 0 1% (N = 2)
   Prosthesis 12% (n = 44) 4% (N = 4) 15% (N = 40) ª
   Allograft 1% (N = 4) 3% (N = 3) 1% (N = 3)
Concomitant procedures 51% (N = 184) 32% (N =30) 58% (N = 154) ª
Aortic cross clamp time 
min (SD; range)
142 (58; 0 - 357) 132 (30; 79 - 248) 145 (65; 0 - 357)
Perfusion time 
min (SD; range)
198 (78; 79 -589) 176 (40; 116 - 316) 206 (86; 79 - 589)
Circulatory arrest (N = 35)
min (SD; range) 
4 (14; 0 - 163) 0 5 (17; 0 - 163)
Procedure related CABG 2% (N = 6) 0 2% (N = 6)
Bleeding requiring reoperation 13% (N = 47) 14% (N = 13) 13% (N = 34)
Permanent pacemaker 4% (N = 16) 4% (N = 4) 5% (N = 12)
Perioperative CVA 3% (N = 11) 3% (N = 3) 3% (N = 8)
Early mortality (< 30 days) 5.9% (N = 21) 4.3% (N = 4) 6.5% (N = 17)
ª Statistical significant difference between the 2 groups (unpaired t-test or Mann–Whitney U-test)
*Endocarditis excluded
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FIGURE 1. Evolution of indication for allograft implantation over the years.
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Early mortality and morbidity
Operative mortality concerned six patients. This was attributed to persistent massive 
bleeding in three patients (one had an active endocarditis with abscesses, one with an 
acute dissection, and one patient who underwent a reoperation for paravalvular leakage 
of a mechanical valve), left ventricular failure in two patients (one patient with an active 
prosthetic-valve endocarditis and one patient with acute endocarditis including a fistula 
to the left atrium), and finally one patient who died during a salvage procedure of a 
prosthetic aortic valve endocarditis with extensive tissue destruction of the left ventricular 
outflow tract and proximal ascending aorta with abscesses. Another 15 patients died 
within 30 days postoperative or during the same hospitalization. The causes of death were 
registered as cardiac and not valve-related in 10 patients. Three valve-related early deaths 
concerned two patients who died of a major intracerebral bleeding and one patient 
with a myocardial infarction caused by kinking of the reimplanted right coronary artery. 
Another patient had an acute endocarditis and died as a result of a stroke caused by septic 
emboli, and finally one patient who was operated on because of an active endocarditis of 
a biological valve substitute who developed multi-organ failure and died. Early mortality 
was 5.8%. 
In six patients additional CABG for complications related to reimplantation of the coronary 
arteries was necessary, of which two subsequently died. In one patient, coronary orifice 
stenosis occurred because the left coronary artery button was too small. Another patient 
had annular calcifications extending up to the right coronary ostium that was qualitatively 
poor and ruptured after reimplantation. A third patient had an active bioprosthetic 
endocarditis with abscesses, and after reimplantation the edematous right coronary artery 
(RCA) button ruptured. Two other patients experienced right ventricular dysfunction due 
to kinking of the reimplanted RCA. In another patient, the coronary artery buttons were 
large, possibly causing malperfusion of the right and left coronary artery.
Late survival
During follow-up another 113 patients died. There were 72 non-valve-related deaths. 
In addition, 42 patients died from a valve related cause: 26 patients died sudden, 
unexpected, and unexplained; 5 patients died from a major bleeding (3 of them were on 
anticoagulation therapy because of atrial fibrillation in 2, and a mechanical mitral valve 
prosthesis in 1 patient); 4 patients who had structural (allograft) valve deterioration died 
of heart failure; 3 patients died due to endocarditis; another patient died after a CVA. The 
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cause of death could not be retrieved in 3 patients. Cumulative survival (including early 
mortality) was 98.20% (95% CI 96-99%) at 1 year, 87.5% (95% CI 83-90%) at 10 years, and 
40.0% (95% CI 32-49%) at 20 years respectively. Figure 2 shows the KM-curve of cumulative 
late survival, including early mortality.
FIGURE 2. Top) Cumulative survival (all patients) including 95% CI. Blue line indicates general Dutch population 
(mean age 45 years). Under) Survival by subgroup. Upper-line indicates patients aged 0 to 20 years; Middle-line 
indicates patients aged from 21 to 60 years; lower-line indicates patients aged 61 and older.
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Patients were subsequently subdivided in 3 age categories:  
1) 0 to 20 years at operation, 2) 21 to 60 years at operation, and 3) 61 and older. Patients 
in the latter category have a significant worse survival compared to other categories. 
Additionally, multivariable (independent) predictors of late mortality in our Cox model 
were: patient age at operation (HR 1.06, 95% CI 1.03-1.08; p < 0.001) and preoperative 
ventilation support (HR 2.58, 95% CI 1.20-5.32; p = 0.01).
Competing risk for death or subsequent reoperation
A total of 110 patients were reoperated because of an allograft related cause. Reason 
for reoperation was SVD in 93 patients, non-structural valve deterioration (NSVD) in 9 
patients, and endocarditis in 8 patients. The allograft was replaced by a mechanical valve 
substitute in 62 patients, a composite valve replacement (Bentall) in 31 patients, allograft 
in 3 patients, autograft in 4 patients, stented bioprosthesis in 12 patients, and TAVI in 2 
patients. In one patient the allograft could be saved by removal of a vegetation from the 
proximal anastomosis of the allograft 3 weeks after the initial operation because of active 
endocarditis. Ten years later this allograft was replaced with a mechanical valve. In another 
patient a false aneurysm of the allograft was closed operatively. Finally, in another patient 
a fistula from the allograft towards the right atrium was closed. Reoperation mortality was 
3.9%. During follow-up 99 patients died without a reoperation and 104 were reoperated 
who were still alive at last follow-up date. Competing-risks analysis predicted that after 
20 years from initial allograft implantation, 31% had died without a reoperation, 39% 
underwent a reoperation, and 30% remained alive without reoperation (Figure 3).
Valve related complications
Structural and non-structural valve deterioration
A total of 98 patients experienced SVD. Replacement of the allograft due to SVD was 
performed in 100 patients. The other 4 patients died due to structural valve deterioration 
while being treated medically. Structural valve deterioration was mainly due to the 
calcification of the aortic (allograft) root in the second decade of follow-up. The progression 
of aortic gradient in time is displayed in Figure 4.
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FIGURE 3. Competing-risks analysis for subsequent reoperation on the allograft or death.
All patients were included at the time of initial allograft implantation (n = 353) and could transition to either death or a 
subsequent reoperation on the allograft.
FIGURE 4. Progression of aortic gradient over time.
The dashed-lines denote 95% confidence intervals.
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Non-structural valve deterioration occurred in 9 patients, and it was mainly due to 
(paravalvular) leakage as a result of technical error in patients who received an allograft 
using the subcoronary implantation technique.
Endocarditis
There were 14 cases of endocarditis. Endocarditis was the reason for reoperation on the 
allograft in 8 patients. In addition, 3 other patients were diagnosed with endocarditis, 2 
of them were treated medically without the need of reoperation and 1 patient was a drug 
user who could not be operated because of brain abscesses and was treated medically and 
died eventually. As described in the late survival section above, 3 other patients died from 
endocarditis. Reoccurrence of endocarditis occurred in 6 patients. In 4 of these patients 
there was an active endocarditis noticed at the operation time of allograft implantation. 
Other valve-related complications
During follow-up 20 cerebrovascular events were registered, one patient died because of 
a CVA, as described above. Besides the five lethal bleedings described earlier, there was 
another (non-lethal) major bleeding. 
Echocardiographic variables
A subset of 308 patients was followed by means of standardized echocardiography 
with a mean of 6 echocardiograms (range 1-13). Variables in the joint model predicting 
higher hazard of mortality were: severe (grade 3 and/or 4) aortic regurgitation (HR 1.06, 
CI (1.0-1.1); p = 0.03) and enlargement of left ventricle end systolic dimension (HR 1.05, 
CI (1.01-1.09); p = 0.007). Variables predicting (joint model) a higher reoperation hazard 
were: progression of the gradient over the allograft (HR 1.40, CI (1.13-1.76); p = 0.001); 
progression of allograft valve regurgitation (HR 1.05, CI (1.01–1.09); p = 0.005), and 
increase in aortic annulus diameter (HR 2.33, CI (0.99-5.88); p = 0.053).
There is a progression of aortic valve (i.e. allograft) regurgitation (Appendix 6). Largely 
patients with grade 1 AR progress to grade 2 AR over time. Mixed effect modeling reveals 
the following predictors to be correlated with progression of regurgitation over the aortic 
allograft: time from operation (p = < 0.001), subcoronary technique (p = < 0.001), and 
active endocarditis (p = 0.02). 
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DISCUSSION
After almost three decades we observe good long-term outcome after allograft 
implantation with regard to mortality and occurrence of thromboembolic and hemorrhagic 
events. However, the risk of a reoperation due to SVD in the second decade after allograft 
implantation is increased. Furthermore, survival and freedom from reoperation is roughly 
comparable to other biological valve substitutes [9]. Despite a decrease of implantation 
of allografts in aortic position over the years, use in selected cases of active aortic root 
endocarditis and complex aortic root pathology may still be useful.
In the 80’s an enthusiasm existed for the use of allografts for aortic valve or root replacement 
as a superior durability of human tissue valves compared to bioprostheses was envisioned. 
However, with time it became evident that allograft durability was not better, but more 
or less comparable to bioprostheses and inferior to mechanical prosthesis [9, 10]. This 
is reflected in the current ESC/EACTS guidelines for the management of patients with 
valvular heart disease that have  no specific recommendations in favor of allografts for 
aortic valve replacement, except for active endocarditis with perivalvular lesions [11].
Survival and reoperation
Our findings regarding patient survival and reoperation rates show good results 
even after 3 decades of follow-up, with median survival of around 20 years.  Patient 
survival is comparable to patients after a biological valve in aortic position; however 
there seems to be a slightly higher hazard of reoperation in allografts. This was 
also shown in a clinical trial by El-Hamamsy et al. comparing allografts to freestyle 
biological valve substitute [10]. Of note, the patient characteristics in El Hamamsy’s 
study differed from ours, as there were just a few patients with endocarditis as 
etiology of disease in their randomized control trial. Valve related event occurrence 
such as SVD and reoperation hazard is comparable with earlier reports [12, 13]. 
Additionally, another option for the treatment of aortic valve disease, especially at younger 
age, is the Ross procedure. Some great results have been achieved, with freedom from 
reoperation of about 90% to 99% at 15 years of follow-up [14, 15]. However, these results 
have only been achieved in slightly different patients groups and in highly specialized 
centers. 
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SVD and mode of failure
Early valve failure occurred mainly in the subcoronary implanted allografts in the first few 
years after implantation, and was mainly due to technical errors during the implantation. The 
suboptimal results of the subcoronary implantation technique were noticed and therefore 
we started to use the subcoronary technique less frequently and stopped using it after 1998. 
If one disregards the early technical failures in the subcoronary allografts, then the 
pattern of SVD is comparable to root replacement allografts in the first postoperative 
decade [12]. In the second postoperative decade it appears that subcoronary implants 
have a slightly better SVD pattern compared to root replacement allografts, but the 
low number of patients still at risk at that point in time prohibits any firm conclusions. 
In long-term follow-up the main reason for reoperation was SVD in most cases. SVD is 
known to be the main cause of allograft failure [1, 3]. During reoperation we noticed that 
in most cases the allograft sinuses of Valsalva were calcified, with or without fenestration/
rupture of the valve leaflets, causing valvular stenosis and/or regurgitation. Although we 
know from the literature that a reoperation after allograft implantation can be challenging 
and associated with higher hazards of less favorable outcome [1, 16], hospital mortality 
was relatively low in our patients, as described by Bekkers et al. earlier [5]. Notably, almost 
all reoperations were performed by one the same surgeon and this expert experience 
could be of influence in obtaining these excellent results. Additionally, our rigorous follow-
up regimen with annual clinical and biennial echocardiographic standardized follow-up 
allowed us to detect allograft failure early on and carefully plan for an elective reoperation 
in most cases.
Other valve related complications 
The occurrence of endocarditis was low, as expected, and the main indication for allograft 
use nowadays [17, 18]. In addition, the reoccurrence of endocarditis in patients who had 
received an allograft because of infective endocarditis was low. This should be taken into 
consideration when looking for a suitable valve substitute to treat an infective endocarditis 
in aortic position, especially with complex aortic root pathology with abscesses and/
or fistula formation around the root. In these cases it may be difficult to use the Bentall 
prosthesis to cover the entire aortic root without leaving behind cavities and is an allograft 
a good alternative. 
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Thromboembolic event occurrence was uncommon, highly favorable in comparison with 
mechanical valve prostheses [19], and comparable to biological valve prosthesis [4, 10, 20], 
and underlines once more the advantages of biological valve substitutes in this regard. 
Hemorrhagic events occurred in only five patients of whom 3 were on anticoagulation 
therapy: two patients because of atrial fibrillation, and one due to earlier implanted mitral 
valve prosthesis. The avoidance of anticoagulation therapy in allograft aortic valve or 
root replacement is particularly important for patients with an active lifestyle as well as in 
female patients who have a desire of future pregnancy, especially given the notion that 
pregnancy is not associated with allograft failure [21]. 
Echocardiographic outcome
We found that enlargement of left ventricle end systolic dimension and progression of 
aortic (allograft) regurgitation is associated with a higher mortality hazard probably due 
to less favorable hemodynamics. Additionally an increase in aortic annulus diameter; 
progression of the gradient over the allograft, and progression of allograft regurgitation 
is associated with a higher reoperation hazard. This information should help to be able 
to intervene earlier in the process in order to adjust treatment where possible, and to 
help evaluate the patients at risk more accurately and maybe more frequently, certainly 
in the second decade after allograft implantation where SVD play a significant role. The 
challenging goal is still to find out which specific dynamic variables and variations are 
associated with worse outcome, and what exactly the timing for (surgical) intervention 
must be.  
To estimate the association between a single measure and time to event, standard 
statistical tools such as Cox regression are applicable. However, when it comes to the 
analysis of repeated measurements in relation to time-to-event, the Cox model including 
time-dependent covariates, has been widely used. However, problems arise from the fact 
that repeated measurements may contain biological variation which is not taken into 
account by the time-dependent (covariates) Cox model. The problem with ignoring this 
biologic variation and using the time-dependent covariates Cox model is that derived 
results may be substantially biased. Therefore the joint model for longitudinal and 
survival data have been proposed. Despite the appropriateness of these models, there 
are some disadvantages. The joint models of longitudinal and survival data are not easily 
applicable by any physician since a level of expertise in programming may be required. 
The complexity of analyses of SVD and risk factors related to an increased risk of SVD is 
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addressed recently by Blackstone [22], and the importance and usefulness of such models 
have been demonstrated [23, 24]. More recently there are more statistical tools available 
as the joint modeling approach for the prognostic evaluation of serial biomarkers 
[25], and specifically the concept of joint modeling of longitudinal and survival data in 
repeated valve function measurements after implantation of an allograft is introduced by 
Andrinopoulou et al. in 2012 [8]. The translation of the longitudinal data to a predictive-
model using thesestatistical tools should allow us to understand the association between 
the serial measured parameters influencing SVD (i.e. aortic gradient, aortic regurgitaion, 
verntricul dimentions etc.), and important clinical endpoints such as survival and 
reoperation. 
Limitations
Our study concerns a single-center experience with a heterogeneous etiology of disease, 
with a relatively large proportion of patients with endocarditis, and furthermore significant 
differences between patients receiving allografts as a subcoronary implant comparing 
to recipients with full root replacement. This may lead to interpretations that are not 
necessarily applicable to other patient cohorts.  
CONCLUSION
Implantation of an allograft in aortic position is associated with low valve-related events 
peri-operatively. From this prospective observational cohort study that spans almost 30 
years it becomes evident that although allograft aortic valve or root replacement yields 
excellent clinical results in the first postoperative decade, in the second postoperative 
decade a structural valve deterioration pattern that resembles bioprostheses becomes 
apparent. Reoperation on degenerated allografts proofs challenging but can be 
managed well through systematic clinical and echocardiographic follow-up and careful 
planning of elective reoperation. In selected patients, especially those less favorable for 
anticoagulation therapy, and patients with active endocarditis with complex aortic root 
pathology, allografts may still be considered, accepting an increased life-time risk of 
reoperation. 
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ABBREVIATIONS
LVED = Left Ventricular End Diastolic Diameter
LEVSD = Left Ventricular End Systolic Diameter
STJ = Sinotubular Junction
CABG = Coronary Artery Bypass Grafting 
TAVI = Transcatheter Aortic Valve Implantation
SVD = Structural Valve Deterioration
NSVD = Non Structural Valve Deterioration
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APPENDIX 1
Number of allografts and the surgical technique used for implantation by year of operation.
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APPENDIX 2
Potential urivariable risk factors for increased early and late mortality.
Variable HR 95% CI P-value
Early mortality
Age 1.1 1.0-1.1 < 0.001
Active Endocarditis 3.8 1.6-9.2    0.003
Severe renal disease 13.7 3.9-47.8 < 0.001
Ventilation support 5.5 3.8-16.8    0.003
Preop non-SR 2.1 1.3-3.3    0.002
Surgical procedure 2.7 1.7-4.6    0.002
Late mortality
Age 1.05 1.04-1.07 < 0.001
Active Endocarditis 2.05 1.38-3.06 < 0.001
Hypertension 2.39 1.56-3.68 < 0.001
Severe renal disease 3.61 1.75-7.45    0.001
Ventilation support 3.06 1.71-5.48 < 0.001
Preop non-SR 1.65 1.32-2.08 < 0.001
Surgical procedure 1.11 1.04-1.18    0.001
Urgency 2.88 1.75-4.75 < 0.001
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APPENDIX 3
Variables that were tested (univariable) as potential risk factors for hospital mortality, late mortality, and re-operation.
Variable Specification
Patient age Continuous variable (years)
Gender
Preoperative ventilation support
Preoperative abnormal cardiac rhythm Any rhythm other that sinus rhythm
Preoperative renal function Creatinine, continuous  (mmol/l)
Severe renal disease requiring either dialysis or transplantation
Prior cardiac surgery
Marfan disease
Ischemic heart disease
Etiology of heart valve disease 
Preoperative hypertension
Systolic left ventricular function Good/ impaired/ moderate/ bad
Pior cerebrovascular accident (CVA)
Preoperative New York Heart Association (NYHA) class  From I to IV
Emergency of the procedure
Cardiopulmonary bypass time Continuous (minutes)
Hemodynamic diagnosis* 
Allograft diameter* Continuous (mm)
* Exclusively for re-operation
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APPENDIX 4
Statistical model building for mixed-effects models:
Likelihood ratio test was used for the fixed part and the mixture distribution of chi-square 
for the random part. We used linear time for Aortic gradient (p-value = 0.9302), Annulus 
diameter (p-value = 0.1391) and nonlinear for Left Ventricle End Systolic (LVES) diameter 
(p-value < 0.0001) for the fixed and the random effects. For the ordinal longitudinal 
outcome linearity was assumed due to convergence problems. Furthermore, we used 
clinically relevant baseline covariates in the fixed part, namely for LVES, Aortic gradient 
and Annulus diameter we included: Sex, left ventricle function, Hypertension, Etiology of 
disease and patient age at operation. For AR we included Sex, LVfunction, Hypertension, 
Diagnosis and Etiology. Finally, no serial correlation term in the residual errors was 
assumed since it could result in estimation problems.
Specification of mixed-effects models and joint models of longitudinal and 
survival data
Let T
i
* denote the true failure time for the i-th individual (i = 1,…, n), and d C
i
 the censoring 
time, then T
i
 = min(T
i
*,C
i
) represents the observed failure time for the i-th patient. Moreover, 
δ
i
 = 0,1 is the event indicator where 0 indicates censoring. 
For the longitudinal part, we let  γ
i
 consist of longitudinal responses that may be obtained 
at different time points t
ij
 and have length n
i
.To describe the subject-specific evolutions 
over time of the longitudinal outcome we utilize a linear mixed-effects model. Specifically, 
it takes the form, 
y
i
(t) = f
i
(t) + ε
i
 = χT
i
 (t)β + zT
i
(t)b
i
 = ε
i 
,
where χ
i
(t) denotes the design vector for the fixed effects regression coefficients β and z
i
(t) 
the design vector for the random effects b
i
.
Finally, we assume that a normal distribution for the random effects describes the 
evolution of the longitudinal outcomes, i.e.,
b
i
~N(0,σ
b
),
Where σ
b  
is the variance of the random intercept.
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For the survival process we have:
h
i
(t,θ
s
) = h
0
(t)e{γTωi+αfi(t)},
where θ
s
 is the parameter vector for the survival outcomes, ω
i
 is a vector of baseline 
covariates with a corresponding vector of regression coefficients γ, and α denotes the 
strength of association between the longitudinal and survival outcomes. Moreover, a 
Weibull baseline hazard h
0
(t) = ψtψ-1 was assumed.
Syntax for one joint model
Variable notation in the model:
Gender(male of female) = Sex
Left ventricle function = LVfunction
Patient age at operation = ptageatok
Hypertension = Hypertension
Etiology  of disease = Etiology
Echotime =’ time of echocardiogram
Annulusdiameter = diameter of annulus
MaxOfFUP = maximum follow-up time
Active.endocarditis = Active endocarditis
VentilationSupport = Ventilation support
Type.of.operation = subcoronary or full root
Urgency.code.for.operation = Urgent (<24hours), within the same hospitalization or 
elective
FUPreop = follow-up time for reoperation
Reop = reoperation
library(JM)
fm1 <- lme(Annulusdiameter ~ echotime + Sex + LVfunction + Hypertension + Etiology 
+ ptageatok.x, data = data, na.action = na.exclude, random = ~ echotime | IDnr)
coxFit.avD. <- coxph(Surv(MaxOfFUP, LastOfDeath.) ~ Active.endocarditis + Hypertension 
+  VentilationSupport + Type.of.operation +  Urgency.code.for.operation, data = 
data.id, x = TRUE)  
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coxFit.avR. <- coxph(Surv(FUPreop, Reop) ~  Hypertension +  Etiology + Sex + LVfunction 
, data = data.id, x = TRUE)   
jointFit.avD <- jointModel(fm1, coxFit.avD., timeVar = “echotime”, method = “piecewise-
PH-aGH”, verbose = TRUE, iter.EM = 80) summary(jointFit.avD)
jointFit.avR <- jointModel(fm1, coxFit.avR., timeVar = “echotime”, method = “piecewise-
PH-aGH”, verbose = TRUE, iter.EM = 80) summary(jointFit.avR)
Additional software package
Joint modeling of longitudinal and survival data; Package: JM (version: 0.8-3)
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APPENDIX 5
Allograft statistics.
All patients 
(N= 353)
SC technique 
(N = 92)
Root replacement 
(N = 261)
Type of allograft
   Aortic 98% (N = 348 ) 95% (N = 88) >99% (N =260)
   Pulmonary 2% (N = 5) 5% (N = 4) <1% (N = 1)
Allograft size (mm) 
   Mean (SD; range)
22.7 (2.1; 14 – 30) 23.3 (2.4; 19 – 30) 22.4 (1.9; 14 – 28) ª
   ≤ 24 mm 84% 70% 89% 
   ≥ 24 mm 16% 30% 11% 
Donor age (years) 
   Mean (SD; range)
40 (13; 8 – 62) 36 (13; 12 – 60) 42 (13; 8 – 62) ª
Preservation method
   Cryopreserved 98% 94% >99% 
   Fresh 2% 6% <1% 
ª Statistical significant difference between the 2 groups (unpaired t-test or Mann–Whitney U-test)
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APPENDIX 6
Progression of AR grade during years.
A mixed effect model was used to predict variables associated with progression of AR grade. Blue line indicates grade 0 AR, 
red line grade 1 AR, green line grade 2 AR, black lines grade 3 and 4 AR.
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Pregnancy outcomes in women 
with aortic valve substitutes
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ABSTRACT
Young women who require aortic valve replacement (AVR) need information on the 
potential cardiac and obstetric complications of pregnancy for the different available 
valve substitutes. We therefore assessed pregnancy outcome in women who received 
an autograft, homograft, or mechanical valve in the aortic position. Women who were 
pregnant after surviving AVR in our institution between 1987 and 2011 were included. 
Information on cardiac status and pregnancy outcome was obtained through hospital 
medical records and by means of an extensive patient questionnaire. Forty women 
experienced 67 pregnancies of which 55 (82%) completed pregnancies, 6 (9%) 
miscarriages, and 6 (9%) terminations of pregnancy. Eighteen (45%) women had a 
pulmonary autograft, 13 (32%) a homograft, and 9 (23%) a mechanical valve. Mean age 
at first pregnancy was 30.0 ± 5.7 years. There was no maternal mortality, but 1 fetal death 
(1.8%) and 1 neonatal death (1.8%) occurred. Maternal cardiac complications occurred 
in 13% and obstetric complications in 38% of the completed pregnancies. Heart failure 
(9%), arrhythmias (7%), hypertension-related disorders (7%), preterm delivery (24%), 
and small for gestational age infants (15%) were most often encountered. Mechanical 
valve recipients had the highest incidence of both cardiac and obstetric complications. 
In conclusion, pregnancy-associated complications after AVR were common and human 
tissue valves should be considered in the discussion for the optimal aortic valve substitute 
in a young female. However, careful obstetric monitoring is mandatory.
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When a young woman requires aortic valve replacement (AVR), it is important to incorporate 
reliable information on potential pregnancy complications and pregnancy outcome when 
considering the available surgical options. In mechanical valve recipients, complications 
due to anticoagulation therapy represent a threat for both mother and her unborn child.1-3 
Accelerated valve dysfunction due to degeneration may be a point of concern in biological 
valve substitutes although more recent studies report that pregnancy does not increase 
structural deterioration or reduce survival.4-6 There is limited evidence available on the 
rate of cardiac and obstetric complications in young women who become pregnant after 
AVR. Most available information concerns mechanical –mainly mitral- valve recipients and 
shows increased risks of anticoagulation-related complications and increased maternal 
and fetal mortality and morbidity.1, 2, 5, 7-10 Also for human tissue valve recipients, reports 
on pregnancy related outcomes are scarce.5, 10-12 In this perspective, the aim of the present 
study was to determine the occurrence of cardiac and obstetric complications in women 
who experienced a pregnancy after implantation an autograft, homograft, or mechanical 
valve in the aortic position in our institution.
METHODS
Women who were pregnant after surviving an AVR with a pulmonary autograft, a 
homograft, or a mechanical valve prosthesis in the Erasmus University Medical Center, 
were aged 50 years or younger at time of surgery, were operated between April 1987 
and January 2011, and were at least 16 years at the last clinical follow-up, were invited 
to participate. The study protocol was approved by the Institutional Review Board (MEC 
2010-272) and informed consent was obtained. All patients who receive a human tissue 
valve substitute in our institution are followed prospectively (MEC 2000-813). Eligible 
patients were identified through our prospective cohort study of human tissue valve 
recipients and through our departmental patient information system.13, 14
Information on pregnancy and cardiac status of the patients until January 1st, 2011 was 
obtained through hospital medical records and structured patient questionnaire that 
was conducted between December 1st 2010 and September 1st, 2011. We collected data 
on underlying valve etiology at last surgery, hemodynamic diagnosis, previous surgical/
interventional procedures, age at surgery, type (and size) of aortic valve substitute, 
concomitant procedures, time from surgery to first pregnancy, age at conception, and 
preconceptional systolic left ventricular function (LVF), maximum aortic jet velocity 
(Vmax), and peak pulmonary artery pressure (PAP).
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Pregnancy was defined as positive HCG test or obstetric ultrasound. Miscarriage was 
defined as spontaneous loss of pregnancy <20 weeks of gestation. Information about 
each completed pregnancy (duration >20 weeks of gestation) included: New York Heart 
Association (NYHA) functional class, medication, physical examination, pregnancy 
duration, mode of delivery. For each baby, gender, birth weight, and APGAR score was 
registered. 
Registered cardiac complications were: arrhythmia (symptomatic sustained documented 
arrhythmia), heart failure (requiring treatment), persistent NYHA functional class 
deterioration (≥1 year postpartum), syncope, thrombo-embolic complications, aortic 
dissection, and/or endocarditis. Obstetric complications included: pregnancy-induced 
hypertension (PIH; de novo onset of hypertension after ≥20 weeks of gestation), 
preeclampsia (hypertension and proteinuria), eclampsia (preeclampsia with grand mal 
seizures), Hemolysis Elevated Liver Enzymes Low Platelets (HELLP) syndrome, preterm 
premature rupture of membranes (membrane rupture <37 weeks gestation),  premature 
labor (spontaneous onset of labor <37 weeks gestation), postpartum hemorrhage 
(>1000 ml), placental abruption, premature delivery (<37 weeks of gestation), small-for-
gestational-age (birth weight <10th percentile), fetal death (≥20 weeks of gestation), and 
neonatal death (<30 days postpartum).15  The incidence of complications and mode of 
delivery in this study was compared to data derived from the 2008 Dutch Perinatal Registry. 
In this registry, maternal and fetal data of all deliveries occurring in the Netherlands are 
recorded (about 180,000; 96% complete). It included both home as well as hospital 
deliveries and contained information on the presence of cardiovascular disease in the 
mother (no further specification) and neonatal congenital defects ( cardiac 0.41%; non-
cardiac 2.38%).16 
Anticoagulation therapy administered in our institution to mechanical valve recipients 
was according to our local protocol and initiated in close collaboration with the 
hematologist.17 As soon as pregnancy was confirmed, acenocoumarol was changed to a 
weight adjusted therapeutic dose of low molecular weight heparin (LMWH) until the end 
of the first trimester and when necessary monitored with anti-Xa levels. Acenocoumarol 
was then restarted until 36 weeks of gestation. Hereafter a therapeutic dose of LMWH was 
given until spontaneous onset of labor or the day before induction of labor or elective 
cesarean section. After delivery, LMWH was initiated again, along with acenocoumarol 
until 2 consecutive appropriate INR levels were reached.
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TABLE 1. Patient characteristics of the 40 women who experienced ≥1 pregnancy after aortic valve replacement.
Variable
All
(n=40)
Autograft
(n=18)
Homograft
(n=13)
MP
(n=9)
P-value
Intervention/surgery before AVR
   0 23 (58%) 10 (56%) 9 (69%) 4 (44%) .46
   1 8 (20%) 2 (11%) 4 (31%) 2 (22%) .46
   > 1 9 (23%) 6 (33%) 0 3 (33%) .07
Diagnosis
   Aortic stenosis 15 (38%) 10 (56%) 4 (31%) 0 .02
   Aortic regurgitation 13 (33%) 3 (17%) 6 (46%) 5 (55%) .10
   Mixed 12 (30%) 5 (28%) 3 (23%) 4 (44%) .61
Etiology
   Congenital 26 (65%) 16 (89%) 8 (62%) 2 (22%) <.01
   Rheumatic 12 (30%) 2 (11%) 4 (31%) 6 (67%) .01
   Aneurysm/Dissection 2 (5%) 0 1 (8%) 1 (11%) .49
Age at last surgery (years) 25.4 ± 7.7 21.5 ± 6.6 26.9 ± 5.0 31.2 ± 9.0 <.01
Concomitant procedures
   None 28 (70%) 16 (89%) 8 (62%) 4 (44%) .04
   Coronary bypass 3 (8%) 1 (6%) 0 2 (22%) .23
   Mitral valve surgery 6 (15%) 0 3 (23%) 3 (33%) .04
Size prosthesis (mm) - - 22 (21-22) 21 (21-23)
Time surgery-1stpregnancy (years)* 3.1 (1.6-6.1) 5.5 (1.8-9.4) 2.3 (1.4-4.6)
2.1 (1.5-
4.6)
.14
Total number of pregnancies 67 33 22 12 .39
   1 40 (60%) 18 (55%) 13 (59%) 9 (75%) .46
   2 20 (30%) 11 (33%) 6 (27%) 3 (25%) .83
   3 7 (10%) 4 (12%) 3 (14%) 0 .46
Pregnancy age (years)*
   1st (n=40) 30.0 ± 5.7 27.0 ± 4.1 30.2 ± 4.6 35.7 ± 5.9 <.01
   2nd (n=20) 30.9 ± 4.7 30.0 ± 3.9 31.9 ± 5.0 32.1 ± 8.0 .75
   3rd (n=7) 32.1 ± 5.5 32.7 ± 7.0 31.3 ±  4.0 - .86
LVF preconceptional (n=66)
   Good
   Moderate   
64%
36%
61%
39%
77%
23%
50%
50%
.18
.18
PAP preconceptional (mmHg) (n=62) 6 (3-15) 13 (9-18) 3 (2-3) 4 (1-11) <.01
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Vmax preconceptional (m/s)*
   1st pregnancy (n=38) 1.78 ± 0.69 1.36 ± 0.42 1.85 ± 0.60 2.60 ± 0.55 <.01
   2nd pregnancy (n=19) 1.70 ± 0.54 1.41 ± 0.46 2.01 ± 0.36 2.23 ± 0.38 .01
   3rd pregnancy (n=7) 1.83 ± 0.80 1.41 ± 0.48 2.39 ± 0.87 - .23
Completed pregnancies 55 (82%) 28 (85%) 20 (91%) 7 (58%) .05
Miscarriage 6 (9%) 3 (9%) 0 3 (25%) .05
Termination pregnancy 6 (9%) 2 (6%) 2 (9%) 2 (17%) .64
   Social reasons 4 (6%) 2 (6%) 2 (9%) 0 .70
   Maternal cardiac indication 1 (1%) 0 0 1 (17%) .18
   Fetal spina bifida 1 (1%) 0 0 1 (8%) .18
MP = mechanical aortic valve prosthesis, n = number of patients, AVR = aortic valve replacement, LVF = systolic left ventricular 
function, PAP = peak pulmonary artery pressure, * = all 67 pregnancies, including miscarriages and terminations. Data are 
presented as number of patients (%), unless indicated otherwise. Continuous variables are presented as mean ± standard 
deviation or as median with interquartile range.
Normality of the distribution of continuous data was tested with the Kolmogorov-Smirnov 
test with Lilliefors correction. Continuous data are displayed as means with standard 
deviations or in case of a skewed distribution, as medians with interquartile ranges and 
were compared using the one-way analysis of variance test or the Kruskal-Wallis test. 
Discrete data are presented as absolute numbers and percentages and compared using 
the Pearson’s Chi-Square test or Fisher’s exact test. 
Univariable logistic regression analysis was performed to identify possible factors 
associated with the incidence of pregnancy-related complications. Missing values were 
imputed by the mean. Age at surgery, maternal age at first pregnancy, valve type, time from 
surgery until first pregnancy, duration of pregnancy, caesarean section, preconceptional 
LVF, Vmax, and PAP were considered as co-variables in the univariable model for cardiac 
and obstetric events. For comparison of the event incidence with the general Dutch 
population the Chi squared test was used. All statistical tests were two-sided and a p-value 
≤ 0.05 was considered significant. For data analysis SPSS 17.0 for Windows (SPSS, Chicago, 
Illinois) was used.
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RESULTS
Forty patients experienced at least 1 pregnancy after AVR in our institution (Table 1). 
There were 67 singleton pregnancies in these 40 women. Fifty-five pregnancies continued 
beyond 20 weeks (47% males) in 35 women. All 6 spontaneous miscarriages were <14 
weeks of gestation. Six pregnancies were terminated (Table 1). The only termination of 
pregnancy for maternal cardiac reason was performed in a mechanical valve recipient 
with pulmonary hypertension, tricuspid insufficiency, and moderate stenosis of the 
mechanical prosthesis in aortic position of 3.3 m/s. One termination was performed in a 
fetus with spina bifida. There were no acenocoumarol associated embryopathies. Table 
2 displays the mode of delivery for the 55 completed pregnancies differentiated by type 
of valve substitute; Figure 1 illustrates the modes of delivery in comparison to the Dutch 
general population. There was no maternal mortality. 
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FIGURE 1. Mode of delivery of the 55 completed pregnancies compared to the Dutch Perinatal Registry. 
CS = cesarean section.
Heart failure was the most common cardiac complication with a persistent NYHA 
deterioration in 3 patients (Table 2).  One mechanical valve recipient with permanent 
atrial fibrillation developed prosthetic valve thrombosis and subsequent heart failure 
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at 33 weeks gestation. Anticoagulation was converted to intravenous heparin and the 
woman underwent a caesarean section at 36 weeks. A girl of 2,150 g was born. Five weeks 
later she underwent a re-AVR with another mechanical valve. 
The most common obstetric complications concerned hypertension-related disorders, 
preterm delivery, and small-for-gestational-age infants (Table 3; Figure 2). Five of the 
13 pregnancies which ended prematurely were induced before 37 weeks for cardiac 
indication: congestive heart failure in 2 patients (1 mechanical valve prosthesis; 1 
pulmonary autograft), prosthetic valve thrombosis (mechanical valve prosthesis), Marfan 
syndrome (homograft), and dilated aortic root with aortic and pulmonary regurgitation 
(pulmonary autograft).
TABLE 2. Mode of delivery of the 55 completed pregnancies in 35 women who underwent aortic valve replacement
Variable
All
(n=55)
Autograft
(n=28)
Homograft
(n=20)
MP
(n=7)
P-value
Vaginal delivery* 42 (76%) 19 (68%) 17 (85%) 6 (86%) .32
   Spontaneous 11 (20%) 3 (11%) 5 (25%) 3 (43%) .25
   Assisted delivery 13 (24%) 7 (25%) 5 (25%) 1 (14%) .67
   Epidural anesthesia 11 (20%) 4 (14%) 5 (25%) 2 (29%) .80
   Induction of labour 20 (36%) 11 (39%) 7 (35%) 2 (29%) .53
Elective caesarean section 8 (15%) 5 (18%) 2 (10%) 1 (14%) .89
   Maternal cardiovascular risk 5 (9%) 3 (11%) 2 (10%) 0 .72
   Prosthetic valve thrombosis 1 (2%) 0 0 1 (14%) .13
   Fetal presentation 1 (2%) 1 (4%) 0 0 1.00
   Fetopelvic disproportion 1 (2%) 1 (4%) 0 0 1.00
Emergency caesarean section 5 (9%) 4 (14%) 1 (5%) 0 .42
   Fetal distress 2 (4%) 1 (4%) 1 (5%) 0 1.00
   Placental abruption 1 (2%) 1 (4%) 0 0 1.00
   Fetopelvic disproportion 2 (4%) 2 (7%) 0 0 .62
MP = mechanical valve prosthesis, n = number of pregnancies, fetal distress = decelerations on cardiotocography, * = 
overlapping categories.
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FIGURE 2. Incidence of obstetric and perinatal complications of the 55 completed  pregnancies compared to the Dutch 
Perinatal Registry.16 PIH = Pregnancy induced  hypertension.
There was 1 fetal death in a mechanical valve recipient at 20 weeks and 4 days which 
presented with absent heart rate, growth restriction, and fetal hydrops on ultrasound. 
A macerated male infant (190 gram) with a placenta of 30 gram was born. Fetal 
autopsy was declined by the parents. Placental pathology showed severe placental 
insufficiency. One postnatal death occurred in a pulmonary autograft recipient who 
was on oral anticoagulation therapy because of a protein C deficiency and prior deep 
venous thrombosis. At 19 weeks, she had preterm premature rupture of membranes 
and fetal growth restriction. Despite the poor prognosis the woman opted for expectant 
management. At 30 weeks, she spontaneously delivered a 600 g boy who died on the first 
postnatal day due to lung hypoplasia.
No potential predictors of cardiac complications could be identified. Obstetric complications 
were more common in patients with cardiac complications during pregnancy (OR 13.2; 
95% CI 1.5-119.5; p=0.02). There was no correlation between preconceptional Vmax over 
the aortic valve and birth weight (r -0.01; p=0.95).
Two women with a completed pregnancy were not treated according to the current ESC 
guidelines for the use of anticoagulation in pregnant mechanical valve patients.17 One 
patient received an insufficient dose of oral anticoagulation therapy and developed 
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a prosthetic valve thrombosis. The other patient was treated with a combination of 
acenocoumarol and LMWH until a healthy girl was born by spontaneous vaginal delivery 
at 40 weeks.
TABLE 3. Outcome of the 55 completed pregnancies in 35 women who underwent aortic valve replacement.
Variable
All
(n=55)
Autograft
(n=28)
Homograft
(n=20)
MP
(n=7)
P-value
Pregnancy duration (weeks) 38 (36-40) 38 (35-40) 39 (38-40) 36 (31-39) .20
Birth weight (kg) (n=54) 3.0 (2.5-3.3) 3.0 (2.4-3.3) 3.1 (2.9-3.3) 2.7 (1.9-3.0) .11
Birth weight percentile (n=54)* 31 (14-54) 30 (11-54) 34 (21-54) 16 (11-80) .47
APGAR score ≥8 at 5 minutes 94% 96% 95% 86% .55
Cardiac complications** 7 (13%) 4 (14%) 1 (5%) 2 (29%) .21
   Heart failure 5 (9%) 2 (7%) 1 (5%) 2 (29%) .20
   Supraventricular arrhtymias 4 (7%) 1 (4%) 1 (5%) 2 (29%) .09
   Persistent NYHA deterioration 3 (5%) 1 (4%) 1 (5%) 1 (14%) .71
   Valve thrombosis 1 (2%) 0 0 1 (14%) .13
Obstetric complications** 21 (38%) 11 (39%) 6 (30%) 4 (57%) .50
   Hypertension related disorders 4 (7%) 0 4 (20%) 0 .02
      PIH 2 (4%) 0 2 (10%) 0 .14
      Preeclampsia 2 (4%) 0 2 (10%) 0 .14
   Premature labor 4 (7%) 3 (11%) 0 1 (14%) .33
   PPRoM 3 (5%) 3 (11%) 0 0 .26
   Placental abruption 1 (2%) 1 (4%) 0 0 1.00
   Preterm delivery 13 (24%) 8 (29%) 2 (10%) 3 (43%) .14
      Spontaneous 5 (9%) 4 (14%) 0 1 (14%) .24
      Cardiac maternal indication 5 (9%) 2 (7%) 1 (5%) 2 (29%) .20
      Obstetric indication 3 (5%) 2 (7%) 1 (5%) 0 1.00
   Small for gestational age 8 (15%) 5 (18%) 3 (15%) 0 .67
   Fetal death 1 (2%) 0 0 1 (14%) .13
   Postpartum hemorrhage 2 (4%) 2 (7%) 0 0 .36
       Postpartum blood loss (ml)
300
(200-425)
300
(200-650)
350
(300-400)
200
(200-500)
.48
   Neonatal death 1 (2%) 1 (4%) 0 0 1.00
MP = mechanical aortic valve prosthesis, n = number of pregnancies, APGAR = appearance, pulse, grimace, activity, 
respiration, NYHA = New York Heart, Classification, PIH = pregnancy induced hypertension, PPRoM = preterm premature 
rupture of membranes, * = adjusted for gestational age, fetal sex, and parity, ** = overlapping categories. Data are presented 
as number of pregnancies (%) and continuous variables are presented as median with interquartile ranges.
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DISCUSSION
Pregnancy in patients after AVR with a human tissue valve or a mechanical valve substitute 
was associated with serious maternal cardiac and obstetric complications in half of the 
patients in our study. However, all patients survived pregnancy. Human tissue valve 
recipients had a lower incidence of cardiac maternal and obstetric complications than 
patients with mechanical valve prostheses. Mechanical valve recipients were at risk for 
miscarriage, supraventricular arrhythmias, heart failure, and preterm delivery.
Pregnancy elicits major hemodynamic changes.18, 19 In addition, pregnancy induces 
alterations in the maternal coagulation cascade which makes it difficult to provide sufficient 
anticoagulation therapy in mechanical valve recipients and is therefore associated with 
maternal morbidity and mortality.1, 9, 10 However, more intensive anticoagulation may lead 
to hemorrhage. A recent review of maternal mortality considers care as suboptimal when 
there has been inappropriate management of anticoagulation, which can contribute 
to maternal cardiac death.20 A Danish cohort study describes 2 maternal deaths in 107 
mechanical valve recipients of which 1 was anticoagulation related.1 The mechanical valve 
patient in our cohort who developed a prosthetic valve thrombosis failed to comply with 
het anticoagulation therapy leading to inadequate anticoagulation. While appropriate 
dosing of oral anticoagulation can be challenging in pregnancy, patient compliance has 
also to be taken into account.
Another important cardiac complication in our study population was symptomatic heart 
failure during pregnancy which occurred in 5 patients, of whom 3 experienced a persistent 
New York Heart Association (NYHA) deterioration after 1 year. Heart failure is described as 
a serious complication in pregnant patients who underwent prior valve replacement;1, 21-23 
it was the cause of maternal death,1 but also an indication for termination of pregnancy.22 
Two of the 5 patients with heart failure in our study were advised against pregnancy 
prior to conception; both had persistent NYHA deterioration after pregnancy. Although 
preconceptional counseling has the intention to reduce the risk on severe maternal 
cardiac events during pregnancy, it is the patient and her family who finally decides to 
pursue or decline a pregnancy based on the informed wishes and expectations. 
In the present study, hypertensive related disorders occurred significantly more often 
in homograft recipients. Of the reports on pregnancy outcomes in homograft patients,2, 
10, 21, 24, 25 only 1 study describes a case of pre-eclampsia.24 The aortic gradient increases 
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significantly in homograft patients during pregnancy, but this is also seen in mechanical 
valve recipients,21 and probably reflects the increased cardiac output (increased stroke 
volume) and decrease in systemic vascular resistance.  Unfortunately, we could not identify 
a specific reason for the increase in hypertensive related disorders among homograft 
patients.
Almost all newborns of mechanical recipients were vaginally delivered without excessive 
maternal hemorrhage during labor or caesarean section (Figure 2). The Danish cohort 
on the other hand reports a postpartum bleeding incidence of 12% and reported 1 fatal 
bleeding.1 This underlines the importance of careful anticoagulation monitoring during 
delivery. Our study illustrates that through careful anticoagulation monitoring during 
delivery it is possible for mechanical valve recipients to deliver a baby without extensive 
bleeding.
There was 1 fetal death and 1 postnatal death, both in patients on oral anticoagulation 
therapy. Although the risks appears to be decreasing in the last few decades, mechanical 
valve recipients still have up to 9% fetal death risk.1, 9, 26 Perinatal death risk is reported to 
be up to 6% in mechanical valve recipients,9, 26, 27 and up to 8% in the mostly small cohorts 
of human tissue valve recipients.10-12, 21, 24, 25 Dore and Somerville report 1 perinatal death 
among 14 pregnancies in pulmonary autograft patients, although not directly related to 
cardiac reasons.11
Preterm delivery occurred more often (24%) in our study population as compared to the 
general Dutch population, especially in mechanical valve recipients. This high rate of 
preterm delivery was also found in the Danish cohort which found a rate of 49%.1 Of the 
13 cases of preterm delivery in the current study, 8 were induced on medical indication of 
which 5 due to cardiac reasons. As preterm delivery is the leading cause of infant mortality 
and morbidity, it is crucial to understand which risk factors are associated with preterm 
delivery.28 Maybe the treating physicians are too cautious with this particular patient 
group and therefore it is mainly a ‘doctors decision’ to intervene earlier as compared to 
the normal Dutch population. Maybe with good advice how to guide the anticoagulant 
management during delivery (new ESC guidelines) and some reinsurance, based on our 
findings, less preterm deliveries can be reached for.
Counseling of young female patients who require AVR and may contemplate pregnancy, 
requires a multidisciplinary discussion including several important issues. These patients 
should be individually informed about the (dis)advantages of the different available 
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valve substitutes and corresponding potential pregnancy-associated maternal and fetal 
complications.3 The high incidence of preterm delivery and valve thrombosis in mechanical 
valve recipients illustrates that these valves are far from ideal in patients during pregnancy. 
On the other hand, the curious finding of a high incidence of hypertension related disorders 
in homograft recipients calls for further studies and indeed careful monitoring of the last 
stage of pregnancy in this patient group. Although human tissue valves needs careful 
obstetric monitoring, they provide female patients a biological solution that eliminates 
the daily burden of anticoagulation, in particular during pregnancy, and their durability 
is not influenced by pregnancy.29 Therefore, human tissue valves should be considered as 
aortic valve substitute of choice in young patients with severe aortic valve disease who 
are planning to start a family.
As in most studies on this topic, patient numbers in the present study are relatively small 
and treatment took place in a tertiary hospital which necessitates careful interpretation 
of the results. 
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There is insufficient published evidence about the potential degenerative effects of 
pregnancy on the homograft and pulmonary autograft in aortic position. To assess the 
association between pregnancy and accelerated degeneration of human aortic valve 
substitutes, we conducted a retrospective analysis of a prospective cohort study of female 
patients who received a human tissue valve in aortic position at our institution. 
Patients 
All patients who receive a homograft or autograft in aortic position in our center since 
1987 are enrolled in an ongoing prospective follow-up study (1). Patients undergo annual 
clinical follow-up and biennial standardised serial echocardiography (aortic gradient 
(Vmax), aortic regurgitation (AoI), annular and sinotubular junction diameter (AD and 
STJ). We identified 108 female patients who underwent 59 homograft and 49 autograft 
procedures, and were 50 years or younger at time of surgery and at least 16 years old at 
the time of study (mean age 29 years; SD 13). Informed consent was obtained from the 
patients to interview them (December 2010) for additional information on pregnancy and 
cardiac status (institutional review board number 2010-272).
Freestanding root replacement with reimplantation of the coronary arteries was performed 
in most patients. Fifteen homograft patients underwent a subcoronary homograft 
implantation and 2 autograft patients an inclusion cylinder aortic root replacement. 
Outcome was reported according to the 2008 AATS/EACTS/STS guidelines for reporting 
mortality and morbidity after cardiac valve interventions. Mixed-effects models were 
used to assess changes in echocardiographic measurements over time while accounting 
for within-patient correlation between repeated follow-up measurements (2). Total 
follow-up was 1,448 patient years and 99% complete. Ninety-nine patients had 1 or more 
echocardiographic examinations (median 6; range 1-11). 
Thirty-one patients (13 homograft and 18 autograft) experienced 55 pregnancies, 
including 48 completed pregnancies, 4 elective abortions for non-cardiac reasons and 
3 miscarriages. Homograft recipients without pregnancies were older than homograft 
recipients who became pregnant (35 versus 28 years; p=0.02). There were no other 
differences in patient characteristics between homograft and autograft patients without 
pregnancies and those who became pregnant.
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During follow-up, 9 homograft patients and 4 autograft patients died. Fifteen-year survival 
in homograft patients was 80.0% ± 7.3% for patients without pregnancies and 100% for 
patients with pregnancies; in autograft patients this was 94.1% ± 4.0% for patients without 
pregnancies and 94.4% ± 5.4% for patients with pregnancies (P=NS). 
Fifteen homograft patients required reoperation for a calcified and degenerated 
homograft; 2 additional homograft patients were reoperated for paravalvular leak. Twelve 
autograft patients were reoperated for neo-aortic regurgitation and dilatation of the neo 
aortic root, including eleven autograft replacements and one valve sparing aortic root 
replacement (Yacoub procedure). Freedom from aortic valve reoperation at 15 years 
was 63% (95%CI: 57-69%) in homograft patients; in autograft patients 75% (95%CI: 63-
87%). Freedom from reoperation was comparable between patients who experienced 
pregnancy and those who did not, in both homograft and autograft recipients (P=NS).
Figure 1 shows progression of Vmax, STJ diameter, AD and AoI over time. Pregnancy was 
not associated with changes in Vmax over time, STJ diameter over time, AD over time or 
AoI grade over time for either valve type. 
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DISCUSSION 
Pregnancy is known to provide significant hemodynamic changes with an increase in 
heart rate, plasma volume and cardiac output (3). This may impose a burden on biological 
valve substitutes, accelerating degeneration. However, we found that pregnancy was 
not associated with either homograft or pulmonary autograft valve reoperation and 
echocardiographic valve function over time. This is in concordance with previous, but very 
limited, evidence (4,5). 
The question remains what the best valve substitute choice is for young female 
patients who require aortic valve replacement, and who may contemplate pregnancy. 
Bioprosthetic valves are an option, but valvular deterioration seems to be accelerated 
during pregnancy (6). Mechanical prostheses are far from ideal during pregnancy because 
of anticoagulation therapy-related complications, although in some patients mechanical 
valves are the only option. Human tissue valves do not require anticoagulation therapy 
and have good haemodynamic performance, but homografts –in contrast to autografts- 
do not increase in size with the growing child. In addition, autografts have a superior 
hemodynamic profile (7), which in particular during pregnancy has potential beneficial 
effects on cardiac function. On the other hand, neo-aortic root dilatation and neo-aortic 
regurgitation cause an increased need for reoperation (8).
CONCLUSION  
Because human tissue valve durability is not influenced by pregnancy, it offers an 
attractive biological option for aortic valve replacement in young female patients. Young 
female patients who (may) contemplate pregnancy should consider human tissue valves 
as a suitable aortic valve substitute. 
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ABSTRACT
Objective. Symptomatic severe aortic stenosis is an indication for aortic valve replacement. 
Some patients are denied intervention. This study provides insight into the proportion 
of conservatively treated patients and into the reasons why conservative treatment is 
chosen. 
Methods. Of a patient cohort presenting with severe aortic stenosis between 2004 and 
2007, medical records were retrospectively analyzed. Only symptomatic patients (n=179) 
were included. We studied their characteristics, treatment decisions and survival. 
Results. Mean age was 71 years, 50% were male. During follow-up (mean 17 months, 
99% complete) 76 (42%) patients were scheduled for surgical treatment (63 conventional 
valve replacement, 10 transcatheter, 1 heart transplantation, 2 waiting list) versus 101 
(56%) who received medical treatment. Reasons for medical treatment were: perceived 
high operative risk (34%), symptoms regarded mild (19%), stenosis perceived non-severe 
(14%) and patient preference (9%). In 5% the decision was pending at the time of the 
analysis and in 20% the reason was other/unclear. Mean age of the surgical group was 68 
versus 73 years for medically treated patients (p=0.004). Predicted mortality (EuroSCORE) 
was 7.8% versus 11.3% (p=0.006). During follow-up 12 patients died in the surgical group 
(no 30-day operative mortality), versus 28 in the medical group. Two-year survival was 
90% versus 69%. 
Conclusions. A large proportion (56%) of symptomatic patients does not undergo aortic 
valve replacement. Often operative risk is estimated (too) high or hemodynamic severity 
and symptomatic status are misclassified. Interdisciplinary team discussions between 
cardiologists and surgeons should be encouraged to optimize patient selection for 
surgery. 
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INTRODUCTION
The prevalence of aortic stenosis increases with age to up to 8% in the elderly [1]. 
Meanwhile the Western population increases to age during the last decades and this trend 
is expected to continue [2]. Therefore aortic stenosis constitutes a growing health burden. 
While the treatment of asymptomatic patients with severe aortic stenosis remains 
debatable, both European and American guidelines on the management of valvular heart 
disease recommend that symptomatic patients have aortic valve replacement [3,4]. This 
recommendation is not only based on the survival advantage that can be expected after 
surgery but also on the improvement in functional class, even in elderly patients [3-5]. 
Recent literature suggests that a considerable proportion (33-60%) of patients with 
symptomatic severe aortic stenosis does not receive aortic valve replacement (AVR) [6-
9]. We sought to confirm that many symptomatic patients remain unoperated and were 
interested in the reasons and the consequences of the decision to operate or not. The goal 
of our study was therefore to gain insight into decision making and survival in patients 
with severe symptomatic aortic stenosis.
METHODS
Study design and data collection
A retrospective search in the echocardiography database of our department revealed 115 
patients with severe aortic stenosis. An additional 140 patients were recruited from the 
echocardiography laboratories in the outpatient cardiology clinics of 7 hospitals in the 
Rotterdam region. All echocardiograms were made between October 2004 and December 
2007. Patients had at least one of the following inclusion criteria: aortic valve area < 1.0 
cm2, maximum aortic jet velocity > 4.0 m/s, peak aortic gradient > 64 mmHg or mean 
aortic gradient > 40 mmHg. To avoid missing low-output aortic stenosis, patients were 
also included if the ratio between the velocity time integral over the aortic valve and the 
left ventricular outflow tract was > 4.0. 
Information was gathered on medical history, cardiovascular risk factors and symptomatic 
status at the time of the echocardiogram. Asymptomatic patients were excluded from the 
eventual analysis. For all symptomatic patients, anticipated operative risk was calculated 
using the logistic EuroSCORE risk model (www.euroscore.org).
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Treatment strategies and their reasons were retrieved from notes in the patients’ medical 
charts. Reasons for ‘conservative/medical treatment’ were classified in 6 main categories: 
1) anticipated high operative risk (including advanced age or left ventricular dysfunction); 
2) only mild symptoms; 3) stenosis non-severe; 4) patient preference; 5) decision not final 
yet; 6) other, including ‘reason unclear’. 
The study protocol was approved by the institutional review board, patient informed 
consent was waived (MEC 06-066, MEC 08-022). The authors had full access to the data 
and take responsibility for its integrity. All authors have read and agree to the manuscript 
as written.
Study population
Of the 255 patients that were initially identified, 73 asymptomatic patients were excluded 
plus 3 patients of whom symptomatic status could not be retrieved, leaving 179 
symptomatic patients in the study cohort. Mean age was 71 years, 50% were male. 
TABLE 1. Patient characteristics
Patient characteristics
AVR
n= 76
Conservative
n= 101
Age (mean ± SD in years) 67.9 ± 12.4 73.3 ± 12.3
Male (%) 49 51
Follow-up (mean ± SD in months) 20.3 ± 11.8 15.1 ± 11.5
Echocardiographic parameters (mean ± SD)
Maximal transaortic velocity (m/s)
Peak gradient (in mmHg)
AV/LVOT VTI ratio
Aortic Valve Area (cm2)
4.4 ± 0.8
82 ± 32
4.9 ± 1.8
0.68 ± 0.24
4.0 ± 0.8
66 ± 26
5.0 ± 2.3
0.71 ± 0.26
NYHA class (%)
II
III
IV
Missing
42.1
38.2
13.2
6.6
54.5
34.7
8.9
2.0
Left Ventricular Function (%)
Good/impaired (EF >50%)
Moderate (EF 30-50%)
Poor (EF <30%)
Missing
56.6
38.2
2.6
1.3
57.4
30.7
7.9
4.0
Logistic EuroSCORE (mean ± SD) 7.8 ± 7.9 11.3 ± 9.6
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During follow-up (mean 17 months, median 13.6, range 0.1-40) 76 patients (42%) 
underwent AVR or were scheduled for surgery (Figure 1). There were 63 conventional 
aortic valve replacements, 9 percutaneous and 1 transapical valve implantations. Two 
patients were on a waiting list for AVR and 1 patient required a heart transplantation 
during follow-up. Medical treatment was given in 101 patients (56%). Two patients were 
lost to follow-up (99% completeness). Mean age of the surgical group was 68 versus 73 
years for the medically treated patients (P=0.004). Predicted operative mortality according 
to the logistic EuroSCORE was 7.8% versus 11.3% (P=0.009). More patient characteristics 
are given in Table 1.
Statistical Analysis
Continuous data are presented as mean ± 1 standard deviation, and median. Categorical 
data are presented as proportions. Chi-square testing was used for comparison of 
categorical variables. Continuous variables were compared using the Student’s t-test. A 
p-value < 0.05 was considered significant. Survival curves were estimated by the Kaplan-
Meier method. Differences in survival were not statistically assessed. Statistical analyses 
were performed with SPSS for Windows (release 15.0; SPSS Inc, Chicago, Illinois).
RESULTS
There was no 30-day mortality. During follow-up 12 patients died in the surgical group, 
versus 28 patients in the medical group. One- and two-year survival was respectively 93% 
and 90% for the AVR group and for the conservative group 77% and 69% (Figure 1). 
Reasons for choosing non-surgical treatment were: operative risk deemed ‘too high’ 
(34%), symptoms regarded as ‘mild’ (19%), stenosis regarded as ‘non-severe’ (14%) and 
patient preference (9%). In 5% the decision to operate was still under consideration by 
cardiologist and/or patient. In 20 patients (20%) the reason behind decision making could 
not be retrieved accurately. Of the latter 20 patients, 11 were in NYHA class II, 6 were in 
NYHA III and 3 were in NYHA class IV. 
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FIGURE 1. Flow chart of main results.
AVR
Conservative
treatment
AVR
Conservative
FIGURE 2. Kaplan Meier survival for the conservatively treated group and the AVR group.
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Of the 34 patients in whom the reason not to operate was ‘high risk’, the mean age was 
75.7 years and the mean EuroSCORE was 11.6%. Eight of them had a history of malignancy 
or active malignancy (six of these patients eventually died during follow up). Eighteen 
patients had a EuroSCORE <10% and only 9 of the 34 patients in whom the operative risk 
was deemed too high had a EuroSCORE > 15%. 
DISCUSSION
Although treatment consensus seems to exist on symptomatic patients with severe aortic 
stenosis, it is not uncommon to diverge from these guidelines [6,8-10]. Advanced age and 
left ventricular dysfunction are known reasons to deny surgery in a symptomatic patient 
[6,11]. Instead of using patient characteristics to predict whether a patient gets AVR or 
not, our study was designed to investigate the decision making. Therefore it provides a 
different perspective: in our cohort an overestimation of operative risk, underestimation 
of symptoms and misclassification of hemodynamic severity are common causes 
why symptomatic patients are denied AVR. Furthermore, we found that survival of the 
conservative group is not as pessimistic as reported by others [12,13].
‘Overestimation’ of operative risk?
In a third of the patients who were treated conservatively, an anticipated high operative 
risk was the main reason not to go for AVR. This subgroup had a mean age of only 76 years, 
and only 9 of the 34 patients had a EuroSCORE > 15%. Perhaps it is even more important 
that more than half (18 patients) had a relatively low operative risk with a EuroSCORE 
<10%. 
From literature it is known that remission of symptoms after starting medical treatment 
can be a reason to stay conservative and that patients who are treated conservatively 
are generally older and more often have impaired left ventricular function than surgically 
treated patients [6,7]. Yet, both remission of symptoms, advanced age and depressed left 
ventricular function are debatable reasons not to operate on a symptomatic patient. Even 
elderly patients can be operated upon with acceptable morbidity and mortality, and can 
expect a considerable quality of life [5,11]. 
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Note that 10 patients in the AVR group underwent a minimally invasive valve replacement. 
They were deemed not amendable for surgery. This indicates that even in a region with 
a tertiary center that uses new percutaneous and transapical techniques to replace the 
aortic valve, the majority of patients are treated conservatively.
Eight patients had either a malignancy in medical history or an active malignancy, risk 
factors which are not taken into account by the EuroSCORE. Another issue with risk models 
is that they do not score characteristics such as ‘vitality’ or ‘biological age’. Furthermore 
there is a large variability between different risk models, and the one most commonly 
used (EuroSCORE) seems to overestimate the actual operative risk most [14]. Perhaps this 
adds to the large variance in treatment advise that exists among cardiologists which was 
already found by Bouma et al [7].
Underestimation of symptoms?
Due to inactivity or gradual adjustment of daily activities to developing symptoms, patients 
with aortic stenosis often do not acknowledge the presence of symptoms or attribute 
them to the ageing process. Exercise testing is recommended in asymptomatic patients 
with aortic stenosis in order to exclude symptoms with more certainty [15-17], and up 
to 37% of patients previously considered asymptomatic have limiting symptoms when 
they are tested [17]. According to the European Heart Survey exercise testing is highly 
underused [3,18]. This could lead to an underestimation of the proportion of symptomatic 
patients treated medically that was reported by others and in the current study [6,8-10]. 
In this study, the classical aortic stenosis symptoms such as dyspnea, syncope or angina 
were documented for several patients but regarded as ‘mild’ or non-debilitating. Having 
only ‘mild’ symptoms does not exclude a patient from being an AVR candidate [3,4]. It 
is furthermore known that even íf symptoms are recognized, the resulting functional 
disability is often underestimated by physicians [19]. Symptomatic patients with severe 
aortic stenosis from our cohort suffer from both physical and emotional impairment 
hampering normal daily activities (unpublished data). These are clear reasons to assess 
symptomatic status accurately, and to reconsider a conservative approach when 
symptoms are present.
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Underestimation of hemodynamic severity 
As much as 14% of the symptomatic patients who were denied surgery were not referred 
because the stenosis was classified ‘non-severe’ by the treating cardiologist during the 
initial assessment. According to the guidelines they should however have been classified 
as severe [3,4]. Since only patients with a severe stenosis are recommended to have 
surgery, these misclassified patients are at increased risk of left ventricular deterioration 
and sudden death [20].
Even íf the stenosis severity is only just below the ‘severe’ threshold, it can be disputed that 
’watchful waiting’ is the best treatment. Peak aortic gradient increases 10-15 mmHg/year 
and aortic valve area decreases 0.1-0.12 cm2/year [21-23]. Given these progression rates, 
borderline patients will enter the ‘severe’ category within a few months or at most a year 
later. Meanwhile left ventricular function will only get worse.
Survival in the conservative and in the surgical group
Survival in the medically treated group cannot easily be compared with the surgically 
treated group because the patients have quite different characteristics, which could 
account for a large part of the difference in survival. It is therefore questionable if, and to 
what extent, the survival of the total study group would have improved supposed more 
patients would have had aortic valve replacement. 
From the survival curve of the non-AVR group it can be seen that a decline in survival 
already occurs in the first year after the echocardiogram (Figure 2). Still, survival in the 
conservative group is not as bad as expected based on previous reports [12,13,20]. 
Perhaps improvement in medical treatment over the past years plays a role, but survival 
in the conservative group highly depends on referral strategy as well; if more high 
risk patients are operated upon, the patients with a really bad prognosis are left for 
conservative treatment, resulting in low survival in this category. Therefore the relatively 
‘good’ prognosis of our medically treated group could be a reflection of the conservative 
approach of the cardiologists in our region. 
Because of its dependence on referral, ‘natural history’ of aortic stenosis is very difficult 
to study. If one would like to gain a clear view on ‘natural history’, theoretically all eligible 
patients should be excluded from having AVR, or they should be randomised to receive 
either surgical or conservative treatment. In practice this would be impossible and 
ethically incorrect. 
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Future prospects
Microsimulation methods can accurately estimate life-expectancy for patients after 
AVR [24,25], but have yet to be developed for patients who are treated conservatively. 
Our department intends to develop these models, but this requires large datasets with 
extensive numbers of variables and some patient factors, such as vitality, will be difficult 
to grasp in a model.
CONCLUSION
A considerable proportion of patients with symptomatic severe aortic stenosis is not 
referred for surgery although theoretically they have an indication for aortic valve 
replacement. Often operative risk is estimated (too) high, and misclassification of both 
hemodynamic severity and symptomatic status occurs frequently. 
Most patients who were treated conservatively were simply not referred to a surgical 
department. Referral to surgical departments should be encouraged in order to have 
more interdisciplinary team discussions between cardiologists and surgeons. Hopefully, 
this will result in better patient selection for surgery, possibly resulting in better survival 
of patients with severe symptomatic aortic stenosis. 
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ABSTRACT
Objective. Valve-sparing aortic root replacement has gained popularity for treating aortic 
root aneurysm. This study aims to report on valve-related outcome and quality of life after 
valve sparing aortic root reimplantation. 
Methods. Between 2001 and 2014, 41 consecutive patients underwent valve-sparing 
aortic root reimplantation. Patient characteristics, survival, freedom from reoperation 
and valve-related events were analyzed. Standardized echocardiography was performed 
comparing preoperative and last follow-up measurements. Health-related QoL was 
explored by means of SF-36 forms and compared to the aged-matched Dutch population. 
Results. Median age was 39 (range 18-65) years (78% male). Etiology was connective-
tissue-disease (51%), idiopathic aortic aneurysm (32%), and aortic root dilatation 
after Ross-procedure (17%). During follow-up (mean 5.1 years; range 0.4 to 13.9; 100% 
complete), one patient died. Freedom from reoperation after 8 years was 78% (95% CI 60-
90%) for all patients and 88% (95% CI 67-96%) excluding post Ross-procedure patients. 
All reoperations were because of aortic regurgitation. Ross-procedure (HR 8.5; 95% CI 1.9-
38.5; p = 0.005), greater sinotubular-junction diameter (HR 1.6; 95% CI 1.0-2.6; p = 0.04), 
and annulus diameter (HR 1.2; 95% CI 1.0-1.6; p = 0.06), were associated with reoperation. 
Only 2 valve-related (thrombo-embolic) events occurred. Quality of life was comparable 
to the general age-matched Dutch population.
Conclusions. In our experience, valve-sparing aortic root replacement using the 
reimplantation technique provides excellent clinical outcome and quality of life in the 
first postoperative decade. However, despite low valve-related complication rates, there 
is a hazard of reoperation due to progressive valve regurgitation, particularly in patients 
after the Ross-procedure. 
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INTRODUCTION
Since the introduction of the composite aortic root replacement [1], this has been the “gold 
standard” treatment for aortic root aneurysm. Alternatively biological valve prostheses are 
available. However, both are associated with valve-related complications. 
Valve sparing aortic root replacement (VSARR) techniques are gaining popularity as an 
alternative treatment for aortic root aneurysm, with or without aortic regurgitation, in 
the absence of calcification, preserving the native aortic valve, avoiding anticoagulation 
therapy and the risk of biological valve deterioration. The most frequently used techniques 
are remodeling (Yacoub ) [2] and reimplantation (David) of the aortic root within a 
prosthetic conduit [3]. 
Good durability results of the repaired valves are reported from experienced centers. 
However, these results may contain a positive publication bias. Consequently, there are 
no clear recommendations in the current guidelines regarding valve-sparing techniques 
[4]. The main concern remains the probability of valve failure and need for reoperation. 
Moreover, there are only a few studies presenting the quality of life after VSARR. In this 
light we conducted this study to report on clinical outcome and quality of life after valve 
sparing aortic root replacement using the David procedure [3], and to investigate potential 
risk factors leading to VSARR failure.
MATERIALS AND METHODS
From January 2002 to September 2014, forty-one consecutive patients underwent VSARR 
using the David reimplantation procedure [3] at the Department of Cardiothoracic 
Surgery of the Erasmus MC, Rotterdam. Institutional Review Board approval was obtained 
for this study (MEC 14-518), and informed consent was obtained. The medical records 
of all patients were reviewed. Patient characteristics and echocardiographic data were 
collected and are displayed in Table 1. Perioperative characteristics are displayed in Table 
2.
Valve-related events were registered according to the 2008 American Association for 
Thoracic Surgery/Society of Thoracic Surgeons/European Association for Cardiothoracic 
Surgery guidelines for reporting mortality and morbidity after cardiac valve interventions 
[5].
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All patients who were not reoperated on the aortic valve after VSARR were invited for 
a standardized echocardiographic follow-up, and a Short Form-36 health related quality 
of life questionnaire. For all other patients the first preoperative and the latest available 
echocardiogram before reoperation or death was obtained and analyzed in a structural 
manner.
TABLE 1. Patient characteristics.
Patient characteristics Total cohort (N = 41)
Age (SD; range) yrs 39,1 (15; 16 - 65)
Female (n, %) 9 (22%)
Prior cardiac surgery (n, %) 8 (19.5%)
   Ross operation 7 (17.1)%
   VSD closure 1 (2.4%)
Hypertension (n, %) 10 (24.4%)
Mean Creatin level μmol/L (range) 67 (42 -92)
Etiology (N; %)
Connective tissue disease 21 (51)
   Marfan Syndrome 11 
   SMAD 3 mutation 9 
   Loeys- Dietz Syndrome 1 
Post Ross operation 7   (17)
Idiopathic 13 (32)
Aortic valve regurgitation 
No/Trace 27 (65.9%)
Mild 6 (14.6%)
Moderate 2 (4.9%)
Severe 6 (14.6%)
Aneurysm diameter (mean; SD) 48 (10.2) mm
Systolic LVF (N; %) 
   Good 33 (81)
   Impaired 8   (19)
   Moderate/Severe 0
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Echocardiography
All echocardiographic measurements were conducted and reported according 
to standardized echocardiogram based on criteria of the AVIATOR registry 
workgroup [5]. All echocardiographic images were evaluated by a cardio-
thoracic and cardiology resident. In case of doubt a senior cardiologist was 
consulted. Furthermore, preoperative and perioperative parameters were 
analyzed in order to find potential risk factors for repair failure and reoperation. 
For all patients data on AR preoperatively and at last follow-up was available. However, for 
12 patients there were no complete or only postoperative in-hospital echocardiograms, 
which were excluded from the analysis of other echocardiographic parameters. Appendix 
1 shows a detailed description of echocardiographic measurements.
TABLE 2. Perioperative characteristics. 
Characteristics Total cohort (N = 41)
Concomitant procedure (N) 8 
   CABG 2
   MVP 2
   Hemiarch aortic replacement 3
   VSD closure 1
   PVR 1
Aortic cross clamp time (min (SD; range) 159 (25,8 (123-227))
Perfusion time (min (SD; range) 199 (13 (138 - 307)
Circulatory arrest (min (SD; range) (N = 3) 14 (4 (12 - 19)
Bleeding requiring reoperation 5 (12,2%)
Rhytm disturbance postoperative 6 (14,6%)
    Supraventricular 6 (100%)
    Ventricular 0
Permanent pacemaker 1 (2,4%)
CVA 0
CABG: Coronary artery bypass grafting; MVP: mitral valve plasty; VSD: ventricular septal defect; PVR pulmonary valve 
replacement. 
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Quality of life
The Dutch version of the SF-36 was used to evaluate the health-related quality of life. 
This questionnaire contains questions clustered into 8 domains: physical functioning, 
role limitations due to physical health problems, general health perceptions, bodily 
pain, vitality, social functioning, role limitations due to emotional problems, and general 
mental health. These questions are summarized to form 2 components, namely Physical 
Component Scale (PCS) and Mental Component Scale (MCS). The scales are from 0 to 100 
and are obtained by summing the items together within a domain. Thereafter the scores 
are divided by the range of scores and transformed into the scale. The mean score of both 
components is 50 with a standard deviation of 10. Higher scores represent better health 
status [6]. The study by Aaronson et al. was used to compare QoL between the general 
Dutch population and the study population [7]. 
Surgical technique
All patients were operated through a median sternotomy, using cardiopulmonary bypass 
and St. Thomas cardioplegia. All dilated sinus of Valsalva tissue was resected leaving a 2 
to 3 mm rim of aortic tissue distal of the aortic valve attachment. The coronary buttons 
were dissected and were mobilized. Graft size was measured by a Hegar sizer at the level 
of the ventriculo-aortic junction, adding 2-3 mm in diameter for the appropriate size. 
Reimplantation of the aortic valve was performed by anchoring the aortic annulus and 
subcommissural triangles inside a tubular graft. Horizontal (Prolene 4-0) sutures were 
placed circumferentially in the left ventricular outflow tract, at the level of the nadir, 
except in the region of the perimembranous septum, and used to attach the proximal 
end of the vascular prosthesis. In most patients a Vascutek Valsalva vascular prosthesis 
(Terumo, Ann Arbor, MI) was used. Subsequently the residual aortic rim was sutured to the 
prosthesis with a running Prolene 4-0 suture (Ethicon, Inc., Somerville, NJ) and coronary 
buttons were reimplanted. From 2013 onward we used the caliper cusp measurement 
instrument introduced by Schäfers in order to asses optimal coaptation height of the 
aortic valve leaflets [8]. In 2 patients an additional plication of the coronary cusps was 
performed. Three patients were operated under deep hypothermic cardiac arrest with an 
open distal anastomosis.
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Statistical Analysis
Continuous variables are displayed by the mean and standard deviation and by the 
median and range where appropriate. The distribution of the continuous variables was 
tested by Kolmogorov-Smirnov test. Categorical variables are displayed as counts and 
percentages. The Mann-Whitney U-test (for categorical variables) or unpaired t-test (for 
continuous variables) was used to compare unpaired groups.
The one-sample t-test was used to compare health-related QoL between the study 
population and the general Dutch population mean. To compare preoperative to 
postoperative echocardiographic measurements the paired-sample T-test and the 
Wilcoxon signed-rank test (continuous parameters) or Mc Nemar’s test (binominal 
parameters), and Marginal Homogeneity test (ordinal parameters) was used. A Cox-
regression model was used to test for variables associated with reoperation hazard; 
multivariable analyses was not performed (low number of events). All tests were 2-sided, 
and a p-value of 0.05 or less was considered statistically significant. Patient survival and 
freedom from reoperation were analyzed using the Kaplan-Meier method. The statistical 
analyses were performed using IBM-SPSS 21 (IBM Corp., Armonk, NY). Graphs were 
constructed using GraphPad Prism 5.0 (San Diego, CA, USA).
RESULTS
The mean clinical follow-up was 5.1 years (SD 3.1 years; range 0.4-13.9 years) 100 
% completed, containing a total of 297 patient-years. Mean time to last follow-up 
echocardiogram was 3.6 years (SD 2.6 years; range 0.5-10.1 years), 90% complete.
Early mortality and morbidity
There were no early deaths. Coronary artery bypass grafting (CABG) due to complications 
related to reimplantation of the coronary artery with kinking of the RCA was necessary 
in one patient. One patient was diagnosed a post-operative third-degree AV-block and 
received a permanent pace-maker during the hospital stay. Another 5 patients had re-
sternotomy because of hemorrhage or tamponade. 
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Late survival
One patient, a 22-year old man with Marfan’s syndrome, died suddenly 4 months after 
surgery. A post-mortem CT-scan showed asphyxia, probably related to aspiration of blood. 
The aortic valve and root appeared to be as expected after a David procedure. Overall 
cumulative survival at 10 years of follow-up was 98% (95% CI 93-100%). 
Reoperation 
Six patients were reoperated on the aortic root (2.4 %/patient year) due to severe AR and one 
because of moderate to severe AR with symptoms. Reason for reoperation was structural 
valve deterioration (SVD). Four of these patients had undergone VSARR because of aortic 
root dilatation after a Ross procedure, and three for Marfan’s syndrome. In all reoperated 
patients the aortic root was replaced using the composite valve replacement technique 
(Bentall). There was no reoperation mortality. Cumulative freedom from reoperation on 
the aortic root was 98% (95% CI 82-99%) at 1 year, and 78% (95% CI 59-89%) at 8 years; 
and 88% (95% CI 78-99%) when excluding (seven) patients with congenital heart disease 
and Ross procedure in the past. Figure 1 displays the Kaplan-Meier-curve of freedom 
from reoperation. Additionally, one of the first operated patients, a 16 year old male with 
Loeys-Dietz syndrome, was reoperated within 2 weeks after the operation because of 
severe mitral regurgitation. The fixation sutures in the left ventricular outflow tract had 
perforated the base of the anterior mitral valve leaflet. The mitral valve was repaired using 
an autologous pericardial patch. At last follow-up echocardiogram (4 years) there was no 
sign of mitral or aortic regurgitation. 
VSARR after Ross-procedure was associated with higher reoperation hazard in our Cox 
regression model (HR 8.5, 95% CI 1.9-38.5; p = 0.005). Additionally, preoperative STJ 
diameter and annulus diameter were associated with higher reoperation hazard (HR 
1.6, 95% CI 1.0-2.6; p = 0.043 and HR 1.2, 95% CI 1.0-1.6; p = 0.056 respectively). Detailed 
information of variables tested is displayed in Appendix 2. 
Valve related complications 
There were seven cases of SVD due to prolapse of the leaflets and sagging 
of the commissures, as described above (LOR 2.4% per patient-year). 
Another 2 patients were diagnosed with a thromboembolic event (LOR 0.7% per 
patient-year; one case of TIA and one lung embolism). Both patients were diagnosed 
with aneurysms-osteoarthritis syndrome (SMAD3 mutation) [9], one of whom with 
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multiple aneurysms and TIA in the past treated with coiling of cerebral arteries. 
There were no hemorrhagic events, no endocarditis and no non-structural valve 
deterioration during follow-up. Figure 2 demonstrates follow-up AR in 2 groups; patients 
with pre-operative AR grade 0 and 1 and patients with grade 2 or greater.
FIGURE 2. Aortic regurgitation preoperative compared to last follow-up. A: Patients with preoperative AR grade 0 or 1. 
B: Patients with preoperative AR grade 2 or higher. 
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TABLE 3. Echocardiographic parameters preoperative compared to last follow-up.
Parameter Preop Last FUP P-value
AR
    Trace/mild 80% 83% 0,7
    Moderate/severe 20% 17%  
LVEDD (mm) 53,8 53,7 0,9
LVESD (mm) 36 35,3 0,7
Coaptation height (mm) 11,3 9,9 0,3
Annulus diameter (mm) 26,1 22,4 0,001
Mean gradient (mmHg) 1,1 0,8 0,3
LVF 
    Good 81% 82% 0,6
    Impaired 19% 18%  
 
Echocardiographic parameters 
Four of the 33 invited patients had no or only postoperative in-hospital echocardiograms, 
which were excluded from the analysis. Therefore 29 patients had structural 
echocardiogram measurements. Mean time to last follow-up echocardiogram was 3.6 
years (SD 2.6; range 0.5-10.1 years). During this follow-up time we found no significant 
change in LVESD and LVESD. Coaptation height of the leaflets increased from 8.1 mm to 
11.5 mm and annulus diameter decreased from 26.1 to 22.4 mm. Moreover, there was 
no change in LVF comparing preoperative to last follow-up values. Table 3 displays a 
comparison of echocardiographic parameters measurements preoperative to last follow-
up.  
Quality of life
The SF-36 quality of life questionnaire was completed by 21 patients. Of the 33 invited 
patients, 5 were not available for the follow-up questionnaire due to missing contact 
information or mental disease, and another 7 did not fill in the questionnaire after several 
requests, despite initial agreement. The SF-36 showed a quality of life comparable to the 
general age-matched Dutch population, displayed in Figure 3. Remarkably, ‘emotional 
role functioning’ and ‘bodily pain’ were experienced better in our study population 
compared to the general Dutch population, while “physical functioning” was worse. 
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Additionally, aggregated composite Mental component and Physical component scores 
were 50.1 and 53.7. None of the tests mentioned above were statistically significant. 
Moreover, we excluded 3 patients (2 diagnosed with aneurysms-osteoarthritis syndrome 
and 1 with Marfan’s syndrome) who recently had operations and disabilities clearly linked 
to their disease (i.e. abdominal aneurysm surgery, coiling of cerebral artery and TIA, and 
thromboses and osteoporosis with musculoskeletal symptoms). If we would not have 
exclude these 3 patients there would still be no significant difference between our study 
population and the general Dutch population, although there would be no better quality 
of life in aggregated composite mental component. 
FIGURE 1. Freedom from reoperation. Blue indicates all patients included. Red indicates patients with Ross-procedure 
in the past excluded. 
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FIGURE 3. Quality of life compared to age-matched general Dutch population.
PF: physical functioning; RP: role physical; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: 
role emotional; MH: mental health; PC: physical component score; MC: mental component score
DISCUSSION 
Our study shows excellent midterm survival after valve sparing aortic root replacement 
using the David technique. In addition, valve-related events other than structural 
valve deterioration are rare. Taking into account the quality of life comparable to the 
general population after VSARR and the great hemodynamic results, the reimplantation 
technique (David procedure) is a good alternative to composite valve replacement and 
biological valve prosthesis for the treatment of aortic root aneurysm, with or without 
aortic regurgitation. However, there is a reoperation hazard due to aortic regurgitation 
and in our experience in all cases within 3 years of operation, which indicates non-optimal 
surgical results in specific patients, more specifically in patients with a Ross-procedure in 
the past. According to the European and US guidelines on valvular heart disease VSARR 
should only be considered in experienced centers [4, 10]. Our experience may encourage 
“smaller” centers to use the valve sparing techniques with good results, at least in younger 
patients who lead an active life and will preferably avoid anticoagulation therapy.
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Survival 
Both early as well as late survival are excellent in this study population. There were no 
early deaths and only one patient died after the operation and probably not related to the 
aortic root surgery. Cumulative survival is comparable or even better than most published 
studies by greater centers, although the mean age was slightly higher in these studies 
(range from 45 to 51years), and data was from non-homogeneous cohorts [11-13]and this 
could (partly) explain the better survival. 
Reoperation 
Out of the seven patients who were reoperated due to progression of aortic regurgitation 
there were 4 patients with congenital aortic heart disease who had a pulmonary 
autograft operation (Ross-procedure) in the past. Ishizaka and colleagues [14] published 
good results in 4 patients, without any reoperations after reimplantation technique in 
patients post Ross operation. However, mean follow-up was shorter than 1 year and the 
results may differ after longer follow-up. Another study from an experienced center in 
Brussels by De Kerchove et al. containing 26 patients after Ross operation who received 
a VSARR on the autograft shows similar results to our study, with cusp repair as a risk 
factor for higher reoperation rates [15].  Finally, a multicenter retrospective cohort 
study in 86 patients requiring VSARR after Ross-procedure shows a freedom from 
reintervention of 76% (95% confidence interval: 57%-87%) at 8 years, with even higher 
reoperation hazard in patients with isolated and/or severe autograft regurgitation [16]. 
In our experience patients requiring a VSARR of the autograft after Ross-procedure are 
associated with high reoperation rates thus consequently we would not recommend 
using VSARR technique in these patients. When excluding post Ross-procedure patients, 
the freedom from reoperation is almost 90% after 8 years, which is in agreement with the 
rate of reoperation found in a large systematic review on VSARR by our research group 
[17]. Moreover, in comparison to a larger cohort published by David and colleagues, with 
more than 300 patients included with (mean follow-up of 7 years), there was a freedom 
from reoperation of 94% [18], suggesting achievable excellent results, at least in specific 
patients and by experienced surgeons.          
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Mode of failure 
Reoperation was due to progression of aortic regurgitation in all cases and occurred within 
3 years after the valve sparing operation, indicating less optimal technical results. It is 
assumed that an early postoperative AR grade II or greater is associated with reoperation 
hazard [12], therefore only a postoperative AR grade I or less was accepted in our study. 
However, in these seven reoperated patients there was a rapid progression. Main reason 
of valve failure was prolapse of the cusps, with retraction of one or more commissures in 
all cases. In valve-sparing procedures, reduction of the dilated STJ and annulus brings the 
leaflets inward and thereby increases their coaptation, but alternately it may also lower 
the level of coaptation. As a consequence the coaptation height may drop extremely. 
This is especially the case in elongated free margins of the leaflets as well as in extended 
reduction of STJ [19, 20]. The lowered coaptation height 
is associated with an increased hazard of progressive AR resulting in reoperation, as shown 
by Pethig et al. [21]. Additional cusp repair might alleviate this prolapse [8]. Additionally, 
new onset of valve prolapse after graft implantation may be due to modification of the 
valve geometry while reattaching the commissures into the graft. Also the size of the 
tube-graft may play a role in postoperative AR. Several measuring formulas have been 
proposed, but there is no consensus about standardized implementation of these 
methods [22-24]. De Kerchove et al. [12] suggest that downsizing of the graft is probably 
worse than oversizing, especially when the leaflets are large. In our study patients with 
Ross-procedure in the past had relatively larger annulus diameters. Three of the four 
patients reoperated after initial valve-sparing procedure had an annulus diameter 
of ≥29 mm and received a tubular prosthesis of smaller size. According to the reports 
mentioned above this may have played a role in the progression of AR and consequently 
resulted in a reoperation. However, more data is needed to confirm these results. 
 
Moreover, in the first 20 patients operated, five were reoperated during follow-up (mean 
follow-up time to reoperation 6.0 years), while in the last 21 patients, only 2 patients were 
reoperated (mean follow-up time to reoperation 2.4 years). Most reoperations occurred 
at approximately 3 years. Hence, learning curve may have influenced the results, but this 
difference could also be due to a difference in follow-up time. 
Furthermore, the absence of sinuses is believed to cause change in the mobility 
characteristics of the cusps, which may induce thickening and rolling of the free margins 
of the leaflets [25].
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Echocardiographic outcome
From our echocardiographic measurements we conclude that hemodynamics of the valve 
and the left ventricle are excellent, with a very low gradient over the aortic valve (mean 
gradient < 1mmHg) and no deterioration of left ventricular function. Additionally, we found 
a small reduction in de end diastolic and end systolic left ventricle dimensions assuming 
remodeling of the left ventricle after valve-sparing surgery. Although the reduction was 
trivial and not statistically significant in our study, others have shown left ventricular 
remodeling and improvement after valve sparing aortic root replacement [26, 27]. 
However, we had no patients with severe or moderate left ventricular dysfunction. Out of 8 
patients with preoperative mild left ventricular dysfunction, 2 patients improved to good 
LVF and 6 remained the same. Left ventricular remodeling may be of more hemodynamic 
importance in patients with preoperative severe ventricular dysfunction.
Four of the seven patients reoperated due to progressive AR where patients who had 
VSARR after Ross operation. In other patients there was no or trivial AR at last follow-up. 
This suggests that when properly performed in adequately selected patients, there is no 
or very low progression of AR. The challenge is to find preoperatively risk factors indicating 
early failure in patients in order to have durable valve repair. We expect that the AVIATOR 
registry will provide these answers in the coming years [5].
Quality of life
The quality of life has been an actual issue in medicine in the last few years. To our 
belief there are no large studies describing quality of life after valve sparing aortic root 
replacement. A study by Aicher and colleagues comparing Ross operation, Bentall, and 
valve sparing technique, shows a better QoL in patients with valve sparing procedures, 
although not statistically significant. Notably, in this study patients with mechanical 
valve prosthesis feared a valve failure significantly more than valve repair patients 
[28]. Additionally, another study published by Franke et al. investigating the difference 
in QoL between patients after valve sparing reimplantation technique and the Bentall 
operation, shows also better quality of life in the valve sparing patients. Our results are 
in concordance with the mentioned studies and accentuate the arguments in favor to 
perform valve sparing root replacement. 
The fact that mental health was experienced slightly better (although not statistically) 
than the general Dutch population is probably due to the coping mechanism of patients. 
A substantial part of the patients were diagnosed a connective tissue disease without 
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hemodynamic consequences at the moment of surgery, however knowing that they are 
potentially at risk of an acute medical emergency, like acute dissection. Hence, after the 
operation patients may feel released from those feelings and may experience life more 
positive, and this might lead to a better reported mental health status.  
Limitations
As this was a single-center study, with a small number of participants, non-participating 
patients and no long-term follow-up, we are not able to discriminate for survival, valve 
durability, and quality of life for subgroups. In addition, statistical techniques to test 
possible factors associated with outcome are limited and may not find any association in 
these relatively small numbers. Moreover, we were not able to include all patients for the 
quality of life analysis, which may have led to less adequate interpretation of these data. 
 
CONCLUSION
This study shows that valve-sparing aortic root replacement with the reimplantation 
(David) technique for patients with aortic regurgitation and/or root aneurysm is safe, has 
satisfactory midterm valve durability with a low occurrence rate of valve-related events, 
and provides good hemodynamics. Additionally, there is a good quality of life that is 
comparable to the general Dutch population. Additionally, valve-sparing aortic root 
replacement in patients after Ross-procedure is associated with a higher reoperation risk.
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GENERAL DISCUSSION 
The aim of this thesis was to provide an overview of clinical outcome after surgical 
treatment of aortic valve and/or root disease, and to put this into a broader perspective 
taking into account patient characteristics, quality of life and patient preference. This 
chapter attempts to put the research questions posed in the introduction section  and 
the findings of the presented studies in this thesis into the perspective of treatment 
of patients with aortic valve and/or root disease and in particular optimal selection of 
surgical treatment for the individual patient. Additionally, it provides recommendations 
with regard to optimization of treatment selection and future research.
Indications for surgery in aortic valve and root disease
Aortic valve or root surgery concerns surgical therapy for individual patients with a wide 
variety of diagnoses, such as aortic valve stenosis,  isolated aortic valve regurgitation,  or 
combined stenosis and regurgitation,  with or without aortic root aneurysm, and  isolated 
aortic root (ascending aortic) aneurysm needing aortic root replacement in order to 
prevent dilation of sinus of Valsalva and thus aortic regurgitation or aortic dissection [1]. 
Aortic valve stenosis is predominantly a degenerative disease that occurs mainly in elderly 
in the western population [2], while aortic regurgitation is,  in developed countries, most 
often due to aortic root dilation, bicuspid aortic valve disease, and calcific valve disease 
(stenosis) [3] and occurs in relatively younger patients.
According to the 2012 European ESC/EACTS guidelines on the management of valvular 
heart disease  [4] all symptomatic patients with severe aortic stenosis (AS) and impaired 
left ventricular function, or patients with severe AS undergoing CABG, surgery of the 
ascending aorta or another valve,  have an indication for aortic valve replacement (AVR). 
AVR is also recommended in asymptomatic patients with abnormal exercise test showing 
symptoms (clearly related to AS) on exercise. The same is recommended according to the 
US AHA/ACC 2014 guidelines on the management of patients with valvular heart disease 
[5] (level of recommendation: Class I for both guidelines). 
In addition, the ESC/EACTS guidelines report that AVR should be considered in 
asymptomatic patients with severe AS and abnormal exercise test showing fall in blood 
pressure and in patients with moderate AS undergoing coronary bypass or other valve 
surgery. The AHA/ACC guidelines find AVR reasonable in these same patients, with the 
same level of recommendation (both Class IIa).
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The same  ESC/EACTS and AHA/ACC  guidelines state that patients with severe aortic 
regurgitation who are experiencing symptoms, have an indication for aortic valve surgery, 
as do asymptomatic patients with a resting LVEF < 50% and patients who require CABG or 
surgery of the ascending aorta or another valve. In addition, surgery should be considered/
is reasonable in asymptomatic patients with resting ejection fraction more than 50% with 
severe LV dilatation.
Additionally, in the ESC/EACTS guidelines surgery of the ascending aorta (root) is 
indicated when the diameter of the dilated ascending aorta exceeds 50 mm in patients 
with Marfan syndrome,  regardless of the severity of AR. Surgery should be considered 
all patients when the ascending aortic diameter exceeds 55 mm; in patients with Marfan 
syndrome with additional risk factors (i.e. family history of aortic dissection and/or aortic 
size increase .2 mm/year, severe AR or mitral regurgitation, desire of pregnancy), and in 
patients with a bicuspid aortic valve (BAV) with an aortic diameter of greater than 50 mm 
with additional risk factor (i.e. coarctation of the aorta, systemic hypertension, and family 
history of dissection or increase in aortic diameter 2 mm/year). 
The latest AHA/ACC  guidelines (2014) are less specified regarding aortic dilatation and 
have no recommendations regarding aortic dilatation and connective tissue disease. 
Different from the European ESC/EACTS guidelines regarding intervention in patients with 
bicuspid valve and ascending aortic dilatation, the U.S AHA/ACC guidelines recommend 
surgical treatment of the ascending aorta in bicuspid artic valves when ascending artic 
diameter greater than 55 mm. Additionally, surgical treatment is reported to be reasonable 
in BAV patients with ascending aorta of  ≥ 50 mm and a risk factor for dissection, and in 
those undergoing aortic valve surgery because of severe AS or AR if the diameter of the 
ascending aorta is greater than 45 mm (Chapter 2).
Treatment options
Several surgical options to treat aortic valve and root disease are available. At present the 
‘’gold standard’’ is valve replacement with or without aortic root replacement, depending on 
the presence and extent of aortic root dilatation. Valve replacement can be done with either 
a mechanical or biological valve substitute. Biological valve substitutes include stented 
and stentless bioprostheses, allografts, and the pulmonary autograft (Ross) procedure. 
Additionally, isolated aortic regurgitation can be treated by isolated valve repair while 
aortic root aneurysm can be treated by valve sparing aortic root replacement. All surgical 
options carry a number of advantages and disadvantages.
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According to current European ESC/EACTS guidelines on the management of valvular 
heart disease, a mechanical valve prosthesis is recommended according to the desire of 
the informed patient, without contraindications for anticoagulation therapy, in patients 
at risk of accelerated structural valve deterioration (aged < 40 years) or those already 
on anticoagulation therapy. Below the age of 60, and in patients with a reasonable life 
expectancy for whom future redo valve surgery would be of high risk a mechanical 
valve should be considered.  A mechanical prosthesis may be considered in patients 
already on long-term anticoagulation therapy due to high risk of thromboembolism. 
A bioprosthesis is recommended according to the desire of the informed patient and when 
good quality anticoagulation is unlikely or contraindicated because of high bleeding risk, 
and for reoperation for mechanical valve thrombosis despite good long-term anticoagulant 
control. Additionally, the same guidelines report that a bioprosthesis should be considered 
in young women contemplating pregnancy and in patients for whom future redo valve 
surgery would be at low risk, and in those aged 65 or older. Main difference with the AHA/
ACC guidelines is that in the latter a bioprosthesis is recommended in patients of any age 
for whom anticoagulant therapy is contra-indicated, cannot be managed appropriately, 
or is not desired, and that a biological valve is reasonable in patients aged 70 and older.
 
The main advantage of mechanical valve prostheses is their outstanding durability, 
and therefore low risk of reoperation. On the downside, because of the increased 
thrombogenicity of mechanical valve prostheses, life-long use of anti-coagulation 
therapy is required. Anticoagulation therapy is associated with an increased bleeding 
risk. The currently available anticoagulants require frequent monitoring of the level of 
anticoagulation and may impose a burden on patient compliance. Chapter 4 describes 
the excellent long-term durability of mechanical prostheses in young adult patients after 
aortic valve replacement. Nevertheless, a substantial proportion of patients experience 
valve-related morbidity (mainly anticoagulation-related but also reoperations) and a life 
expectancy that is severely impaired compared to the general population, as evidenced 
by the microsimulation analyses. In case of aortic root dilatation with aortic valve disease 
(e.g. connective tissue disease or degenerative aortic aneurysm), the “gold standard” 
surgical treatment has been composite valve graft replacement (better known as the 
Bentall procedure) since its introduction in 1968 [6]. This procedure shows the same 
mechanical valve related complications as the isolated mechanical valve replacement, 
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and equally depends on anticoagulation therapy. However, early mortality is higher after 
the Bentall procedure which may be due to the higher complexity of the surgery and due 
to concomitant disease (e.g. connective tissue disease, other congenital disease). 
In Chapter 3, we found a pooled early mortality of 6% and late mortality rate of 2.02% per 
patient-year, an average aortic root reoperation rate of 0.46% per patient-year and an aortic 
valve reoperation rate of 0.30% per patient-year after the Bentall procedure. Bleeding and 
thrombo-embolic event rates were 0.64%, and 0.77% per patient-year respectively, and 
endocarditis rate of 0.39%. This highlights that although the Bentall procedure remains 
an utmost valuable treatment for the diseased aortic root, the late mortality, major 
bleeding and thromboembolic complications, but also reoperation remain a concern. In 
many, certainly younger patients without contraindications for anticoagulation therapy, 
the Bentall procedure remains an adequate treatment. Nonetheless, its advantages and 
disadvantages should be taken into account and discussed with patients during the 
decision-making process of prosthetic heart valve selection. 
The main advantage of biological valve substitutes is their absent need for anticoagulation 
therapy and thus the avoidance of bleeding complications associated with anticoagulant 
use. On the downside, all biological valves have a limited durability, mainly due  to 
structural valve degeneration, that may necessitate a re-intervention, usually in de second 
decade after the initial valve replacement. The ESC/EACTS guidelines describe a grey area 
of ages 60 to 65 years, where both mechanical and biological valves should be considered, 
taking into account not only patient age, but also patient characteristics and preference. 
The AHA/ACC guidelines report both mechanical and biological valves to be reasonable 
options in patients aged 60 to 70 years. Interestingly, in recent years biological valves 
are increasingly implanted in patients under the age of 60-65 years. For example, the 
percentage of patients aged 60 to 65 receiving a biological valve in the United Kingdom 
has doubled from 30% in 2004 to 60% in 2010, and this number is still increasing, also in 
the US [7, 8], while for patients aged 50 to 69 in Sweden, this percentage has grown from 
17% in the period of 1997-2002 to 65% in 2009-2013[9]. 
Stented bioprostheses are the most commonly used biological valve substitutes. 
Stentless xenograft bioprostheses are an alternative to stented bioprostheses. They claim 
to show better hemodynamics and may also be used to replace the aortic root. Especially 
in patients with a relatively small aortic annulus, stentless valves are useful in order to 
avoid prosthesis-patient mismatch as stentless bioprostheses have a larger effective 
orifice area which provides lower transvalvular gradients [10]. Stentless biologic valves 
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can be implanted using different techniques: the subcoronary implantation technique or 
aortic root replacement. The subcoronary technique has the main advantage of avoiding 
the manipulation of and the need to reimplant the coronary ostia as is the case with the 
root replacement techniques, a technique that leads to a more complex operation with 
longer cross-clamp times in comparison to stented valve prostheses. The disadvantages 
of the subcoronary technique could be difficulties occurring in patients with a small aortic 
annulus and calcified aortic root, and the risk of valve insufficiency by changing the shape 
of the stentless valve prosthesis. 
The current  ESC/EACTS guidelines report that biological valves should be considered in 
patients aged greater than 65 years, when life expectancy is lower than the presumed 
durability of the bioprosthesis, in young women contemplating pregnancy, in patients for 
whom future redo valve surgery would be at low risk, and in patients with contraindication 
for anticoagulation therapy [4]. Notably, in the past decade progressively more centers are 
implanting biological aortic valve prosthesis in younger patients (younger than 60 years) 
[11] Although there is an accelerated rate of structural valve deterioration in younger 
patients [12], especially younger patients may put a greater value on living without 
the burden of anticoagulation for 1-2 decades at the cost of a reoperation than facing 
this burden of anticoagulation. Another argument to use a biological valve in younger 
patients is the potential prospect of transcatheter aortic valve implantation that could in 
due time be used as a valve in valve in biological valve prostheses. However, this argument 
cannot be supported by evidence as there are no data available on outcomes in young 
patients with biological valves who have been consequently treated with valve-in-valve 
implantation [13]. Nonetheless, given the value-sensitive nature of the choice between a 
mechanical or a biological valve it still remains debatable which valve substitute to choose 
for the individual patient and there seems no single right answer at this point in time.
Allografts are another option to treat the diseased aortic valve and/or root. Chapter 7 
presents a long-term follow-up, prospective cohort study of patients with aortic valve 
disease who have been treated with allografts. It shows good results and low reoperation 
rate after complex endocarditis, although  the subcoronary implantation of allografts 
is associated with higher reoperation rates, possibly due to technical errors. The use 
of allografts in general has decreased enormously in the last decades.  The ESC/EACTS 
guidelines on management of valvular heart disease mention that allografts are used 
in less than 1% of the patient population undergoing aortic valve surgery and the main 
indication for their, although under debate, is acute infective endocarditis with perivalvular 
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lesions. Nevertheless, a randomized prospective trial showed comparable results in terms 
of survival and recurrence of endocarditis, but a higher reoperation rate in comparison 
with Freestyle® aortic root prosthesis [14]. Interestingly, in the 2014 AHA/ACC guidelines 
there is no indication reported for allografts in the aortic position. Given the restricted 
availability of allografts and easily available stentless bioprostheses with possibly superior 
durability, it is most probable that the end of an era for the implantation of allografts in 
the aortic position has come.
Pulmonary autograft valve replacement, better known as the Ross procedure, is yet 
another (stentless) human aortic valve substitute, where the patient’s own pulmonary 
valve is used to replace the diseased aortic valve, with concomitant pulmonary valve 
replacement commonly with an allograft. This procedure is mainly used in children and 
young adults, because the pulmonary autograft increase in diameter along with somatic 
growth in children. The pulmonary autograft operation can be performed with low 
mortality and valve related events, and provides excellent hemodynamics. Nonetheless, 
it is well established that autograft function may deteriorate over time resulting in a 
reoperation and valve replacement [15-17].
There are several techniques to perform a pulmonary autograft procedure: Subcoronary 
implantation, full root, and the root inclusion method. Although the subcoronary 
technique was the initial method described for this procedure and is a more accepted 
approach for isolated aortic valve replacement the full root replacement technique is 
nowadays the most commonly used technique to perform the Ross procedure. Sievers 
and colleagues reported excellent hemodynamics and freedom from any valve-related 
intervention of 95% in the first decade after the subcoronary Ross implantation [18] , 
while Skillington et al. reported a freedom from reoperation of 99% after 15 years using 
the inclusion cylinder method [19]. Additionally, Charitos et al. reported on the value of 
autograft reinforcement to preserve function after the Ross procedure, with a freedom 
from reoperation of 94% after 10 years follow-up. Longer follow-up points at a further 
decline in autograft function and an increased number of reoperations. Additionally, a 
previous randomized controlled trial, including patients between 18 and 69 years with 
aortic valve/root disease, demonstrated beneficial survival outcome and reoperation 
rates in patients after the Ross procedure over allograft [20]. Nevertheless, even in these 
patients there is the problem of neo-aortic root dilatation and (as a consequence) aortic 
valve regurgitation, demanding  a reoperation in the second , or following, decade 
after the initial surgery [21, 22]. The Ross procedure remains a complicated procedure 
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that needs special expertise. Technical errors relating to prosthesis sizing and failure to 
achieve appropriate geometry within the aortic root resulting in early valve failure and 
the pulmonary valve allograft inserted into the right ventricular outflow tract that may 
provide additional hazard for valve-related complications, are amongst reasons why this 
procedure is not used in a broader range [15]. Both ESC/EACTS and AHA/ACC guidelines 
report that candidates for the Ross procedures should be referred to centers that are 
experienced and successful in performing this operation.
Although outcome after aortic valve replacement has improved over the past decades, 
the concerns about prosthetic valve-related complications remain. In this light several 
surgical strategies to repair or spare the aortic valve have been developed in the setting 
of aortic regurgitation and/or aortic root dilatation. Chapter 5 describes pooled outcomes 
after valve sparing aortic root replacement for aortic aneurysm using both remodeling 
∼better known as Yacoub procedure∼ [23] and reimplantation -better known as David 
procedure- [24], and shows no difference in outcome between these techniques, at least 
when annuloplasty with the use of a ring is added in the remodeling technique. On the 
downside, specific surgical expertise is required as these procedures are technically really 
demanding. Moreover, durability is limited, and patients may need a reoperation later in 
life. However, specialized centers have published excellent results with a freedom from 
reoperation of more than 90% in the first decade after valve-sparing root replacement 
[25-27]. This could be explained partly by better patient selection, and partly by an 
experienced team, but the role of patient characteristics need to be further explored. 
There is a need for large studies containing homogeneous data for the analysis of potential 
risk factors associated with reoperation hazard and valve related events, in order to select 
patients with specific clinical and valve characteristics that may have a beneficial influence 
on these outcomes. Currently, initiatives like the AVIATOR registry, an international multi-
center prospective registry where all consecutive potentially repairable aortic valves 
will be included, regardless of whether the valve is replaced or repaired/spared, can 
contribute to optimizing surgical treatment selection [33]. A main challenge remains 
patient selection. For example, in case of a 75 year old patient with aortic root disease, 
it is less attractive to perform a valve sparing operation, while a biological alternative 
will adequately help the patient with a much lower chance of reoperation on the 
aortic valve. On the other hand, a 35 year old patient, without any contraindications for 
anticoagulation therapy, and for whom a lower chance of being reoperated on the aortic 
valve (e.g. due to SVD, a common valve-related event especially in young patients) is more 
important, a mechanical valve substitute would probably be a more adequate treatment. 
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There are also no specific recommendations on valve-sparing root replacement except 
for that it should be performed in specialized centers. A classification system comparable 
to Carpenter’s mitral valve disease could help standardize the valve sparing technique. 
Although several propositions on this theme have been made [28, 29], there is still not an 
accepted classification that is systematically used worldwide. 
Pregnancy and outcome after aortic valve surgery
In case of women with the (potential) desire to become pregnant, there is no ideal 
prosthetic valve. Mechanical valve prostheses have an excellent hemodynamic 
performance and long-term durability, but there is a need for anticoagulation therapy 
with the risk of increased fetal and maternal morbidity and mortality [30]. On the other 
hand, biological valve prostheses also provide good hemodynamics and do not require 
anticoagulation therapy. However, especially in young patients, there seems to be a high 
risk of structural valve deterioration [1]. There is conflicting evidence as to whether or 
not pregnancy accelerates bioprosthetic degeneration [21]. Another option, especially in 
younger women, is the human tissue valve (i.e. Ross procedure and allografts). The Ross 
procedure is associated with good hemodynamics and there is no need for anticoagulation 
therapy, as described earlier. However, few data are available about pregnancy in women 
who have undergone aortic valve surgery [31].
During pregnancy there are several physiological changes in the female body, for example 
increased blood volume, heart rate (hence cardiac output), and hypercoagulability, that 
may influence durability of prosthetic heart valves [21, 32, 33]. Additionally, uterine 
contractions, pain, stress and exertion, all impose an extra demand on the cardiovascular 
system [34].  According to the ESC Guidelines on the management of cardiovascular 
diseases during pregnancy [35], in female patients who are contemplating pregnancy, 
a biological valve prosthesis may be considered. Nonetheless, the choice for the valve 
prosthesis should be based on patient preference, after informing the patient with features 
of both mechanical and biological valves. In addition, women with a dilated aortic root are 
at higher risk of aortic dissection or rupture due to elevated pressure in the aorta and 
should be monitored carefully, and in women with a bicuspid aortic valve and an aortic 
diameter of 50 mm or greater, surgical treatment should be considered. However, some 
recent studies failed to confirm this association [2, 32]. The question remains what the best 
surgical treatment is in these young female patients with the desire to become pregnant.
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Chapters 8 and 9 describe the clinical outcome of mother and newborn after aortic valve 
replacement. Although there is an excellent survival, maternal complications like heart 
failure and arrhythmias occurred frequently in these young female patients. Additionally, 
obstetric complications like pre-term delivery, newborns small for gestational age, and 
hypertension related complications (e.g. pre-eclampsia) occurred during pregnancy. Both 
maternal and obstetric complications were more common in patients with mechanical 
valve substitutes, and this may be due to the volume overload during pregnancy and 
the hemodynamic consequences. Nonetheless, it is hard to monitor and determine the 
optimal anticoagulation therapy during pregnancy because of the altered coagulation 
state during pregnancy, which could be of influence on the thromboembolic event risk, 
thus with survival of mother and child [33]. Therefore, management of labor, delivery, and 
post-partum surveillance require specific expertise and should take place by a specialized 
team, in experienced maternal–fetal centers [36-38]. Furthermore, Chapter 8 describes that 
human aortic valve substitutes do not hemodynamically deteriorate during pregnancy. 
In particular, echocardiographic measurements on aortic regurgitation, ventricular 
dimensions and gradient over the human tissue valve (both pulmonary auto graft and 
allograft) show no deterioration during pregnancy. Human tissue valves shows good 
performance throughout pregnancy and are recommendable in young female patients 
with valvular aortic disease. We found no difference in outcome between allograft and 
pulmonary autograft (Ross procedure) recipients. However, only 31 patients became 
pregnant, and this may have limited the power to identify differences in outcome.
In summary, it is evident that in young women who have the (potential) desire to become 
pregnant, individual counseling and weighting of obstetric complications with respect to 
maternal outcome is challenging. Thus young female patients with potential pregnancy 
desire should be carefully informed about the available types of valve substitutes and 
their cons and pros. In the process of choosing the most suitable valve for the individual 
patient, the doctor should inform the patient on the different features of mechanical valves 
(with relatively higher pregnancy related complications, but lower chance of reoperation), 
and biological valve substitutes (with lower complication rates during pregnancy, but at 
the potential cost of a reoperation later in life). Since there is no ideal valve prosthesis and 
several types of prostheses described above have both advantages and disadvantages that 
may play a different role in every individual patient, patients should actively participate in 
this shared decision making process, in order to optimally tailor treatment.
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Quality of life after aortic valve surgery
The main goal of aortic valve surgery, whether replacement of the valve with a biological 
or mechanical valve substitute or sparing the valve, is not only optimizing clinical 
outcomes but also to improve patient quality of life. Therefore it is highly recommendable 
that during the decision-making on a particular surgical strategy to consider the available 
evidence on quality of life after aortic valve surgery.  Quality of life after aortic valve 
surgery improves in particular in patients with an impaired quality of life before surgery. 
Interestingly, patients with a relatively high preoperative quality of life have little to gain 
after surgery, but potentially a lot to lose [39, 40]. Although evidence is scarce on specific 
treatment options, an observational study in young adult patients showed a lower physical 
capacity in patients with mechanical valve substitutes, a higher prevalence of disability, 
and poorer disease perception compared to bioprosthetic valve recipients [41]. Another 
observational cohort study demonstrated that patients after aortic valve repair and Ross 
procedure show better physical functioning, general health and mental health, and 
surprisingly less cardiac anxiety compared to mechanical valve recipients.  [42]. Chapter 
11 describes a single center study of relatively young patients after valve-sparing aortic 
root replacement with ∼besides excellent survival and few valve related complications∼ 
a quality of life that is comparable to the Dutch general population, and specifically 
a very good mental health. It may be that preservation of the patient’s own valve has 
(positively) influenced the mental health, but of course this is a non-comparative study 
and a cause-effect relationship cannot be determined.  Although the results of this study 
were not compared to patients with other types of surgical treatment, these findings do 
add evidence to the data already published regarding quality of life after valve sparing 
treatments, namely that the majority of patients have a good quality of life. Although 
valve-sparing techniques may be applicable only in a limited proportion of patients with 
aortic root disease, and there is a relatively higher chance of reintervention compared 
to composite ARR, the process of decision making concerning the most suitable surgical 
treatment should also take into consideration patient’s quality of life. Where one patient 
may live happier not risking a higher chance of reoperation after the initial treatment, 
another patient may be willing to take the “chance” and live as long as possible without 
the burden of anticoagulation therapy, although (possibly) at cost of a reoperation later 
in life. 
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Optimal treatment choice
The most important insight that this thesis provides is perhaps that there is no single 
perfect surgical strategy for the treatment of the diseased aortic valve and root. It is far 
more important to choose a tailored treatment that is safe and effective for the patient, and 
that will fit the patient’s needs, values and expectations. In order for patients to participate 
in this decision making process, there needs to be sufficient information available 
about the different aspects of the several available treatments. Tools like websites with 
specific treatment information and (web)applications may be helpful. After gaining this 
information, there should be enough time for the patient to evaluate the consequences 
of different treatment options in their own context and to discuss this with their physician 
in order to reach an optimal tailored decision shared by the patient and physician.
CONCLUSION
In summary, from this thesis a number of insights emerged:
There is no perfect valve prosthesis for the treatment of aortic valve and root disease. 
Mechanical valve prostheses have a lower reintervention rates, however, late mortality, 
major bleeding, and thromboembolic complications remain a concern. On the other 
hand, biological valve substitutes are associated with relatively higher structural 
valve deterioration and thrombo-embolism, although other valve related events (like 
hemorrhagic events) are less frequent. In isolated aortic regurgitation or aortic root 
aneurysm, valve sparing root replacement techniques show good survival and low valve 
related event occurrence, but hazard of reoperation later in life should be considered 
carefully. Hence, choosing the optimal treatment for aortic root disease remains a patient 
tailored procedure, taken into surgeons experience and patients preferences.
There is no association between pregnancy and deterioration of human tissue valves 
(autografts and allografts). Human tissue valves may be considered as a good alternative 
to mechanical valves in young female patients contemplating a pregnancy. On the other 
hand, cardiac; obstetric; and prenatal complications are frequent in female with aortic 
prostheses, especially with mechanical valves. 
Quality of life is as good as the general population after valve-sparing root replacement in 
young adults with aortic valve and root disease. However, valve-sparing root replacement 
is only applicable in patients with aortic regurgitation and/or root dilatation. Thus, in other 
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etiologies (e.g. aortic stenosis) the choice of a mechanical or biological valve remains 
arbitral and should take into account clinical outcome and the individual expectations of 
patients. 
PROSPECTS  AND RECOMMENDATIONS
The need for standardization in aortic valve repair: AVIATOR 
The guidelines currently available for patients with aortic valve regurgitation and/or 
ascending aortic aneurysm are based on (single- center) studies with small number of 
patients, with a limited follow-up duration. The aortic valve repair working group within 
Heart Valve Society has therefore initiated the international prospective multicenter 
registry (AVIATOR) in 2013. It is a multicenter, prospective registration with the goal of 
combining forces and sharing experience to advance knowledge in the field of surgical 
treatment of patients with aortic root dilatation and/or aortic valve regurgitation, and on 
the determinants of outcome. By combining surgical experience from multiple centers, 
and applying uniform definitions of echocardiography data and outcome parameters, 
there will be a base to provide an evidence based treatment and to standardize the most 
suitable surgical technique (repair versus replacement) in aortic valve surgery.
Minimal invasive/transcatheter aortic valve replacement therapy
Since the introduction of transcatheter aortic valve implantation (TAVI) in 2002 [33], the 
treatment of aortic stenosis has changed. While medical therapy with or without balloon 
aortic valvuloplasty was for long the only option for inoperable patients, recently TAVI 
has become a widely accepted treatment for these patients and merged even as an 
alternative for high-risk and intermediate-risk operable patients. Currently, surgical aortic 
valve replacement (SAVR) remains the “gold standard” for patients at low risk. However, 
as there are comparable results between TAVI and SAVR in the high-risk population, there 
is a trend towards TAVI even in intermediate-risk patients in anticipation of the results 
of randomized trials in that population (PARTNER trial and SURTAVI trial). Nevertheless, 
questions still remain regarding TAVI involving paravalvular leak, pacemaker requirements, 
stroke, and durability that remain to be answered before TAVI can routinely be performed 
in a broader, lower risk population. These complications are less frequent in surgical aortic 
valve replacement, both mechanical and biological. Although, improvements in patient 
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selection, imaging, and devices have decreased the incidence of paravalvular leak and 
vascular complications, the longer term durability of TAVI devices and a role for post-
procedure antithrombotic management remain unanswered. 
Hence, until these questions are answered, we should be careful not to rush into less 
acceptable complication risks in intermediate risk patients. Long-term outcome of the 
Partner II trial and the SURTAVI trial should give us answers to, at least part, of these 
questions. In addition, in selected patients with calcified aortic root and small aortic 
annular diameter, other surgical options, like sutureless aortic valve prostheses, may be 
valuable [43-45]. 
Tissue engineering 
Another, experimental, treatment option for the diseased aortic valve is a tissue 
engineered aortic valve. First of all a sufficient extracellular matrix, the so-called scaffold, 
is needed to utilize a three-dimensional structure in order to create a tissue engineered 
valve. These scaffolds are made out of polymers in general or out of decellularized allo- 
or xenogenic materials. The goal of aortic valve tissue engineering is to regenerate a 
functional structure (i.e. the new valve to be) containing endothelial and interstitial cells 
capable of continuously remodeling the extracellular matrix that functions structurally 
and biomechanically as a valve leaflet. Despite an exciting potential for tissue engineered 
heart valves, significant technical barriers should be overcome before widespread clinical 
application can be proposed [46]. Nonetheless, there are several experimental studies 
performed on tissue engineered valves implanted in the aortic position, and these data 
support the feasibility to implant these valves, into the systemic circulation. Although 
the first clinical results are promising [47, 48], long-term results must be awaited before 
tissue engineered valve become a real, widespread option in the treatment of aortic valve 
disease [49].
Patient involvement, quality of life and decision support
The selection of the most suitable valve substitute for aortic valve replacement is a complex 
procedure that should be as individualized as possible and should take into account 
patient preference and lifestyle. Different life goals and patient characteristics may play an 
important role in which valve prosthesis will turn out to be the most appropriate one. In 
an era where patients are more aware of the several choices and are easily truly or falsely 
informed e.g. (through internet) about the (dis)advantages of several types of prosthetic 
14570-arabkhani-layout.indd   231 10/05/2017   10:39
232
valves, physicians must try to provide the information that is needed in order to be able 
for patients to choose a prosthesis that will be safe and match to their wishes and lifestyle. 
Interestingly, cardiologist and cardiothoracic surgeons seem to have different views on 
which valve prosthesis (mechanical or biological) is more appropriate for their patients, 
with cardiologist tending more towards mechanical and surgeons toward biological 
valve substitute, and patient may be less involved in this process [50]. The next step in 
providing patients the most suitable valve substitute is to develop a shared-decision 
tool which provides the information needed for the patients to choose the most optimal 
valve prosthesis suitable to their lifestyle and expectations. Currently our department 
intends to develop such tools; i.e.  an online decision-making models where patient can 
fill in questionnaires about their wishes and their life-style, which will raise awareness on 
pros and cons of the available valve prosthesis. This way, both patient and physician are 
actively involved in this process and patients’ compliance to medical treatment regarding 
their prosthetic valve may increase. Moreover, the quality of life in the several treatment 
options (valve-sparing, mechanical and biological) may be a tool that can be used to 
answer these questions. A prospective randomized trial on the quality of life, including 
these treatment options in comparable patient populations should give us more insights 
on patient preference adding another tool to use when informing patients about their 
surgical options and choosing the most suitable option for the individual patient. 
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SUMMARY
Chapter 1 
Presentation of the introduction, the hypotheses and outline of this thesis. Aortic valve 
disease is the most common valvular heart disease in the developed countries. The aim 
of this thesis is to explore the various surgical techniques and several valve prostheses 
currently available for the treatment of diseased aortic valve and root, and to expand 
the current knowledge on patient outcome after aortic valve/root operation in terms of 
survival and quality of life. 
Chapter 2 
A book chapter that illustrates an overview of indications for surgery in aortic regurgitation, 
surgical options, and subsequent outcomes after aortic valve repair and valve replacement. 
Chapter 3 
A systematic review of literature and a meta-analysis that outlines the hazard of valve 
related outcome after composite valve replacement (Bentall) in patients with aortic root 
disease. Aortic root reoperation after the Bentall procedure has decreased over the years. 
However, valve related events such as late mortality, major bleeding, and thromboembolic 
complications remain a concern.
Chapter 4 is a systematic review and microsimulation after mechanical aortic valve 
replacement in young adolescents estimating the occurrence rate of valve related 
outcome in time. This study shows that mechanical valves in non-elderly adult patients 
is associated with substantial excess mortality over time and considerable lifetime risk of 
anticoagulation-related complications, and also reoperation. Hence, there is no prefect 
valve prosthesis for non-elderly patients and shared decision-making process is of great 
importance in the setting of prosthetic valve selection.
In Chapter 5 a systematic review of literature and a meta-analysis was undertaken 
on outcome after valve sparing aortic root replacement in relatively young patients, 
presenting an overview and testing surgical technique as well as variables associated 
with valve related outcome. Both remodeling and reimplantation techniques show 
good survival and valve durability results, and low valve-related events, providing a valid 
alternative to composite valve replacement.
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In Chapter 6 a meta-analysis and microsimulation model provides an overview on 
outcome after bioprosthetic aortic root replacement in middle-aged patients, showing 
acceptable results in terms of freedom from reintervention and valve-related events 
after bioprosthetic aortic root replacement, regardless of the prosthesis type (stented or 
stentless). There was a relatively high thromboembolic event hazard that may (partly) be 
explained by older patient age.
Chapter 7 provides insight into long-term outcome after aortic valve replacement with 
allografts in a prospective single center study and studies potential echocardiographic 
factors for the prediction of reoperation and death in a joint model. The indication for 
use of allografts in aortic position has become selective, mainly because of progressive 
structural valve deterioration over time. In case of complex aortic root pathology and 
active endocarditis allografts may still be useful. 
Chapter 8 addresses the results of maternal, cardiac and obstetric complications in 67 
pregnancies in 40 women who have undergone an aortic valve replacement in the past 
with a mechanical valve or a human donor valve (allograft or Ross procedure). Maternal 
and obstetric complications occurred in respectively 13% and 38% patients, however, 
mainly in patients with mechanical valve prosthesis. For young female patients with aortic 
valve disease who are planning to become pregnant, human donor valves should to be 
considered as a valuable option. Nevertheless careful obstetric monitoring remains very 
important in these patients. In Chapter 9 the impact of pregnancy on durability of human 
donor valves in young women is examined. Pregnancy is not associated with prosthetic 
valve durability. Therefore, the human donor valve should be considered as a suitable 
valve prosthesis in young female patients who desire a pregnancy in the future. 
Chapter 10 
This chapter describes the difference between conservative treatment and surgery 
regarding symptomatic patients with severe aortic stenosis and timing of the operation, 
and deals with this discrepancy by studying the reasons why more than half of the patients 
studied, received medical treatment instead of surgery. Operative risk, hemodynamic 
severity and symptomatic status appear to be misclassified frequently leading to an 
(surgical) under treatment.
Chapter 11 describes early and late outcome after valve sparing aortic root replacement 
(David procedure), echocardiographic changes in valve function during follow-up, and 
the reported quality of life after valve sparing aortic root replacement. There was an 
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excellent clinical outcome and quality of life in the first postoperative decade. However, 
despite very low valve-related complication rates, there is a hazard of reoperation due to 
progressive valve regurgitation, particularly in patients after the Ross-procedure.
Chapter 12 
This chapter outlines the general discussion, conclusion and recommendations following 
from this thesis. It provides an overview of clinical outcome after surgical treatment of 
aortic valve and/or root disease, in a broader perspective taking into account patient 
characteristics, quality of life and patient preference. There are several surgical solutions 
for the diseased aortic valve and root (mechanical and biological prosthesis, and 
valve-sparing root replacement), however all these options have their advantages and 
disadvantages. International collaboration on data-gathering and follow-up of patients 
with aortic root disease should help us find the most suitable treatment for specific patients. 
Hence, patients’ preference should be taken into account to improve decision making and 
to choose the most appropriate treatment for the individual patient. 
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SAMENVATTING
Hoofdstuk 1
Dit hoofdstuk omvat de introductie, de hypothesen en de hoofdlijnen van dit proefschrift. 
Aortaklep ziekte is de meest voorkomende hartklepafwijkingen in de ontwikkelde 
landen. Het doel van dit proefschrift is om de verschillende chirurgische technieken en 
verschillende klepprothesen die momenteel beschikbaar zijn voor de behandeling van de 
aangedane aortaklep en de aortawortel te belichten en bij te dragen aan de huidige kennis 
over de uitkomsten na aortaklep en/of aortawortel operatie, in termen van overleving en 
kwaliteit van leven.
Hoofdstuk 2
Een hoofdstuk uit een boek over aortaklepinsufficiëntie dat een overzicht geeft over 
indicaties voor operatieve behandeling van aortaklepinsufficiëntie, verschillende 
chirurgische opties en de daaropvolgende resultaten na aortaklep reparatie en 
aortaklepvervanging.
Hoofdstuk 3 betreft een systematische review van de literatuur en een meta-analyse 
die de klepgerelateerde uitkomst na aortawortelvervanging met een (mechanische) 
klephoudende vaatprothese (Bentall) bij patiënten met aortawortel ziekte schetst. 
Reoperaties aan de aortawortel na de Bentall procedure zijn afgenomen in de loop der 
jaren. Echter, klepgerelateerde complicaties zoals late mortaliteit, grote bloedingen, en 
trombo-embolische complicaties blijven een punt van zorg.
Hoofdstuk 4 is een systematische review van de literatuur en microsimulatie na 
mechanische aortaklepvervanging bij jonge patiënten die het optreden van de 
klepgerelateerde uitkomsten voorspelt. Deze studie toont aan dat de mechanische 
klepprotheses in deze groep patiënten geassocieerd is met een aanzienlijke “oversterfte” 
en een aanzienlijk risico op het krijgen van anticoagulantia-gerelateerde complicaties, 
maar ook kans op reoperatie. Er is dus geen prefect klepprothese voor jonge patiënten 
en een gezamenlijke besluitvorming over het type klepprothese (mechanisch danwel 
biologisch) is derhalve van groot belang.
In hoofdstuk 5 wordt een systematische review van de literatuur en een meta-analyse 
uitgevoerd die een overzicht en de uitkomsten na een klepsparende aortawortelvervanging 
in relatief jonge patiënten weergeeft. Tevens worden verschillende chirurgische 
technieken en variabelen die mogelijk invloed hebben op de uitkomst na klepsarende 
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aortawortelvervanging getest. Zowel de “remodeling” als de “reimplantatie” techniek 
laten een goede overleving van patiënten en duurzaame klepreparatie zien met weinig 
klepgerelateerde complicaties, wat een goed alternatief kan zijn voor mechanische 
klepvervanging (Bentall) in deze patiënten.
In hoofdstuk 6 wordt middels een meta-analyse en microsimulatie model een overzicht 
gegeven van de uitkomsten na aortawortelvervanging met een biologische prothese bij 
patiënten van middelbare leeftijd, wat aanvaardbare resultaten laat zien met betrekking 
tot de kans op een reinterventie en klepgerelateerde complicaties, ongeacht het type 
prothese dat is gebruikt (gestente of stentloze). Er was een relatief hoog risico op trombo-
embolische complicaties die (deels) verklaard kan worden door de hogere leeftijd van de 
patiënten.
Hoofdstuk 7 geeft inzicht in de lange termijn resultaten na aortaklepvervanging met 
‘allogratfs” in een prospectieve, “single-center” studie. Tevens worden echocardiografische 
parameters onderzocht die de kans op een reoperatie en sterfte voorspellen in een 
zogenoemde “joint-model”. De indicatie voor het gebruik van allografts in de aorta 
positie is minder en selectiever geworden, vooral als gevolg van progressieve, structurele 
klepdegeneratie. In geval van complexe aortawortel pathologie en actieve endocarditis 
kan een allograft wel uitkomst bieden.
Hoofdstuk 8 adressert de uitkomst van maternale, cardiale en obstetrische complicaties 
in 67 zwangerschappen bij 40 vrouwen die een aortaklepvervanging hebben ondergaan 
met een mechanische klep of een humane donorklep (allograft of een Ross operatie). 
Maternale en obstetrische complicaties kwamen in respectievelijk 13% en 38%, doch met 
name patiënten met een mechanische klepprothese ondervonden deze complicaties. 
Voor jonge vrouwen met een aortaklepaandoening die een zwangerschapswens hebben 
dienen humane donorkleppen ook als een optie te worden beschouwd. Desalniettemin 
blijven zorgvuldige verloskundige controles erg belangrijk in deze patiënten. In hoofdstuk 
9 wordt het effect van zwangerschap op de duurzaamheid van humane donorkleppen in 
jonge vrouwen onderzocht. Zwangerschap was niet geassocieerd met de duurzaamheid 
van deze donorkleppen. Derhalve dient de humane donorklep overwogen te worden bij de 
jonge vrouwelijke patiënten met een aortaklepaandoening, die een zwangerschapswens 
hebben.
14570-arabkhani-layout.indd   246 10/05/2017   10:39
247
13
Su
m
m
ar
y /
 Sa
m
en
va
tt
in
g 
Hoofdstuk 10 beschrijft het verschil tussen een conservatieve behandeling en chirurgie 
met betrekking tot symptomatische patiënten met ernstige aortaklepstenose en de 
timing van de operatie. Tevens behandelt dit hoofdstuk deze discrepantie door de 
redenen te bestuderen waarom meer dan de helft van deze onderzochte patiënten 
een mecicamenteuze behandeling kregen in plaats van een operatie. Operatierisico, 
hemodynamische ernst van klepstenose en symptomatische status van de patient lijken 
vaak ten onrechte te leiden tot een (chirurgische) onder behandeling.
Hoofdstuk 11 beschrijft de vroege en late uitkomsten na klepsparende 
aortawortelvervanging (David procedure), echocardiografische veranderingen 
van de klep tijdens de follow-up en de kwaliteit van leven na klepsparende 
aortawortelvervanging. Er was sprake van een uitstekende overleving en kwaliteit van 
het leven in de eerste postoperatieve decennium. Desalniettemin, ondanks zeer lage 
klepgerelateerde complicaties, is er een reële kans op een reoperatie door progressieve 
aortaklepregurgitatie, vooral bij patiënten na de Ross-procedure.
Hoofdstuk 12
In dit hoofdstuk wordt de algemene discussie, conclusie en aanbevelingen naar 
aanleiding van dit proefschrift beschreven. Het geeft een overzicht van de klinische 
uitkomst na de chirurgische behandeling van aortaklep en/of aortawortel ziekte, in 
een breder perspectief, rekening houdend met karakteristieken en voorkeuren van de 
patiënt, en kwaliteit van leven. Er zijn verscheidene chirurgische behandelingen voor 
de zieke aortaklep en/of aortwortel (mechanische prothesen, biologische prothesen en 
klep-sparende wortel vervanging), maar al deze opties kennen hun voor-en nadelen. 
Internationale samenwerking op het gebied van dataregistratie en follow-up van patiënten 
met aortawortel ziekte kunnen ons helpen om de meest geschikte behandeling voor 
specifieke patiënten te vinden. Daarom dient de voorkeur van patiënten in acht te worden 
genomen ten tijde van de besluitvorming omtrent het type prothese en behandeling, om 
zo de meest geschikte behandeling voor de individuele patiënt te bewerkstelligen.
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DANKWOORD / ACKNOWLEDGEMENTS
Het voltooien van dit proefschrift is mede te danken aan de inspanning en steun van een 
groot aantal mensen. Graag wil ik dan ook van de gelegenheid gebruik maken om een 
woord van dank uit te spreken, omdat zonder hun bijdrage dit proefschrift nooit tot stand 
zou zijn gekomen. 
Allereerst mijn promotor prof.dr. Bogers. Beste professor Bogers, de afgelopen jaren heeft 
u mij de mogelijkheid geboden om mij te kunnen ontwikkelen als wetenschapper en als 
medicus op uw afdeling. De wetenschappelijke deskundigheid en de snelheid waarmee u 
de manuscripten van waardevol commentaar heeft voorzien zijn belangrijke bouwstenen 
geweest voor dit proefschrift. Tevens voel ik mij bevoorrecht dat ik getuige heb mogen 
zijn van uw chirurgische vaardigheden in de operatiekamer. De beheersing en kalmte 
waarmee u opereert zijn exceptioneel. Het is een zeer waardevolle ervaring geweest en 
mijn grote dank hiervoor.
Mijn promotor prof.dr. Takkenberg. Beste Hanneke, woorden schieten tekort om het 
belang van jouw aandeel in dit proefschrift en mijn dankbaarheid daarvoor te beschrijven. 
Je bent een uitzonderlijk inspirerende vrouw die de gave heeft om het beste in de 
onderzoekers naar boven te halen.  Met een zorgvuldige deskundigheid en een aangename 
persoonlijkheid heb je een enorm internationaal netwerk van vooraanstaande mensen 
opgebouwd, waarin je een zeer gerespecteerd lid bent. Desalniettemin heb je ook alle 
aandacht en steun voor enthousiaste, beginnende onderzoekers die nog dwalen en enige 
sturing behoeven. Daarnaast heb je ook oog voor de mens achter de wetenschapper. Het 
is oprecht een voorrecht om jouw promovendus te zijn geweest. Dank ook voor je begrip 
en steun in tijden van moeilijke (persoonlijke) omstandigheden. Ik heb heel veel van je 
geleerd en hoop dat ook in de toekomst te kunnen blijven doen. 
De leden van de “kleine commissie”. Beste prof.dr. Klautz, ik ben zeer trots dat u deel uit 
wilt maken van deze commissie, daarmee is deze mijlpaal extra bijzonder geworden. 
Graag wil ik u ook bedanken voor uw vertrouwen in mij en dat ik onderdeel mag zijn van 
uw team. Het is werkelijk bewonderenswaardig om te zien hoe u zowel op organisatorisch 
vlak als in de operatiekamer excelleert. Ik hoop nog zoveel mogelijk van u te kunnen leren 
de komende jaren.  Beste prof.dr. Steyerberg, veel dank dat u tijd hebt willen vrijmaken om 
dit proefschrift te beoordelen en plaats te nemen in deze commissie. Nu u ook in Leiden 
gevestigd bent, hoop ik in de toekomst een beroep te mogen doen op uw expertise. Beste 
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prof.dr. Roos-Hesselink. Beste Jolien, jouw deskundige visie en betrokkenheid hebben 
geresulteerd in een paar mooie publicaties. Heel hartelijk dank voor de zeer prettige 
samenwerking en voor alle steun. Het is een eer dat je in deze commissie hebt willen 
plaatsnemen.    
Beste  dr. Bekkers, het completeren van dit proefschrift was erg moeilijk, zo niet onmogelijk, 
geweest  zonder uw steun. Graag wil ik u bedanken voor de tijd en energie die u heeft 
gestoken in mij en in dit proefschrift. Wat mij ook altijd bij zal blijven zijn de serene rust 
en de volledige beheersing waarmee u opereert, het is bijzonder inspirerend en leerzaam 
geweest.  Het feit dat u bereid bent om deel uit te maken van de grote commissie maakt 
deze dag compleet. Beste prof.dr. Deckers, veel dank voor uw bereidheid om deel uit te 
maken van deze commissie en dank ook voor de fijne begeleiding in de allereerste fase 
van de Master of Science (NIHES) opleiding. 
Beste prof.dr. Kappetein, beste Arie Pieter. Ik herinner me de bijzondere zaterdag dat ik 
als eerstejaars student mee mocht lopen op de afdeling en uiteindelijk ook op OK. Het 
maakte zoveel indruk dat ik meteen verkocht was. Kort daarna volgde de introductie in de 
wetenschapswereld van thoraxchirurgie. Daar is ook de basis gelegd voor dit proefschrift. 
Mijn grote dank hiervoor.
Uiteraard mag dr. van Geldorp hier zeker niet ontbreken. Beste Martijn, de eerste stappen 
in de richting van dit proefschrift zijn aan jou te danken. Jouw enorme gedrevenheid 
en werklust (zelfs kerstavond was niet ongelegen om het cardiologie archief in te 
duiken) heeft mij gestimuleerd om verder te gaan in de wetenschap. Dank voor de fijne 
begeleiding en alle wijze raad.
Beste dr. Heuvelman, beste Helena. Hartelijk dank voor de begeleiding en het helpen 
opzetten van mijn eerste echte onderzoeksproject. Het heeft heel wat mooi herinneringen 
opgeleverd, refererend aan onze bel avonden voor de DIAMOND studie. Heel veel succes 
en gezondheid gewenst voor jou en je gezin.  
Mijn paranimfen. Beste Aria, broertje, vriend, reisgenoot in het avontuur dat ons 
meegenomen en gemaakt heeft. Door jouw onvoorwaardelijke steun en liefde, zeker 
in de “grijze” periode, heb ik me altijd sterk en onoverwinnelijk gevoeld. Ik benijd jouw 
evenwichtige kijk op het leven en de rust die je uitstraalt in alles wat je doet. Je bent in 
alle opzichten de broer en vriend die ik me kan wensen. We zijn onlosmakelijk met elkaar 
verbonden en dat koester ik ten zeerste. Het maakt mij ontzettend trots dat je op dit 
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bijzondere moment aan mijn zijde staat en wederom mijn steunpilaar bent. Mijn eeuwige 
dank voor alles!  Uiteraard mag Sofie hier ook niet ontbreken. Ik denk dat ik namens de 
hele familie spreek als ik zeg dat jouw aanwezigheid een verrijking is, in de breedste zin 
des woords, voor ons allemaal. Ik ben erg blij met onze band en hoop dat het alleen maar 
sterker wordt.
Beste Bob (matti), zoals we dat vaker tegen elkaar zeggen als we oude herinneringen 
ophalen, wie had na onze eerste ontmoeting tijdens de Eurekaweek gedacht dat deze 
onbeschrijfelijk prachtige  vriendschap op ons te wachten stond. Ik prijs me erg gelukkig 
dat ik het voorrecht heb gehad om jou op deze manier te leren kennen. Je bent een van de 
weinige mensen die ik blind vertrouw en de meest attente persoon die ik ken. Daarnaast 
beschik je over een intellect en intelligentie waar geen superlatief de omvang ervan, ook 
maar bij benadering, recht aan doet. Ik heb inmiddels heel veel mooie herinneringen 
mogen maken met jou en hoop dat in de toekomst te kunnen multipliceren.  
Alle onderzoekers en vrienden waarmee ik heb mogen brainstormen en waar ik ontzettend 
veel van geleerd heb. Aart, Nelleke, Sahar, Simone, Gerdien en Elrozy; dank voor jullie hulp 
en de gezelligheid. Ik zal de ochtenden missen waarop ik, na een “zware nachtdienst”, 
kwam klagen op de onderzoekskamer. Jonathan, ik zal niet refereren aan een bepaald 
congres, maar het schijnt dat er beelden van te vinden zijn...;). Dank voor je waardevolle 
hulp! Stuart en Ruben, wanneer lanceren we  die app waarmee we wereldfaam verwerven? 
Mostafa, veel dank voor je hulp en voor de wijze raad (en nee, ik heb het niet over Monaco). 
Ik waardeer het enorm!  Natuurlijke mogen hier Anton en Adriaan niet ontbreken (zegt 
Flavio Briatore genoeg?). Ik kijk erg uit naar onze toekomstige samenkomsten! Sabrina 
(Jeopardy partner!), dank voor je hulp en support.
Ook wil ik graag Liesbeth en Usha bedanken voor hun hulp en ondersteuning de afgelopen 
jaren. En uiteraard Marlies, bedankt voor alle steun.
I would like to take this opportunity to kindly thank dr. Lansac for his indispensable 
contribution and help in several projects. I hope to continue working with you in the 
future.    
Mijn opleider Michel Versteegh (werkelijk een alleskunner), maar uiteraard ook de mede-
opleiders die, ondanks de werkdruk die soms met dit prachtige vak gepaard gaat, er 
altijd naar streven om hun vakkundigheid en kennis over te dragen aan de assistenten: 
Jerry Braun, Meindert Palmen, Arend de Weger, Thomas van Brakel, Rob de Lind van 
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Wijngaarden en Martin de Jonge. Vanzelfsprekend ook de congenitaal chirurgen Mark 
Hazekamp, Dave Koolbergen, Vlado Sojak en Jolanda Kluin. Ik kan me goed voorstellen 
dat het opleiden van assistenten bepaald geen sinecure is. Hartelijk dank voor jullie 
geduld en het vertrouwen. Het is een eer om dit vak van jullie te mogen leren. 
Alle stafleden en assistenten (AIOS en ANIOS), NP’s, PA’s en alle andere collegae uit 
Rotterdam en Leiden waarmee ik zeer prettig heb samengewerkt, hartelijk dank voor 
jullie steun.
Afzal, onze vriendschap gaat “way back”. Al vanaf het begin van de studie ben je mijn 
steun en toeverlaat geweest. Uiteraard mag Delal hier ook niet ontbreken. Dank voor jullie 
steun en voor deze dierbare vriendschap. Het betekent veel voor me. Ali, jouw ambitieuze 
instelling en gedrevenheid hebben mij altijd erg geïnspireerd. Ik weet dat ik altijd op je 
kan rekenen en waardeer je betrokkenheid enorm (damet garm). Bedankt voor alles.   
Lieve familie (Kioumars, Elly & Mo, Frank & Ingrid, Payam & Freek, Aram & Michael, Nika, 
Kia, Sadaf, Roya en Celina), jullie hebben mij altijd erg gestimuleerd en gesteund in alles 
wat ik doe. Dank voor jullie onvoorwaardelijke en onmisbare support!
Lieve papa en mama, heel vaak heb ik mij afgevraagd hoe ontzettend moeilijk het leven 
voor jullie geweest moet zijn. Dat je, als gevolg van het nastreven van je idealen en een 
betere toekomst voor ons, alles achter moet laten en ergens, in een ver en onbekend 
land, helemaal opnieuw moet beginnen. Met veel bewondering en respect kijk ik naar de 
manier waarop jullie omgaan met deze “nieuwe situatie”. Hoe jullie je aangepast hebben 
getuigt van een onbeschrijfelijke kracht. Jullie hebben er alles aan gedaan om het leven 
zo mooi en aangenaam mogelijk te maken voor Aria en mij, en daarbij hebben jullie jezelf 
volledig weggecijferd. Er zijn geen woorden die de lading kunnen dekken voor mijn dank 
voor de onvoorwaardelijke liefde en steun die jullie mij hebben gegeven. Lieve baba en 
maman, zonder jullie was het nooit gelukt. Dank voor alles!
Lieve Carina, ik weet niet waar ik moet beginnen. We hebben al zo ongelooflijk veel 
meegemaakt. Je bent een bijzonder sterke vrouw die, ondanks de tegenslagen die soms 
op het levenspad verschijnen, nooit opgeeft en vol overtuiging, bijna altijd met succes, 
voor je doel blijft vechten. Je hebt een zeer sterke wil en een onvoorstelbare gedrevenheid 
in alles wat je doet, maar tegelijkertijd ben je erg zorgzaam en ontzettend lief voor 
iedereen die je dierbaar is. Ik realiseer me heel goed dat mijn baan en dit proefschrift ook 
een behoorlijke impact hebben gehad op jouw (ons) leven, maar jij doet er alles aan om 
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dat zo aangenaam en zo makkelijk mogelijk te maken. Je bent een prachtige vrouw en 
een onwaarschijnlijk geweldige moeder, en ik houd heel veel van je. Zonder jou was het 
zeker niet gelukt. Bedankt voor de onvoorwaardelijke steun en liefde!
Lieve Dante, prachtige zoon. Je bent nu nog te jong om te beseffen dat jouw aanwezigheid 
en lieve  lach het leven een stuk mooier maakt. Ik ben trots op je en houd ontzettend veel 
van je!
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